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SUMMARY 
Non-melanoma skin cancer (NMSC) is the most common cancer in white-skinned 
populations worldwide. The term NMSC encompasses squamous cell carcinoma 
(SCC) and basal cell carcinoma (BCC). The majority of SCC arises from a precursor 
lesion, actinic keratosis (AK). AK provides a useful surrogate endpoint biomarker 
for NMSC chemoprevention trials as it lies directly in carcinogenic pathway to SCC. 
Ultraviolet radiation (UVR) found in sunlight is the primary cause of NMSC. UVR is 
carcinogenic via its mutational and immunosuppressive effects on the skin. UVR 
induces DNA damage directly, causing the formation of cyclobutane pyrimidine 
dimers (CPDs), and also indirectly via reactive oxygen species (ROS)-mediated 
oxidation, resulting in the formation of 8-oxo-7,8-dihydro-2’-deoxyguanine (8-
oxodG). CPDs have been recognized to play a key role in the induction of UV-
immune suppression and there is evidence that ROS contributes to UV-immune 
suppression. Preliminary studies have shown that nicotinamide, an amide form of 
vitamin B3, to have significant protective effect against UV-immune suppression in 
human. Nicotinamide, a precursor for nicotinamide adenine dinucleotide (NAD), 
replenishes cellular energy in irradiated skin cells and prevents the decline in cellular 
energy seen after UVR. Poly(ADP)ribose polymerase-1 (PARP-1) is a nuclear 
enzyme which uses NAD as a substrate but is inhibited by nicotinamide. PARP-1 is a 
DNA damage sensor enzyme, with a key role in DNA repair and maintenance of 
genomic stability. PARP-1 overactivation, on the other hand, has been implicated in 
cellular energy depletion, cellular dysfunction and necrosis. PARP-1 is also involved 
in activation of nuclear factor-kappa beta (NF-κB), which plays a central role in 
inflammation and progression of skin cancer.  
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This project examines the role of nicotinamide in DNA repair and prevention of 
NMSC.  The effect of nicotinamide was first assessed on UVR-induced 
mitochondrial DNA damage, in particular the 4977 bp mitochondria common 
deletion (mtDNA-CD). HaCaT human keratinocytes and primary human fibroblasts 
were repetitively irradiated with UVA and the amount of mtDNA-CD was measured 
with real-time and nested PCR. mtDNA-CD was unable to be detected due to a 
combination of low sensitivity of detection method to detect low copies of mtDNA-
CD induced by low dose of UVA irradiations and inability to give higher cumulative 
dose of UVA irradiations without causing excessive cell death. The effect of 
nicotinamide on nuclear DNA repair in solar-simulated (ss)UV irradiated HaCaT 
keratinocytes was assessed using unscheduled DNA synthesis (UDS) assay, which 
measures DNA synthesis during excision repair. Nicotinamide significantly 
increased both the rates of UDS in each cell and the percentage of cells showing 
UDS in irradiated HaCaTs. Formation and repair of specific UV-induced DNA 
lesions, CPD and 8-oxodG, and the effect of nicotinamide on these were next 
investigated in HaCaT keratinocytes and ex vivo human skin. Using comet assay to 
measure photolesions in a single cell level, nicotinamide enhanced repair of both 
CPD and 8-oxodG in ssUV-irradiated HaCaTs. Immunostaining of whole human 
skin using antibody specific to CPDs and 8-oxodG allows localization of these 
photolesions in human skin. Nicotinamide significantly enhanced repair of both CPD 
and 8-oxodG in ssUV-irradiated whole human skin. Repair rates of both photolesions 
were slower in ex vivo skin than in in vitro keratinocytes. Differential analysis of 8-
oxodG repair in upper and lower epidermis showed similar enhancement of repair 
with nicotinamide. This is particularly important as unrepaired DNA photolesions in 
the lower part of epidermis which contains highly proliferating basal cells are more 
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likely to give rise to mutations and skin cancers. Nicotinamide’s enhancement of 
DNA photolesions repair may be a key mechanism of nicotinamide’s immune 
protective effect from UVR in human, highlighting DNA damage as an important 
mediator for UV-induced immune suppression and skin carcinogenesis. Thus 
nicotinamide is a promising agent for skin cancer chemoprevention in humans. Two 
phase II double-blinded randomized placebo controlled clinical trials were conducted 
in 76 healthy patients with sun-damaged skin and an average of more than 30 AKs 
each. Nicotinamide given at doses of 500mg twice daily (study 1) and 500mg once 
daily (study 2) significantly reduced AKs by 35% and 29% respectively, relative to 
placebo within 4 months. At 2 monhts, AKs reductions relative to placebo were 35% 
and 15% for nicotinamide given at doses of 500mg twice daily (study 1) and 500mg 
once daily (study 2) respectively. Although these trials were not designed to have a 
reduction in new NMSCs as a defined primary end point, a significant reduction in 
NMSCs was observed in the nicotinamide group, while in the placebo group an 
increase in incidence was observed (11 placebo patients developed 20 new NMSCs 
[12 BCCs, 8 SCCs] and 2 nicotinamide patients developed 4 NMSCs [2BCCs, 2 
SCCs]). A phase III double-blinded randomized placebo-controlled involving larger 
numbers of patients and longer durations of study is required to further assess and 
confirm the efficacy of nicotinamide as an oral chemoprevention agent against 
NMSCs.  
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CHAPTER 1 INTRODUCTION 
1.1. ULTRAVIOLET RADIATION AND TERRESTRIAL 
SOLAR SPECTRUM 
Ultraviolet radiation (UVR) is a part of the electromagnetic spectrum (Figure 1.1), 
which includes a broad range of energy including very short-wavelength-high-energy 
radiation such as X-rays and gamma rays, and very long-wavelength, low-energy 
radiation such as microwaves and radio-waves. Terrestrial sunlight is composed of 
UVR (5%), visible light (50%) and infrared radiation (45%). Conventionally, 
photobiologists divide the UVR spectrum into short wavelength UVC (200-290 nm), 
middle wavelength UVB (290-320 nm) and long wavelength UVA (320-400 nm). 
UVA is also further divided into UVA II (320-340 nm) and UVA I (340-400 nm). 
UVR which reaches the earth’s surface consists of approximately 94% UVA and 6% 
UVB (Diffey, 2002). 
 
 
 
 
<0.001                                           700          106     107      109       1011                
1015          
                                                                                                                           
                                                                                                                           
              
                                                                                                                            
 
                   
                 200       290      320         400 
 
 Wavelength, nanometers (nm)      
                                              
 Increasing wavelength (nm), decreasing energy (Joule) 
 
 Figure 1.1. Electromagnetic spectrum. 
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The terrestrial solar spectrum varies throughout the day (relatively more UVA in the 
morning and evening), season, and by latitude and altitude (higher UV with 
decreasing latitude and increasing altitude) (Diffey, 1991). Clouds and 
environmental pollutants in the tropospheric layer, the first major layer of the earth’s 
atmosphere (0-10 km above sea-level), attenuates UV radiation on the earth’s surface 
by scattering of the UVR (Diffey, 2002). Contributing to greater UV exposure on 
earth is reflected UVR from ground surfaces (< 10%), gypsum sand (15-30%), snow 
(up to 90%), and water (5-20%) (Diffey, 2002).  
 
1.2. STRUCTURE OF HUMAN SKIN  
The epidermis is the outer layer of the skin and is approximately 0.05-1 mm in 
thickness (Chu, 2008). It is subdivided into continuous layers of cells, from bottom 
to top: stratum (s) basale, s spinosum, s granulosum, and s corneum. S basale is a 
single layer of cuboidal to columnar epithelial stem cells that continually undergo 
mitotic divisions to produce keratinocytes. These cells migrate upward while 
undergoing morphological and biochemical differentiation in about 30 day-cycles 
(McGrath and Uitto, 2010). The uppermost epidermal layer, s corneum, consists of 
several layers of anucleate cells (corneocytes) embedded in a intercellular lipid-
enriched matrix, which are constantly shed from the skin surface (Kanitakis, 2002).  
 
5-10% of the epidermal cells are Langerhans cells, melanocytes and Merkel cell 
mechanoreceptors. The Langerhans cells are skin-specific, bone marrow-derived 
antigen-presenting cells, which uptake antigen in the skin and migrate to regional 
lymph nodes via lymphatic vessels to present the antigen to T cells. Langerhans cells 
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thus have a major role in skin adaptive immunity. Melanocytes are neural crest-
derived, reside in the basal epidermis (1 melanocyte for 4-10 basal keratinocytes) 
and produce melanin to be distributed to surrounding keratinocytes. Melanin also 
forms an aggregate or “umbrella cap” over keratinocyte nuclei, protecting DNA from 
UVR (Kanitakis, 2002).  
 
The dermis consists of mainly collagen fibers (80-85% of the dry weight of dermis) 
and smaller amounts of elastic and reticular fibers, embedded in a matrix of ground 
substance comprising of proteoglycans and glycoproteins, which provide stability for 
the fibers and flexibility to the skin (McGrath and Uitto, 2010). Fibroblasts make up 
the majority of cells in the dermis. They synthesize collagen fibers, elastic fibers, and 
glycosaminoglycans. Histiocytes are involved in phagocytosis of foreign substances 
in the skin and present them as antigens to T cells. Mast cells are bone marrow 
derived mononuclear cells, which release histamine, heparin, neutrophil chemotactic 
factors, eosinophil chemotactic factors of anaphylaxis, tryptase, chymase, tumour 
necrosis factor (TNF)-like substances, prostaglandins, leukotrienes, and platelet-
activating factors, in response to various stimuli (Kanitakis, 2002).   
 
1.3. BIOLOGICAL EFFECTS OF ULTRAVIOLET 
RADIATION ON SKIN 
There are two mechanisms by which UVR induces its deleterious effects: (1) direct 
absorption of UV photons by chromophores (light absorbing molecules such as 
DNA), which leads to photo-induced reactions; (2) photosensitization of endogenous 
or exogenous sensitisers, which absorb UVR. The exited sensitizer can either revert 
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back to its unexcited state, or damage other cellular components (Pattison and 
Davies, 2006). Cellular damage via excited photosensitisers can be further divided 
into two major pathways. In the first pathway, one electron is transferred from the 
cellular target to the excited photosensitiser, resulting in free radical formation (type 
I reaction). In the second pathway, the excited photosensitiser transfers its energy to 
molecular oxygen, leading to the production of reactive oxygen species (ROS) (type 
2 reaction) (Pattison and Davies, 2006, Svobodova et al., 2006). ROS include singlet 
oxygen (1O2) and the superoxide anion (O2.-). The latter could be converted to 
hydrogen peroxide (H2O2) by superoxide dismutase and subsequently converted to a 
hydroxyl radical (HO.) in the presence of metal cations (Fe, Cu) through the Fenton 
reaction (Svobodova et al., 2006). ROS and free radicals cause oxidative damage to 
DNA, proteins and lipids. 
 
1.3.1. DNA Damage 
UVA and UVB radiation damages DNA by direct absorption and indirectly through 
oxidative stress. Absorption of UVR causes the formation of cyclobutane pyrimidine 
dimers (CPDs) and pyrimidine (6-4) pyrimidone photoproducts [(6-4)PPs] (Cadet et 
al., 2005). The cyclobutane rings of CPDs are formed by covalent bonding of carbon 
atoms at C5 and C6 position of two adjacent pyrimidine bases (thymine, cytosine, or 
5-methylcytosine) on the same strand, whereas the (6-4)PPs are arise through 
covalent binding between C4 and C6 position (Pattison and Davies, 2006). In most 
experimental systems, the yield of (6-4)PPs are considerably less than that of CPDs 
(Mitchell and Nairn, 1989, Yoon et al., 2000). Amongst CPDs, thymine-cytosine 
(TC) and cytosine-cytosine (CC) dimers are the most mutagenic as UV landmark 
mutations: C  T and CC  TT transitions are frequently found in the p53 gene of 
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skin cancer cells (Daya-Grosjean et al., 1995). In vitro studies showed that (6-4)PPs 
and Dewar isomers are more mutagenic than CPDs (Leclerc et al., 1991, Lee et al., 
2000). However, their efficient repair prevents them from being responsible for the 
majority of UV-induced mutations (Ichihashi et al., 2003). Besides CPDs and (6-
4)PPs, UVR also induces other DNA lesions, such as cytosine photohydrates, purine 
photoproducts, and DNA single strand breaks (Melnikova and Ananthaswamy, 
2005). 
 
UVA radiation can induce DNA damage by photosensitization. The guanine base is 
the most susceptible to oxidation via both type I (free radical-mediated) and type 2 
(ROS-mediated) reactions. After guanine, adenine is the second most susceptible 
base, followed equally by thymine and cytosine (Pattison and Davies, 2006). 
Reaction of radical cations with guanine bases produces 2,6-diamino-4-hydroxy-5-
formamidoguanine (FapyGua). In the presence of molecular oxygen (O2), it is 
converted to 8-oxo-7,8-dihydro-2’-deoxyguanine (8-oxodG), a miscoding lesion 
causing G:CT:A tranversion mutations by pairing with an adenine instead of a 
cytosine during replication (Melnikova and Ananthaswamy, 2005). ROS also causes 
damage to other cellular components including cell membranes by peroxidation of 
fatty acids within the phospholipid bilayer of the cell membrane, and damages 
proteins by forming carbonyl derivatives (Svobodova et al., 2006).  
 
1.3.2. Mitochondrial DNA damage and biological 
consequences 
Mitochondria are membrane-bound organelles producing approximately 90% of 
cellular energy via oxidative phosphorylation. Five multi-protein enzyme complexes 
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at the inner membrane of mitochondria form the electron transport chain and two 
non-enzyme electron carriers (coenzyme Q and cytochrome c) create an 
electrochemical proton gradient used to generate adenosine triphosphate (ATP) from 
products of cellular metabolism (Birch-Machin and Swalwell, 2010). Mitochondria 
have their own DNA (mtDNA), a small 16,569 base-pair (bp), circular double-
stranded molecule containing 37 genes, encoding 13 essential components of the 
electron transport chain, 22 transfer RNAs and two ribosomal RNAs required for 
their translation (Anderson et al., 1981, Andrews et al., 1999).  Due to proximity to 
the site of ROS production, mtDNA is very susceptible to oxidative damage. 
Leakage of electrons from electron transport chain during ATP production often 
leads to the generation of ROS, resulting in high turnover of ROS in these organelles. 
Mitochondria are deficient in nucleotide excision repair (NER) (Clayton et al., 1974, 
Sawyer and Van Houten, 1999) but do however possess a base excision repair (BER) 
pathway and increasing evidence supports the presence of single-strand break repair 
(SSBR), mismatch repair (MMR) or double-strand break repair (DSBR) (Kazak et 
al., 2012). Mutation frequency for mtDNA has been reported to be approximately 
10-50-fold higher than that of nuclear DNA (Wallace, 1992, Krutmann and 
Schroeder, 2009). More than 95% of mtDNA consists of exons (compared to 3% of 
nuclear DNA) and therefore mutations are more likely to affect these coding regions 
(Birch-Machin and Swalwell, 2010). However, the mitochondrial genome can 
tolerate very high levels of DNA damage due to the presence of multiple copies (2-
10) of mtDNA per mitochondrion (typical mammalian cell consists of 200 to 2000 
mitochondria) with the wild-type mtDNA compensating for the mutant mtDNA 
(Chomyn et al., 1992).   
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Amongst the spectrum of mitochondrial DNA damage, 4977 bp common deletion 
and a 3895 bp deletion have been identified as markers of photo-damage in human 
skin as their levels were shown to increase in sun-exposed skin, compared to non-
sun-exposed skin (Berneburg et al., 1997, Birch-Machin et al., 1998, Krishnan et al., 
2004). Furthermore, the 4977 bp common deletions have been shown to be inducible 
in vivo in normal human skin (Berneburg et al., 2004) and in vitro in primary human 
fibroblasts (Berneburg et al., 1999) by repetitive UVA irradiations. The 3895 bp 
mtDNA deletions were shown to be inducible in vitro in HaCaT keratinocytes by 
repetitive sub-lethal doses of UVA (Krishnan et al., 2004). The role of mtDNA 
deletions in skin carcinogenesis is currently unclear as although the 4977 common 
deletions were present in most human BCCs and SCCs, they were found at reduced 
rather than elevated levels (Kamenisch et al., 2007). It was thought that mtDNA 
deletions could be present in early skin carcinogenesis and disappear at later stages 
due to a selection mechanism that eliminates cells with intolerably low energy levels 
(Berneburg et al., 2006, Kamenisch et al., 2007).  
 
1.3.3. UVR damage to other macromolecules 
Proteins are highly susceptible to photo-oxidation due to direct absorption of UVR 
by their amino acid side chains (UVB chromophore). Proteins may also be damaged 
by UVR through both type 1 (free radical-induced) and type 2 (ROS-induced) 
photosensitization reactions. UVR also stimulates the activity of xanthine oxidase 
(XO) and nitric oxide synthase (NOS) in human keratinocytes, which lead to 
increased production of superoxide (O2.- ) and nitric oxide (NO) respectively 
(Villiotou and Deliconstantinos, 1995, Deliconstantinos et al., 1996a, 
Deliconstantinos et al., 1996b). O2.-  can combine with NO to produce peroxynitrate 
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(ONOO-) and peroxynitrous acid (HNO3). They can cause protein oxidation and 
nitrosylation, which lead to disruption of protein structure (Morgan et al., 2002, 
Pattison and Davies, 2006). Furthermore, photo-oxidation of proteins and DNA has 
been shown to initiate chain reactions, leading to damage to other macromolecules - 
e.g. peroxides formed on peptides and proteins can oxidize other susceptible protein 
residues and DNA bases, giving rise to DNA-protein adducts, which can damage 
surrounding molecules (Pattison and Davies, 2006). ROS and free radicals induced 
by UVR also cause damage to other cellular components including cell membranes 
by peroxidation of fatty acids within the phospholipid bilayer of the cell membrane, 
and proteins by forming carbonyl derivatives (Svobodova et al., 2006).  
 
1.3.4. UV-induced immune suppression 
Both UVB and UVA are potent suppressors of skin immunity (Halliday and Rana, 
2007). UVR depresses immunity at exposure doses that are a quarter to half of those 
required to cause sunburn (Halliday and Honigsmann, 2009). The importance of 
immunity in preventing cancer is observed in renal transplant recipients on 
immunosuppressive medications. In this population, there is an increased incidence 
of all cancers (13.7-fold increase), non-melanoma skin cancer (NMSC) (33-fold 
increase), and melanoma (3.3-fold increase) compared to an aged-matched non-
transplanted population (Moloney et al., 2006). UVR has also been implicated in 
suppressing immunity to viral infections in humans (Norval, 2006). Models of UVR 
suppression of contact hypersensitivity (CHS) and delayed hypersensitivity (DTH) 
have been used to study UV-immune suppression. CHS and DTH are type IV 
hypersensitivity reactions, which involve T cell mediated-immune responses to 
epicutaneously-applied allergen (e.g. nickel) in the case of CHS and to intradermally 
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injected antigen (e.g. tuberculin purified derivative) in the case of DTH. They differ 
in that MHC class I-restricted CD8+ T cells are thought to primarily mediate CHS, 
whilst MHC class II-restricted CD4+ T cells are involved in DTH (Gocinski and 
Tigelaar, 1990). UVR suppression of CHS and DTH is shown by a decrease in tissue 
swelling and/ or erythema due to a reduction in the immune response. This UV 
suppression of immune responses can both occur locally (i.e. when the site of UV 
and antigen exposure is the same) and systemically (i.e. when the site of UV 
exposure and antigen application is distal to each other) (Halliday, 2005). UVR has 
also been shown to depress both the induction of new immune response (primary 
sensitisation) and elicitation (reactivation) of memory immune responses to CHS and 
DTH antigens (Damian et al., 2001, Wolf et al., 2003). 
 
1.3.5. DNA damage as a trigger for UV-induced immune 
suppression 
DNA damage is now recognised as a molecular trigger for the suppression of 
immunity. The first evidence of this came from a study in the marsupial 
Monodelphus domestica. In these marsupials, endogenous photolyase, which is 
activated by visible light, repairs CPDs. When CPDs were repaired by activated 
photolyase, there was reversal of CHS suppression following UVB exposure 
(Applegate et al., 1989). In humans, application of liposomes containing T4 
endonuclease V (T4N5), a DNA enzyme which repairs CPD was shown to protect 
from UV-induced suppression of CHS to nickel (Kuchel et al., 2005). In this study, it 
was also demonstrated that repair of CPDs prevented UV-induced Langerhans cells’ 
depletion from the epidermis and inhibited epidermal infiltration of Mac387+ 
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macrophages, suggesting that DNA damage is involved in Langerhans cell loss from 
the epidermis, contributing to immune suppression (Kuchel et al., 2005). DNA 
damage also mediates the release of pro-inflammatory immunosuppressive 
cytokines, such as interleukin (IL)-10 and tumour necrosis factor (TNF)-α. 
Treatment with T4N5 liposomes prevented UV-induced IL-10 production by murine 
keratinocytes in vitro (Nishigori et al., 1996) and both IL-10 and TNF-α up-
regulation in humans in vivo (Wolf et al., 2000).  
 
1.3.6. ROS contribute to UV-induced immune suppression 
Some of the evidence that ROS and free radicals are involved in UV-induced 
immune suppression come from studies using Vitamin E.  High dose α-tocopherol 
(biologically active form of Vitamin E) prevented UV suppression of CHS responses 
to 2 4 6-trinitrochlorobenzene via inhibition of epidermal lipid peroxidation (Yuen 
and Halliday, 1997). An in vitro study using mixed epidermal lymphocyte reactions 
(MECLR), which allows a quantitative analysis of Langerhans cells’ function, 
demonstrated that Vitamin E prevented decrease in antigen-presenting function of 
Langerhans cells following UVA irradiation (ClementLacroix et al., 1996). Evidence 
that nitric oxide (NO) is involved in UV-induced immune suppression comes from a 
human study using the NO synthase inhibitor L-NMMA (Kuchel et al., 2003). In this 
study, topical application of L-NMMA prevented UV suppression of CHS to nickel. 
Further examination found that inhibition of NO by L-NMMA prevented epidermal 
Langerhans cells’ depletion and reduced the number of apoptotic keratinocytes 
following UV irradiation (Kuchel et al., 2003). 
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1.4. ACTINIC KERATOSES AND NON-MELANOMA 
SKIN CANCERS  
Actinic keratoses (AKs) are premalignant skin lesions affecting up to 60% of 
Australians over the age of 40 (Marks et al., 1988, Frost and Green, 1994). 
Clinically, AKs are characterised by a rough patch or papule, variably erythematous 
and scaling, typically found on sun-exposed skin in elderly fair-skinned individuals. 
AKs are often asymptomatic, although they may itch or be painful to touch (Moy, 
2000). The presence of AKs is associated with a 6-fold increased the risk of 
developing NMSCs (Chen et al., 2005). The estimated rates of transformation from 
AKs to squamous cell carcinomas (SCCs) vary considerably depending on studies 
from 0.075% to 20% per AK (Marks et al., 1986, Marks et al., 1988, Callen et al., 
1997). The risk of developing SCC over a 10 year-period is approximately 6-10% for 
a typical patient with 7 to 8 AKs (Dodson et al., 1991). Histological contiguity 
between some AKs and many SCCs suggests that AKs are early SCCs (Cockerell, 
2000, Salasche, 2000). UVR is the major causative factor in the development of 
AKs, as it is in NMSCs (Leffell, 2000). UVR causes UV-signature CT transitions, 
found commonly in the p53 tumour suppressor gene in AK lesions, as well as in 
SCCs (Ziegler et al., 1994, Nelson et al., 1994), supporting the malignant potential of 
AKs. Other risk factors for the development of AKs are the presence of 
immunosuppression, previous exposure to arsenic, previous psoralens plus UVA 
therapy (Ricotti et al., 2009), and possibly infection with human papillomavirus 
(HPV) (Forslund et al., 2003). Although most AKs do not progress to SCCs (Marks 
et al., 1986, Marks et al., 1988) and AKs may spontaneously regress (Harvey et al., 
1996), it is a common practice to treat most AKs, especially those with high risk of 
malignant transformation: large (more than 1 cm in diameter) and thick 
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(hyperkeratotic and indurated) AKs, AKs that are growing rapidly, bleeding, and 
erythematous (Quaedvlieg et al., 2006). Inflammation in AK is associated with 
transformation into SCC (Berhane et al., 2002).  
 
NMSCs are the most common cancers in white-skinned population, with the highest 
incidence in Australia was reported as more than five times the incidence of all other 
cancers combined in 2002 (Staples et al., 2006).  In Australia, the total cost of 
treating NMSCs (including diagnosis, treatment and pathology) was $511 million in 
2010. There were 767 347 NMSCs treated in Australia in 2010 and a further 22% 
increase in the numbers and total costs of NMSCs was projected between 2010 and 
2015 (Fransen et al., 2012). SCC tends to occur in those with greater cumulative sun 
exposure whereas BCC tends to occur in those with childhood exposure and strong 
intermittent exposure (Kricker et al., 1995, Rosso et al., 1996). The cytologic origin 
of BCC is still uncertain. BCC is thought to arise from interfollicular basal 
keratinocytes (Krompecher, 1903, Youssef et al., 2010, Sellheyer, 2011). However, 
some authors proposed that the outer root sheath cells of the hair follicle are the cells 
of origin of BCC (Kumakiri and Hashimoto, 1978, Asada et al., 1993). This is 
supported by the common occurrence of BCC on hair-bearing skin. SCC is derived 
from more differentiated keratinocytes (Ricotti et al., 2009). The majority of BCCs 
present as small, pearly nodules with surface telangiectasia. Various histological 
subtypes of BCCs are recognized, including nodular, cystic, micronodular, 
superficial, infiltrating, morphoeic, basosquamous and pigmented (Madan et al., 
2010). SCCs often arise in UV-exposed skin and present as slowly enlarging 
erythematous, scaly or crusted indurated plaques (Madan et al., 2010). BCCs do not 
have a known precursor lesion, whereas SCCs may arise from precursor lesions such 
as AKs and squamous cell carcinoma in situ (Bowen’s disease) (Rowert-Huber et al., 
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2007). Keratoacanthoma (KA) is a subtype of well-differentiated SCC, characterized 
by rapid onset, growth, and regression within months (Beham et al., 1998). BCCs 
usually invade tissue locally (“rodent ulcer”) and rarely metastasize, whereas SCCs 
have higher potential to metastasize. Important factors that increase the likelihood of 
recurrence and rarely metastatic disease in BCC include tumour size of more than 
5cm; tumours located on central face and ears; infiltrative, micronodular, and/ or 
morphoeic histological subtypes; perineural or perivascular involvement; recurrent 
lesions; and immunosuppression (Madan et al., 2010). Factors that indicate poorer 
prognosis and increased metastatic risk in SCC include tumour size of more than 
2cm; tumour depth of more than 2mm; tumours occurring on lip, ear, previous sites 
of radiation, thermal injury, chronic ulceration, inflammation, scar; desmoplastic, 
acantholytic, and spindle-cell features on histology; perineural involvement; 
recurrent lesions; and host immunosuppression (Cherpelis et al., 2002, Veness, 2006, 
Brantsch et al., 2008, Madan et al., 2010).  
 
Treatments for non-melanoma skin cancers (BCCs and SCCs) include physical 
treatments (surgical excision [including Mohs micrographic surgery], curettage and 
electrodessication, cryosurgery, photodynamic therapy, radiotherapy), and medical 
treatment (topical imiquimod, oral vismodegib) (Madan et al., 2010). Current 
approaches in AK treatments include lesion-directed therapies (cryotherapy, shave 
excision, curettage and electrodessication) and field-directed therapies (topical 5-
fluorouracil (5-FU), imiquimod, photodynamic therapy, diclofenac, retinoids, 
ingenol mebutate). Field-directed therapies have the additional benefit of targeting 
subclinical actinic keratoses (field cancerization) (Stockfleth, 2012).  
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1.5. DNA REPAIR AND GENOMIC MAINTENANCE IN 
HUMANS   
There are at least four partly overlapping repair pathways in humans: (1) nucleotide 
excision repair (NER), (2) base excision repair (BER), (3) recombinational repair, 
and (4) mismatch repair (MMR).  
 
1.5.1. Nucleotide excision repair (NER) 
NER repairs bulky DNA adducts including CPDs, (6-4)PPs, and other DNA lesions 
that cause distortions of the DNA double helix or interfere with DNA replication and 
transcription (Hoeijmakers, 2001). There are at least 28 proteins involved in NER 
and two sub-pathways of NER are recognized: global genomic-NER (GG-NER), 
which repairs lesions over the entire genome and transcription-coupled-NER (TC-
NER), which repairs transcription-blocking lesions in the transcribed DNA strands 
(Christmann et al., 2003).  
 
The importance of NER is best illustrated in UV-hypersensitive syndromes 
associated with inborn defects in NER proteins, such as xeroderma pigmentosum 
(XP) and Cockayne syndrome (CS). XP is an autosomal recessive disease caused by 
mutations in one of the seven genes (XPA-XPG, encoding XPA-XPG proteins) or 
deficiency in DNA Polε (involved in translesional DNA synthesis; XP variant). XP 
patients exhibit photosensitivity, increased skin pigmentation, photophobia, 
conjunctival growths, neurological degeneration, internal malignancies and a 10,000-
fold increased incidence of NMSCs and 2000-fold increased incidence of melanoma 
(Kraemer et al., 2007, Bradford et al., 2011). CS is caused by mutations in the CSA 
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or CSB gene, resulting in defect in TCR (“transcription syndrome”). In contrast to 
XP, CS patients do not show an increase in skin cancer incidence, which could be 
explained by the increased sensitivity of cells lacking TCR to apoptosis, hence 
eliminating damaged cells (Ljungman and Zhang, 1996).  
 
1.5.2. Base excision repair (BER) 
Base excision repair (BER) removes damaged DNA bases arising from cellular 
metabolism (ROS, methylation, deamination, and hydroxylation) and from UVR via 
generation of ROS (Hoeijmakers, 2001). The specificity of base repair is determined 
by different types of DNA glycosylases which excise different types of modified 
bases by cleaving the N-glycosidic bond between the damaged base and deoxyribose, 
creating either an abasic (apurinic/apyrimidinic [AP]) site or single strand break 
(SSB) (Fortini et al., 1999, Hoeijmakers, 2001). There is redundancy in the 
specificity of the glycosylases in that specific glycosylases may recognize more than 
one type of base lesion and specific base lesions may be recognized by more than 
one type of glycosylase, e.g. human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) 
specifically cleaves 8-oxodG and FapyG lesions, nei endonuclease VIII-like 1 
(NEIL1) removes FapyG and 4,6-diamino-5-formamidopyrimidine (Morland et al., 
2002, Parsons et al., 2005). AP sites can also occur spontaneously through 
hydrolysis. AP endonuclease (APE) 1 cleaves the DNA strand at the AP site. X-Ray 
Repair Cross-Complementing Group 1 (XRCC1) recruits repair proteins and 
Poly(ADP-ribose) polymerase (PARP) binds to and is activated by DNA strand 
breaks and is involved in chromatin modification. Polynucleotide kinase (PNK) trims 
the 3’-terminal residue of SSB to prepare the strand for repair synthesis. Two BER 
sub-pathways (short-patch BER and long-patch BER) were recognized with the 
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short-patch BER considered to be the dominant mode of BER repair in mammals 
(Hoeijmakers, 2001).  
 
Oxidative DNA damage is widely accepted to be involved in skin carcinogenesis and 
ageing. UV-induced 8-oxodG is highly mutagenic, as it mispairs readily with 
adenine residues, leading to G:CT:A transversion mutations (Shibutani et al., 
1991), frequently found in the basal epidermal layer of human skin cancers (Agar et 
al., 2004). 8-oxodG repairs by BER or NER (TCR). Within the BER pathway, 
hOGG1 is highly specific to excise 8-oxodG adducts from the DNA strand. OGG1 
knockout mice have a greater incidence of UV-induced skin tumours (Kunisada et 
al., 2005) and topical application of OGG1 liposomes to mice chronically irradiated 
with UVB, significantly decreased tumour progression as measured by size and 
grade (Wulff et al., 2008). More recently, there is evidence that lower levels of 
hOGG1 and correspondingly higher level of 8-oxodG was found in human basal cell 
carcinomas (BCC) compared to normal surrounding skin (Huang et al., 2012). BER 
mechanisms have been detected in both nuclear as well as mitochondrial DNA 
(Maynard et al., 2009). The incidence of NMSCs increases with increasing age 
(Madan et al., 2010), and an age-associated decline in hOGG1 (Chen et al., 2003) 
and transport of hOGG1 into mitochondria has been reported (Szczesny et al., 2003).  
 
1.5.3. Recombinational repair 
Both NER and BER repair one strand of DNA in a “cut-and-patch” fashion, 
removing damaged DNA and using the intact complementary strand as a template to 
fill in the gap. Double stranded breaks (DSBs) induced by ionizing radiation, UVR, 
free radicals, chemotherapeutic chemicals and DSBs created during replication of a 
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single strand breaks (SSBs), are repaired by recombinational repair. The 
recombinational repair pathway can be divided into two subpathways: homologous 
recombination (HR) and non-homologous end joining (NHEJ) (Hoeijmakers, 2001).  
 
Ataxia telangiectasia (AT) is an inherited syndrome caused by a defect in 
recombinational repair. It is characterized by a 60-180-fold increased risk of 
malignancy (particularly haematological), immunodeficiency, hypersensitivity to X-
rays, cerebellar degeneration and telangiectasia (Meyn, 1997, Hoeijmakers, 2001). 
Other disorders which may have defects linked to homologous recombination 
include Werner syndromes, Bloom syndromes, Rothmund-Thomson syndromes, and 
Fanconi anaemia (Hoeijmakers, 2001). All are characterized by spontaneous 
chromosomal instability, premature ageing, and increased susceptibility to cancers.  
 
1.5.4. Mismatch repair (MMR) 
Mismatch repair (MMR) removes base mismatches resulting from spontaneous- and 
induced- base deamination, oxidation, methylation, and replication errors (Modrich 
and Lahue, 1996). Inherited mutations in MMR gene(s) lead to hereditary 
nonpolyposis colorectal cancer (HNPCC, Lynch syndrome), characterized by 
significantly increased risk of various types of cancers, in particular colon and 
endometrium (Aarnio et al., 1995, Steinke et al., 2013). Muir-Torre syndrome (MTS) 
is a rare variant of HNPCC in which features of HNPCC present together with 
cutaneous features of multiple sebaceous adenomas, carcinomas, keratoacanthomas, 
and basal-cell carcinomas with sebaceous differentiation (Ponti and de Leon, 2005). 
Microsatellites are sequences of repetitive DNA with repeating units of 1 to 7 bp. 
These regions are prone to replication errors and are normally repaired by MMR. 
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Defects in MMR result in microsatellite instability (MSI), found in most tumours in 
patients with HNPCC and MTS (Steinke et al., 2013).  
 
1.5.5. Roles of poly(ADP-ribose) polymerase (PARP) in 
DNA repair 
Poly(ADP-ribose) polymerase (PARP) nuclear enzyme is recognized to have an 
important role in DNA repair (Christmann et al., 2003).  There are 6 members of the 
PARP family (PARP-1, PARP-2, PARP-3, vault(v)-PARP and Tankyrases 1 and 2). 
Both PARP-1 and PARP-2 were reported to be involved in DNA repair, genomic 
stability, gene transcription, and telomere regulation, although PARP-1 is the most 
abundant and well characterized (Javle and Curtin, 2011). PARP-3 has a role in 
DNA strand break repair (Boehler et al., 2011). PARP-1, physically attached to 
chromatin, is activated by and binds to single-and double strand breaks (SSB, DSB 
respectively) via its zinc finger motifs (Miwa and Masutani, 2007). PARP-1 
activation leads to consumption of NAD and release of nicotinamide to form 
poly(ADP-ribose) polymers. The highly negatively charged poly(ADP-ribose) 
polymers form a scaffold essential in recruitment of XRCC1 (De Murcia et al., 1994)  
and DNA Polymerase-β (Dantzer et al., 1999), both are key proteins in BER. PARP-
2 has been shown to associate with XRCC1, DNA Polymerase-β, and DNA ligase III 
(Schreiber et al., 2002). The poly(ADP-ribose) polymers also interact with 20s 
proteasomes, increasing its proteolytic activity (Mayer-Kuckuk et al., 1999), which 
leads to degradation of oxidatively damaged histones, chromatin remodelling, and 
finally facilitation of access of DNA repair enzymes to the site of DNA damage 
(Christmann et al., 2003). PARP-1 is also considered to have roles in regulation of 
DNA repair, cell cycle, transcription, and apoptosis via poly(ADP)ribosylation of 
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DNA repair and DNA damage response (DDR) proteins  including p53, p21, XPA, 
DNA mismatch repair protein MutS homologue-6 (MSH6), DNA ligase III, XRCC1, 
DNA-dependent protein kinase, catalytic subunit (DNA-PKcs), Ku70, nuclear factor-
kappa beta (NF-κΒ), inducible nitric oxide synthase, caspase-activate DNase, and 
telomerase (Pleschke et al., 2000, Christmann et al., 2003).  
 
1.5.6. Roles of ATP-dependent chromatin-remodelling 
complexes in DNA repair 
Accumulating evidence indicates that ATP-dependent chromatin-remodelling 
complexes play important roles in regulation of transcription, cell-cycle progression, 
replication, and various DNA repair pathways including NER, BER, HR, and NHEJ 
(Menoni et al., 2007, Lans et al., 2012, Lai et al., 2013). Remodelling of chromatin 
structure is necessary in DNA repair and is highly conserved in yeast, Drosophila, 
mice and humans. Chromatin remodelling is dependent on energy from hydrolysis of 
ATP to reorganize DNA-histone (nucleosome) structures to facilitate DNA repair 
(Lai et al., 2013). The nucleosome, the basic structural unit of chromatin, consists of 
147 base pairs of DNA wrapped around a histone octamer (2 copies of each H2A, 
H2B, H3, and H4) (Luger et al., 1997). There are currently four classes of ATP-
dependent chromatin-remodelling complexes: (1) SWI/SNF; (2) inositol requiring 80 
(INO80); (3) chromodomain helicase DNA binding (CHD); and (4) imitation switch 
(ISWI). The ATP-dependent chromatin-remodelling complexes are large, containing 
multiple subunits, including the central ATPase subunit (Lans et al., 2012). In 
humans, there are two known SWI/SNF ATPase subunits, brahma (BRM) and 
brahma-related gene 1 (BRG1) (Mohrmann and Verrijzer, 2005). BRM may also 
function as a tumour suppressor and increased frequency of mutations in this gene 
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has been reported in human BCCs and SCCs (Moloney et al., 2009). More recently, 
it was also reported that both BRM and BRG1 subunits were reduced in both SCCs 
and BCCs, compared to premalignant AKs (Bock et al., 2011).  
 
1.6. GENE MUTATIONS AND INDUCTION OF SKIN 
CARCINOGENESIS 
UV-induced DNA damage is central in the initiation phase of skin carcinogenesis 
(Melnikova and Ananthaswamy, 2005). UV-induced photolesions, including CPDs, 
(6-4)PPs, and 8-oxodG, DNA strand breaks, DNA crosslinks and DNA-protein 
crosslinks are potentially capable of leading to mutations if unrepaired prior to cell 
division.  Mutations in the P53 tumour suppressor gene occur early in cutaneous 
photocarcinogenesis (Ichihashi et al., 2003, Melnikova and Ananthaswamy, 2005). 
Mutations in P53 have been found in approximately 40-60% of human BCCs (Rady 
et al., 1992, Ziegler et al., 1993, Bolshakov et al., 2003), 50-80% of premalignant 
AKs (Nelson et al., 1994, Ziegler et al., 1994) and more than 90% of human SCCs 
(Brash et al., 1991, Ziegler et al., 1993, Nelson et al., 1994).  Of these P53 mutations, 
UV-signature C  T transitions and CC  TT double transitions at dipyrimidine 
sequences were found in more than 65% of BCCs and more than 75% of AKs and 
SCCs (Brash et al., 1991, Rady et al., 1992, Ziegler et al., 1993, Soehnge et al., 1997, 
Bolshakov et al., 2003). UVR, DNA damage, and oxidative stress stimulate an 
increase in p53 proteins, which induces cell cycle arrest at the G1 phase, allowing 
DNA repair to occur before cell replication (Kuerbitz et al., 1992, Zhan et al., 1993) 
or apoptosis when DNA damage is excessive (Yonishrouach et al., 1991). p53 is also 
involved in the NER-GGR pathway by inducing the transcription of XPE, facilitating 
the recruitment of XPC and transcription factor II human (TFIIH) to the site of CPDs 
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and (6-4)PPs (Wang et al., 2003, Fitch et al., 2003, Wang et al., 2004). p53 
stimulates BER by direct interaction with BER proteins APE1, DNA Polymerase β, 
and OGG1 (Zhou et al., 2001, Achanta and Huang, 2004).  
 
Studies in human and murine skin tumours suggest that inactivating mutations in 
tumour suppressor genes such as PTCH1 and/ or INK4α-ARF (p16-p14) and 
activating mutations in protooncogenes such as RAS, are involved in malignant 
transformation (Melnikova and Ananthaswamy, 2005). Germ line mutations in the 
patched 1 (PTCH1) tumour suppressor gene are found in the majority of patients 
with naevoid basal-cell carcinoma syndrome (Gorlin syndrome), an autosomal 
dominant genetic disorder characterized by multiple BCCs, palmoplantar pitting, and 
odontogenic keratocysts (Soufir et al., 2006). In sporadic BCCs, 30-40% the tumours 
had PTCH1 mutations with 41% of the mutated PTCH1 contained UV-specific 
landmark mutations (Lacour, 2002). p16 and p14 tumour suppressor genes are 
encoded within the cyclin-dependent kinase inhibitor 2A (CDKN2A) locus on 
chromosome 9p21 and both function as cell cycle inhibitors via the p53 and 
retinoblastoma (Rb) pathways. Inactivating mutations in either p16 or p14 lead to 
unrestrained cell proliferation, which characterized tumour growth. Brown et al 
analysed 40 human SCCs and found that 76% of the tumours had alterations in 
CDKN2A locus encoding for both p16 and p14 (Brown et al., 2004). Mutations at 
exon 2 of CDKN2A locus (common to both p16 and p14) were detected in 4 out of 
20 human SCCs (20%) and 3 (75%) of the mutated genes contained UV-landmark 
mutations (Soufir et al., 1999). Protooncogenes Harvey(Ha)-RAS, Kirsten(Ki)-RAS, 
and N-RAS encode 21-kDa guanosine triphosphate (GTP)-binding protein ras 
(Barbacid, 1987). Activation of ras downstream effector pathways, including 
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RAF/MEK/ERK mitogen activated protein kinases (MAPK), type I 
phosphatidylinositol-3 kinases/protein kinase B (PI3K/AKT), and protein kinase 
C/phospholipase Cε, leads to promotion of cellular proliferation and tumorigenesis 
(Kern et al., 2011). In murine models of chemical-induced skin carcinogenesis, RAS 
mutation is central in the progression of skin papilloma to SCC (Woodworth et al., 
2004). RAS deletion prevented tumour development in mouse models of chemical 
skin carcinogenesis (Ise et al., 2000). A RAS mutation frequency of 10-40% was 
reported for BCCs and SCCs with most mutations occuring at UV-sensitive 
pyrimidine-rich sequences (Vanderschroeff et al., 1990, Pierceall et al., 1991, 
Campbell et al., 1993, Wilke et al., 1993).  
 
1.7. UV-INDUCED SIGNALLING PATHWAYS  
UVR activates signalling pathways involved in cell survival and proliferation 
(Bowden, 2004). UVB activates MAPK signalling cascases (p38 MAPK, Jun N-
terminal kinase [JNK] and extracellular signal-regulated kinase 1/2 [ERK1/2]), 
which lead to a transcriptional activation of activator protein-1 (AP-1), and 
cyclooxygenase-2 (COX-2) genes (Chen et al., 2001, Bowden, 2004).  AP-1 
induction is implicated in both chemical and UVB-induced skin tumour promotion in 
mouse in vivo and in human keratinocytes (Young et al., 1999, Einspahr et al., 2002). 
COX2, a key enzyme in arachidonic acid metabolism and prostaglandin production, 
plays a key role in UV-induced inflammation, immunosuppression, and keratinocyte 
proliferation (Bowden, 2004). UVB increased COX2 expression in both cultured 
human keratinocytes and human skin (Buckman et al., 1998, An et al., 2002). 
Elevated COX2 and PGE2 expression was also found in AKs and NMSCs (Buckman 
et al., 1998, Muller-Decker et al., 1999). UV-induced oxidative damage mediates the 
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activation of nuclear factor-kappa beta (NF-κB) (Vile et al., 1995), a transcription 
factor involved in a wide range of cellular processes including inflammatory, 
immune responses, cell survival and cell proliferation (Ghosh and Karin, 2002). NF-
κB upregulates expression of proinflammatory cytokines including IL-10 and TNF-
α, known to mediate UV-induced immune suppression (Ichihashi et al., 2003). 
Activation of NF-κB is central in the progression of skin carcinogenesis. NF-κB 
regulates expression of several growth factors, oncogenes, and genes encoding cell 
adhesion proteins and proteases of extracellular matrix, involved in tumour growth, 
invasion and metastasis (Pahl, 1999, Baldwin, 2001). There is evidence that NF-κB 
activation requires PARP-1 with deletion of PARP-1 genes in mice resulting in 
abrogration of NF-κB activation and insensitivity to chemical induced skin 
carcinogenesis (Martin-Oliva et al., 2004).  
 
1.8. PREVENTION OF ACTINIC KERATOSES AND 
NON-MELANOMA SKIN CANCERS IN HUMANS 
1.8.1. Sun avoidance, shade, clothing and filtering of 
sunlight with sunscreens 
Fundamental to the management of AKs is effective preventive measures, including 
avoidance of excessive exposure to natural and artificial UV radiation, wearing wide-
brimmed hats, wrap-around sunglasses and protective clothing, applying broad 
spectrum sunscreen on sun-exposed areas, and regular skin self-examination. 
Regular dermatologic examination in high-risk patients is also highly recommended. 
Daily use of sunscreen has been reported to significantly reduce the development of 
new AKs and to increase the rate of remission of existing AKs when compared with 
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a vehicle cream (Thompson et al., 1993, Naylor et al., 1995) (Table 1.1). Annual 
reductions in AKs with sunscreen use of up to 50% was detected in the later study 
(Naylor et al., 1995). In a case control study of 120 organ-transplant recipients, daily 
use of broad-spectrum sunscreen over 2 years was shown to significantly reduce the 
incidence of both AKs and SCCs (Ulrich et al., 2009). Prolonged sunscreen use (up 
to 8 years) has been shown to reduce the incidence of SCCs by 38% (van der Pols et 
al., 2006). However, there is not yet clear evidence that it prevents BCCs (van der 
Pols et al., 2006, Ulrich et al., 2009) or melanoma (Dennis et al., 2003), although the 
incidence of melanoma may be reduced after prolonged follow-up (Green et al., 
2011).  
 
1.8.2. Chemoprevention of actinic keratoses and non-
melanoma skin cancers 
Oral beta carotene, selenium, topical vitamin E 
Convincing evidence from large randomized placebo controlled clinical trials shows 
that oral beta carotene has no significant protective effect against AKs (Darlington et 
al., 2003), BCCs or SCCs (Greenberg et al., 1990, Green et al., 1999, Frieling et al., 
2000) (Table 1.1). Similarly oral selenium at 200µg daily for an average of 4.5 years 
had no effect on the incidence of BCCs or SCCs in a large randomized controlled 
placebo controlled trial involving 1312 participants (Clark et al., 1996). A 
randomized double-blind, split right and left comparison study on DL-α-tocopherol 
(vitamin E) cream or base cream applied twice daily for 5 months found no 
significant difference in the number of AKs between the two groups (Foote et al., 
2009).  
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Table 1.1. Sunscreen and/ or oral betacarotene studies for AK and/or NMSC chemoprevention in humans 
Study design  Patients  (lesions) Follow-up Treatment effects References 
Sunscreen      
RCT, double-blind 
Broad spectrum sunscreen SPF 17 or 
base cream daily for 7 months 
588 (3498) 7 months Mean AK (±SE): 
Sunscreen: decrease by 0.6±0.3 vs base cream: increase by 
1±0.3 – difference: 1.53 (95%CI:0.81-2.25) 
Reduction in new lesion for sunscreen group compared 
to base group – RR: 0.62 (95%CI: 0.54-0.71) 
Higher remissions for existing AKs for sunscreen group 
compared to base group - OR: 1.53 (95%CI: 1.29-1.8) 
(Thompson et 
al., 1993) 
RCT, double-blind 
Sunscreen SPF 29 or base cream 
daily for 2 years 
50 (baseline mean  
AK±SD: 8.12±17.7 in 
sunscreen group vs 
11.4±15.4 in control 
group) 
2 years Annual rates of AKs (mean±SD AKs/year): 
Sunscreen: 13.6±18.5 vs base cream: 27.9±31.8  
Reduction in annual rate of AK with sunscreen:  
50% (p=0.023, Mann-Whitney U test) 
36% (p=0.001, Poisson regression) 
(Naylor et al., 
1995) 
RCT, double-blind 
Broad spectrum sunscreen SPF 15   
or no sunscreen (discretionary 
sunscreen use) 
1621; 1483 were 
followed up for skin 
cancers 
8 years No effect on incidence of BCC by sunscreen use in the 
overall 8 year follow up 
Late follow up (last 3 years) showed a non-significant 25% 
decrease in BCC incidence in sunscreen group - RR: 0.75 
(95%CI: 0.49-1.14) 
Significantly lower incidence of SCC by sunscreen use: 
both number of SCCs – 38% lower, RR: 0.62 (95%CI 0.38-
0.99) and persons newly affected by SCC – 35% lower, RR: 
0.65 (95%CI:0.43-0.98) 
(van der Pols 
et al., 2006) 
Prospective, case-control  
Broad spectrum sunscreen SPF 50 
plus daily or sun protective 
measures only (sun avoidance, 
protective clothing) 
120 organs 
transplant recipients 
(heart, kidney, liver); 
42 developed 8 new 
SCCs, 11 new BCCs 
24 months Significantly lower incidence of AKs in the sunscreen 
group compared to control group:  
89 vs 273 (mean difference 3.07; p<0.01; 95%CI:1.76-4.36)  
Significantly lower incidence of SCC in the sunscreen 
group compared to control group: 0 vs 8 (p<0.01) 
Non-significant reduction in the incidence of BCC in the 
sunscreen group compared to control group: 2 vs 9, ns 
(Ulrich et al., 
2009) 
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Sunscreen ± oral beta carotene     
RCT, double-blind 
Broad spectrum sunscreen SPF 15 + 
30 mg beta carotene daily or 
sunscreen + placebo tablet daily or 
no sunscreen (discretionary 
sunscreen use) + beta carotene daily 
or no sunscreen + placebo tablet 
daily 
1621 (baseline AK 
count not mentioned) 
4.5 years (Feb 
1992-Aug 
1996) 
 
Ratio of AK count in sunscreen vs no sunscreen:  
In 1994 relative to 1992 – sunscreen: 1.2 (95%CI:1.04-
1.39) vs no sunscreen: 1.57 (95%CI: 1.35-1.84) 
In 1996 relative to 1994 – no significant reduction in the 
rate of AK prevalence  
Reduction in AK in sunscreen vs no sunscreen: 24% 
(equivalent to prevention of 1 AK/person over 1992-1994 
period) 
No effect on the rate of AK prevalence in beta carotene 
compared to placebo groups 
(Darlington et 
al., 2003) 
RCT, double-blind 
Broad spectrum sunscreen SPF 15 + 
30 mg beta carotene daily or 
sunscreen + placebo tablet daily or 
no sunscreen (discretionary 
sunscreen use) + beta carotene daily 
or no sunscreen + placebo tablet 
daily 
1621; 1383 follow up 
for skin cancer; 250 
developed 758 new 
skin cancers  
4.5 years Incidence of first new skin cancers (BCC or SCC) 
No significant difference between sunscreen and no 
sunscreen groups and between beta carotene and placebo 
groups  
Number of skin cancers: 
No effect on incidence of BCC by sunscreen use or by beta 
carotene 
Significantly lower incidence of SCC in the sunscreen 
compared to no sunscreen groups: 1154 vs 1832 per 
100,000; RR: 0.61 (95%CI: 0.46-0.81) 
(Green et al., 
1999) 
Oral beta carotene     
RCT, double-blind 
Beta carotene 50 mg or placebo 
daily 
1805 5 years No significant differences between beta carotene and 
placebo groups: 
 In incidence rate of first new BCC or SCC – RR: 1.05 
(95%CI:0.91-1.22) and in the mean number of new BCC or 
SCC per patient-year 
(Greenberg et 
al., 1990) 
RCT, double-blind 
Beta carotene 50 mg on alternate 
day or placebo on alternate day 
22,071  12 years No significant difference between beta carotene and 
placebo groups in incidence of first new BCC (RR: 0.99; 
95%CI: 0.92-1.06) or SCC (RR: 0.97; 95%CI:0.84-1.13) or 
both (RR: 0.99; 95%CI: 0.92-1.06)  
(Frieling et 
al., 2000) 
RR: rate ratio; OR: odds ratio; ns: not significant.  
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Diet 
In a large prospective cohort study involving 1119 participants followed-up for 4.5 
years, diets rich in oily fish (average 1 serving every 5 days) and wine (average half 
a glass a day) were significantly associated with decreased AKs acquisition by 28% 
and 27% respectively (Hughes et al., 2009). Using the same study populations 
followed-up for 11 years, a significant decrease in the risk of SCCs was associated 
with high intakes of green leafy vegetables and fruits in participants with previous 
skin cancers (Hughes et al., 2006).  A significant increase in the risk of SCCs was 
associated with high intakes of unmodified dairy products (whole milk, cheese, 
yogurt) (Hughes et al., 2006), high total fat intake (Ibiebele et al., 2009) and higher 
intake of meat and fat (Ibiebele et al., 2007). Dietary patterns (“meat and fat” or 
“vegetable and fruits”) and dietary fats were not associated with BCC risk (Ibiebele 
et al., 2007, Ibiebele et al., 2009). However, higher caffeine intake (four cups of 
regular coffee per day) was associated with a 25% lower risk of BCCs. No 
association between SCCs and caffeine intake was found (Miura et al., 2013).  
 
T4 endonuclease V (T4N5) 
T4N5, a DNA repair enzyme isolated from Escherichia coli, repairs UV-induced 
CPDs. When T4N5 is incorporated into liposomes for topical application, it is 
absorbed intracellularly and delivered into the nucleus of keratinocytes and LCs 
(Cafardi and Elmets, 2008). In a randomized double blind vehicle controlled trial in 
30 patients with XP, daily application of T4N5 liposome lotion to face and arms for 
1 year reduced the incidence of AKs by 68% compared to placebo. The mean annual 
rate of new BCCs was 30% lower in the T4N5 group compared to placebo, although 
the rate of new SCC development was not large enough for statistical analysis 
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(Yarosh et al., 2001). In a recent prospective study in 17 participants with mean AK 
count of 10, application of T4N5 lotion twice daily to the entire face for 48 weeks 
significantly reduced AKs compared to baseline AK counts (DeBoyes et al., 2010). 
 
Retinoids 
Topical retinoids have been shown to be an effective treatment for AKs, but 
ineffective in preventing new BCCs or SCCs (Weinstock et al., 2012). Retinoids, the 
most studied chemopreventive agents, are postulated to work via activation of 
nuclear retinoid receptors, down-regulation of AP-1 responsive genes, induction of 
growth arrest, apoptosis and differentiation (Nicholson et al., 1990, Schule et al., 
1991, Niles, 2000). In a randomized double blind placebo controlled trial involving 
2,297 moderate risk patients (more than 10 AKs and at most 2 SCCs or BCCs at 
baseline), oral retinol 25,000 IU daily for 5 years was significantly more effective 
than placebo in preventing SCC, although it had no effect on BCC (Moon et al., 
1997) (Table 1.2). However, both oral retinol 25,000 IU and oral isotretinoin 5-
10mg, taken daily for 3 years, had no significant effect compared to placebo on 
BCCs or SCCs in 525 high-risk subjects (history of at least 4 BCCs or SCCs) 
(Levine et al., 1997). Oral isotretinoin was effective in preventing skin cancers in XP 
patients (Kraemer et al., 1988), although it was ineffective in preventing BCCs in 
normal populations with 2 or more BCCs at baseline (Tangrea et al., 1992). Both oral 
acitretin and etretinate are effective in preventing new BCCs and SCCs in renal 
transplant recipients (Bavinck et al., 1995, Gibson et al., 1998, McKenna and 
Murphy, 1999). Oral retinoids are commonly associated with adverse effects such as 
elevated serum lipids, elevated liver enzymes, dry mucous membranes and skin and 
musculoskeletal symptoms (arthralgia, myalgias, fatigue, muscle weakness, 
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tendinitis). Skeletal abnormalities (diffuse skeletal hyperostosis, osteophyte 
formation) are rarely reported with high dose and prolonged therapy. Oral retinoid is 
also a known teratogen and absolutely contraindicated in pregnancy, nursing 
mothers, and women who are likely to become pregnant and unable to be compliant 
with contraception (Wright et al., 2006).  
 
2-(Difluoromethyl)-dl-ornithine (DFMO) 
DFMO is an irreversible inhibitor of ornithine decarboxylase (ODC), a rate-limiting 
enzyme in polyamine biosynthetic pathway. Polyamines (putrescine, spemidine, 
spermine) are upregulated during the promotion phase of chemical and UVB models 
of mouse skin carcinogenesis. Inhibition of polyamine production by DFMO 
prevented tumour formation in mice (Weeks et al., 1982, Takigawa et al., 1983, 
Verma et al., 1986). In a randomized double blind vehicle controlled right and left 
dorsal forearm comparison study involving 48 patients, 10% DFMO ointment 
applied twice daily for 6 months significantly reduced AKs by 23.5% compared to 
vehicle. 10% DFMO ointment was associated with local skin inflammation with 
severe and moderate skin reactions reported in 4.2% and 10.4% of participants 
respectively (Alberts et al., 2000). In a more recent randomized double blind placebo 
controlled trial, oral DFMO 500 mg/m2/kg daily for 4-5 years had no significant 
effect in preventing new NMSCS compared to placebo, although separate analysis on 
BCC incidence demonstrated significant reduction in the number of new BCCs with 
DFMO compared to placebo. No significant reduction in the number of new SCCs 
was found. Oral DFMO was associated with high-frequency hearing loss in 10.8% of 
participants with 19% of these subjects having persistent abnormal audiogram at 6 
months after stopping the drug (Bailey et al., 2010).  
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Table 1.2. Retinoid studies for AK and/or NMSC chemoprevention in humans 
Study design  Patients  (lesions) Follow-up Treatment effects References 
RCT, double-blind 
Oral retinol 25,000 IU or placebo 
daily for 5 years 
2297 (>10 AKs and at 
most 2 SCCs or BCCs) 
Median follow 
up time 3.8 
years 
Compared with placebo, retinol was effective in preventing 
SCC (hazard ratio for first new SCC 0.74; 95%CI:0.56-0.99; 
p=0.04), but was not effective in preventing BCC (hazard 
ratio for first new BCC 1.06; 95%CI:0.86-1.32; p=0.36) 
(Moon et al., 
1997) 
RCT, double-blind 
Oral retinol 25,000 IU or isotretinoin 
5-10 mg or placebo daily for 3 years 
525 (high risk goup 
with history of at 
least 4 BCCs or SCCs) 
3 years No differences in either time to development of first skin 
cancer or total number of tumors were shown among the 3 
groups 
(Levine et al., 
1997) 
Controlled prospective study 
(comparison of event before, during, 
and after cessation of treatment) 
Oral isotretinoin 2mg/kg (body 
weight) per day for 2 years 
5 patients with XP 
(total 121 tumours in 
2 years interval 
before treatment) 
During 2 
years of 
treatment 
period and 
1 year of 
continued 
observation 
following 
cessation of 
treatment 
During 2 years of treatment with isotretinoin: 
Total 25 tumours (mean 5, range 3-9) 
Average reduction in skin cancers of 63% (p=0.019) 
 
After isotretinoin cessation: 
Increase tumour frequency by an average of 8.5-fold (range 
2- to 19-fold) over the frequency during treatment 
(p=0.007) 
 
(Kraemer et 
al., 1988) 
RCT, double-blind 
Isotretinoin 10 mg or placebo daily 
for 3 years 
981 (2 or more BCC 
during 5 years before 
the study) 
3 years  No difference in occurrence of BCC between the treated 
and placebo groups 
(Tangrea et 
al., 1992) 
RCT, double-blind 
Acitretin 30 mg or placebo daily for 
6 months 
44 renal transplant 
recipients (more than 
10 AKs) 
6 months In patients with no history of skin cancer: 
Acitretin group had significantly lower numbers of patients 
with new skin cancers (BCCs and SCCs) (p=0.01), as well a 
lower total numbers of skin cancers (p=0.009) compared 
with the placebo group 
 
In patients with established history of skin cancer: 
Significant decrease in the numbers of patients developed 
new skin cancers in the acitretin group compared to the 
(Bavinck et 
al., 1995) 
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placebo group (1 of 9 patients vs 7 of 10 patients; p=0.009) 
Acitretin 30 mg daily for 6 months had no damaging effect 
on graft kidney 
Controlled prospective study 
(comparison of event in 5 years 
before treatment and during 5 years 
of treatment) 
Acitretin 0.3 mg/kg daily  
16 renal transplant 
recipients (at least 2 
NMSCs before the 
study) 
5 years 
4 years follow 
up after 
cessation 
Significant decrease in cumulative number of new skin 
cancers (BCCs and SCCs) during the treatment period in 
comparison with pre-treatment interval (21 vs 77; 
p=0.007) 
50% of patients had no skin cancers during treatment 
Most significant reduction in patients with prior history of 
5 or more NMSCs (6 patients in this group had 56 NMSCs 
pretreatment vs 10 NMSCs during treatment interval; 
p=0.004) 
Sustained chemopreventative effect over 4-year period 
No impairment in renal function with acitretin 
(McKenna 
and Murphy, 
1999) 
RCT, double-blind, cross over study 
Etretinate 75 mg or placebo daily for 
2 months before cross over  
50 (baseline number 
of AKs no 
mentioned); 28 
patients had history 
of skin cancer 
4 months 44 patients completed treatment with etretinate – 37 had 
CR or PR of AKs 
42 patients completed treatment with placebo – only 2 
showed CR or PR of AKs 
(Moriarty et 
al., 1982) 
Controlled prospective study 
(comparison of event before and 
during treatment) 
Etretinate 0.3 mg/kg per day for 3, 6, 
12, 18 months 
11 renal transplant 
recipients (at least 2 
NMSCs before the 
study) 
3, 6, 12, 18 
months 
Decrease in numbers of NMSCs during the 3- and 6-month 
treatment interval compared with pre-treatment interval 
(p<0.001) 
Continued decline in skin cancers incidence at 12- and 18-
months (statistically not significant) 
(Gibson et al., 
1998) 
XR: xeroderma pigmentosum; CR: complete remission; PR: partial remission. 
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Oral nonsteroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs inhibit COX activity, decreasing prostaglandins, which are involved in the 
promotion phase of both chemical and UVB induced skin carcinogenesis in mice 
(Pentland et al., 1999, Fischer et al., 1999). In a prospective cohort study in high-risk 
populations (132 SCCs in 1093 participants in 5 years), NSAID use was found to be 
associated with a modest reduction in the numbers of SCCs, and to a lesser extent 
BCCs (Grau et al., 2006) (Table 1.3). However, in another prospective cohort study 
in 2297 subjects with moderate risk (more than 10 AKs and at most 2 SCCs or 
BCCs), significant protection from NMSCs was associated with NSAID use (Clouser 
et al., 2009). A large case-control study that compared 86 participants with SCC with 
187 age- and sex- matched control participants, showed that regular use of NSAIDs 
reduced the risk of AKs and SCCs (Butler et al., 2005). In a recent randomized 
double blind placebo controlled trial, celecoxib 200mg twice daily for 9 months 
significantly reduced the incidence of BCCs and SCCs, although no significant 
reduction in AKs was found (Elmets et al., 2010). Celecoxib 200mg twice daily for 3 
years also caused a significant 30% reduction in the numbers of BCCs, compared to 
placebo in 60 patients with Gorlin syndrome (Tang et al., 2010). Prolonged NSAID 
use is however associated with significant adverse effects including gastritis, 
hypersensitivity, hypertension and gastrointestinal haemorrhage (Barkin et al., 2010).   
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Table 1.3. NSAID studies for AK and/or NMSC chemoprevention in humans 
Study design  Patients  (lesions) Follow-up Treatment effects References 
Prospective cohort study 
Association between NSAIDs use and 
the risk of BCC and SCC 
 
1805 (132 SCCs 
arising in 1093 
participants); use of 
NSAIDs reported in 
over 50% of 
participants 
5 years 
(participants 
asked OTC 
and 
prescription 
medications 
at baseline 
and every 4 
months) 
Modest, non-significant reduction on the numbers of BCCs 
and SCCs with NSAIDs use 
Stronger association with SCCs: 
NSAIDs use during previous year reduced the risk of SCC by 
29% (adjusted OR for baseline use 0.71; 95%CI:0.48-1.04) 
NSAIDs use during the same and previous year reduced the 
risk of SCC by 21% (adjusted OR for baseline use 0.79; 
95%CI:0.52-1.21) 
Weaker association with BCCs: 
NSAIDs use during previous year reduced the risk of BCC 
by 11% (adjusted OR for baseline use 0.89; 95%CI:0.7-
1.09) 
NSAIDs use during the same and previous year reduced the 
risk of BCC by 9% (adjusted OR for baseline use 0.91; 
95%CI:0.74-1.12) 
(Grau et al., 
2006) 
Prospective cohort study 
Association between NSAIDs use and 
risk of BCCs and SCCs – categorized 
by user pattern: continuous users 
(use for the length of study 
duration), new users (use for less 
than the study duration) and non-
users 
2297 (moderate risk 
group with history of 
more than 10 AKs 
and at most 2 SCCs or 
BCCs); 1402 included 
in final analysis data 
set 
5 years Participants who used NSAIDs for less than the study 
duration (new users) were significantly protected from 
SCCs and BCCs (hazard ratio for SCC 0.49; 95%CI: 0.28-
0.87; HR for BCC 0.43; 95%CI:0.25-0.73) 
NSAIDs use of shorter and recent duration (new use) was 
more protective than longer duration of use (continuous 
use) 
Non-aspirin NSAIDs had more significant effect in BCCs 
reduction than aspirin (HR 0.33; 95%CI:0.13-0.8) 
(Clouser et al., 
2009) 
Case-control study 
Association between NSAIDs use and 
risk of AK and SCC 
1621; 86 participants 
with SCC compared 
with 187 age- and 
sex-matched control 
subjects randomly 
9 years Regular use of NSAIDs reduced the risks of SCC and 
decreased AKs counts  
Participants who used NSAIDs 8 or more times per week 
for more than 1 year had a substantially lower incidence of 
SCC (OR=0.07; 95%CI:0.01-0.71)  
(Butler et al., 
2005) 
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selected from within 
the cohort 
Participants who used full dose of NSAIDs 2 or more times 
per week for more than 5 years also had a lower incidence 
of SCC (OR=0.2; 95%CI:0.04-0.96) 
Analysis of AKs were only performed on control group 
only: 
Control participants who were regular users of NSAIDs (2 
or more times per week) had lower AK counts than never 
users (OR=0.52; 95%CI: 0.3-0.91) 
RCT, double-blind 
Celecoxib 200mg or placebo twice 
daily for 9 months 
240 (10-40 AKs) Follow up at 
3, 6, 9, 11 
months;  
9 months (AK 
assessments) 
11 months 
(SCC and BCC 
assessments) 
No difference in the incidence of AKs between the two 
groups at 9 month assessment 
Celecoxib patients had fewer NMSCs at 11 month 
assessment, compared to placebo patients (rate ratio 0.41; 
95%CI:0.23-0.72; p=0.002), as were fewer BCCs (RR 0.4; 
95%CI: 0.18-0.93; p=0.032) and SCCs (RR 0.42; 95%CI: 
0.19-0.93; p=0.032) 
(Elmets et al., 
2010) 
RCT, double-blind 
Celecoxib 200mg or placebo twice 
daily for 3 years 
60 patients with 
Gorlin syndrome; 
only 60% of patients 
with less severe 
disease (<15 BCCs at 
study entry) were 
included in tumour 
burden analysis 
3 years Participants in placebo group had a 50% increase in yearly 
BCCs (yearly BCC burden), whereas participants in 
celecoxib group had a 20% increase in yearly BCCs (30% 
reduction, p=0.024) 
(Tang et al., 
2010) 
 OTC: over the counter. 
  49
1.9. NICOTINAMIDE 
Nicotinamide (pyridine-3-carboxamide) is an active amide form of vitamin B3 
(niacin or nicotinic acid or pyridine-3-carboxylic acid). It is a white, odourless, and 
water-soluble solid or crystalline powder. Nicotinamide can be obtained directly 
from the diet or synthesized endogenously in the liver from the amino acid 
tryptophan. Nicotinamide is also used in food fortification and is commercially 
available as a nutritional supplement. Typical supplemental doses ranges from 20-
500mg/day. The recommended daily adult intake (RDI) of niacin (nicotinamide 
equivalent from food sources) for adults is 16mg/day for men, 14mg/day for women, 
and 18mg/day and 17mg/day for pregnant and lactating women respectively (2006). 
Nicotinamide is found in some over-the-counter skin and hair cosmetic products 
(concentration range 0.001-5%).  
 
1.9.1. Dietary sources of nicotinamide 
The main dietary sources of nicotinamide and niacin are meats, eggs, milk, nuts, 
seeds, legumes, rice, whole-grain, fortified breads and cereals, and also coffee and 
tea (Karthikeyan and Thappa, 2002).  Nicotinamide is mainly obtained from animal 
proteins whereas niacin is the predominant form found in plant products (Marcus and 
Coulston, 2001, Hageman and Stierum, 2001). Nicotinamide is also synthesised 
endogenously in the liver from the amino acid tryptophan and studies in humans 
showed that an estimated 60mg of tryptophan is converted to 1mg of niacin (equals 1 
niacin equivalent [NE]) (Ziegler and Filer, 1996). The exact amount is however 
influenced by dietary, hormonal and genetic factors. Deficiencies of vitamin B2 
(riboflavin), B6 (pyridoxine), iron, and excessive amounts of amino acid leucine 
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have been shown to inhibit conversion of tryptophan to niacin whereas increased 
conversion is observed with dietary protein restriction (Ziegler and Filer, 1996).  
 
1.9.2. Nicotinamide deficiency 
Severe nicotinamide deficiency in humans causes the disease pellagra, which is 
characterised by the four Ds, representing photosensitive dermatitis, diarrhoea, 
dementia and death. The term pellagra is derived from the Italian words “pelle agra” 
meaning rough skin, in reference to the thickened, scaly, hyper-pigmented rough skin 
seen in sun-exposed areas in the late stage of the disease. Symptoms related to the 
gastrointestinal tract include a bright red tongue, vomiting and diarrhoea. 
Neurological symptoms include headache, apathy, fatigue, depression, disorientation, 
and memory loss. If untreated, pellagra can result in death (Jacob, 2001). Although 
pellagra has largely been eradicated from developed countries, it is still endemic in 
areas of Africa and Asia where corn, maize and jowar (Indian millet) are the major 
dietary staple (Stratigos and Katsambas, 1977). Interestingly, pellagra was not 
common in Mexico, where corn was also the main source of diet. This is attributed to 
the Mexican traditional way of preparing corn tortillas by soaking the corn in a lime 
(calcium oxide) solution, prior to cooking. Heating the corn in alkaline conditions 
releases bound niacin, increasing its bioavailability (Gregory, 1998). In present day 
developed countries, pellagra is only rarely seen in individuals with alcoholism or 
psychiatric disease (Stratigos and Katsambas, 1977). Secondary pellagra occurs 
when there is adequate dietary intake of niacin or nicotinamide, but other diseases 
prevent its intake, absorption, and / or processing, such as malabsorption syndromes, 
carcinoid tumour, and abnormalities in trypthophan metabolism (Hartnup’s disease) 
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(Hegyi et al., 2004). In carcinoid syndromes, there is reduced endogenous 
nicotinamide production as most tryptophan is converted into serotonin by the 
tumour cells. Various medications can cause symptoms of pellagra by interfering 
with the tryptophan-niacin pathway. These include isoniazid, 5-fluorouracil, 
pyrazinamide, 6-mercaptopurine, azathioprine, and chloramphenicol (Hegyi et al., 
2004). The clinical manifestations of pellagra are thought to arise from deficient 
NAD(H) levels in maintaining cellular energy. Therefore, it mostly affects tissues 
with high turn-over rates (skin, gastrointestinal tract) and high energy requirements 
(central nervous system) (Hendricks, 1991). Symptoms of pellagra usually respond 
well to oral administration of nicotinamide or niacin (100-300mg/day, in three 
separate doses) (Karthikeyan and Thappa, 2002). 
 
1.9.3. Absorption, metabolism and excretion 
Nicotinamide and niacin are rapidly absorbed from the stomach and the intestine by 
a combination of sodium-dependent transporter (at low concentrations) and passive 
diffusion (at high concentrations) (Jacob, 2001). Most dietary niacin is converted to 
NAD in the intestine or liver, and cleaved by NAD glycohydrolase in the intestinal 
mucosa to release nicotinamide into the portal or systemic circulation. Hence 
nicotinamide is the major form found in the blood stream (Henderson, 1983). In rats, 
rabbits, guinea-pigs and horses, nicotinamide can be deaminated to nicotinic acid by 
intestinal micro-organisms before entering systemic circulation (Jacob, 2001). There 
is no evidence that nicotinamide can be converted to nicotinic acid in humans, dogs 
or cats (Gillmor et al., 1999). Most tissues use nicotinamide to synthesize NAD and 
NADP, although niacin can also be used (Jackson et al., 1995). In cells, nicotinamide 
is converted to NAD with nicotinamide monocleotide as intermediate. Niacin is 
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converted to NAD with nicotinic acid mononucleotide and nicotinic acid 
dinucleotide as intermediates. Dietary tryptophan is converted to quinolinate, and 
then via the kynurenine pathway, it is further converted to nicotinic acid 
ribonucleotide and then into NAD (Hageman and Stierum, 2001). The conversion of 
tryptophan to NAD occurs mainly in the liver (Jacobson et al., 1995). NAD can be 
transformed back to nicotinamide by ADP-ribose transfer reactions.  Both 
nicotinamide and niacin are metabolised into excretory products in the liver and are 
then excreted by the kidneys. In the liver, nicotinamide is oxidised to nicotinamide-
N1-oxide, methylated to N1-methyl-nicotinamide (NMN) or hydroxylated to 6-
hydroxynicotinamide. In humans, N1-methyl-nicotinamide can be further oxidised in 
the liver to N1-methyl-2-pyridone-5-carboxamide (2-pyr) or N1-methyl-4-pyridone-
5-carboxamide (4-pyr) (Jacob et al., 1989, Shibata and Matsuo, 1989). N1-methyl-
nicotinamide, the major metabolite, is renally excreted (Knip et al., 2000). In the 
liver, niacin is metabolized into glycine conjugate and nicotinuric acid (Jacobson et 
al., 1995) and methylated to form N1-methyl-nicotinic acid (NMNA) (Jacob, 2001). 
These metabolites are then excreted via the kidneys (Jacob, 2001).  
 
1.9.4. Pharmacokinetics 
The peak nicotinamide plasma concentration in humans is dose-dependent and 
occurs within about 45 mins to 1 hour of oral ingestion (Horsman et al., 1993, Petley 
et al., 1995). Large variations between individuals in absolute peak plasma 
concentrations and time to reach peak concentration have been reported (Hoskin et 
al., 1995, Dragovic et al., 1995, Kaanders et al., 1997, Bernier et al., 1998). The 
fasting plasma concentrations of nicotinamide and nicotinic acid are approximately 
340 nM and 80 nM respectively as measured by GC-MS (gas chromatography mass 
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spectrometry) (Jacobson et al., 1995). The elimination half-life (T½) of nicotinamide 
is dose-dependent. Utilising HPLC (high performance liquid chromatography), the 
level was reported to be around 3, 6, and 8 hours after taking 1, 3, and 6 gram of 
nicotinamide respectively (Horsman et al., 1993). Due to its high hepatic extraction, 
nicotinamide plasma clearance can be reduced in patients with hepatic insufficiency.  
 
1.9.5. Topical absorption  
In vivo studies in human skin with 14C-labelled nicotinamide dissolved in acetone 
showed that the absorption rate of topically applied nicotinamide for 24 hours was 
about 2-3% of the total dose. Nicotinamide absorption reached its maximum rate 
between 24 to 72 hours and continued for up to 5 days after topical application 
(Feldman and Maibach, 1970). Ex vivo studies from human abdominal skin 
demonstrated a higher absorption rate (28.8% of initial dose) of topically applied 
nicotinamide in acetone at 24 hours (Franz, 1975). However, another ex vivo study 
using split thickness human cadaver skin showed a more similar absorption rate at 24 
hours (1-3%) to the in vivo data. In this study, it was also shown that the rate of 
absorption was independent of the vehicle used (Procter and Gamble, 1998). 
Systemic absorption of topical nicotinamide has been reported to be approximately 
10% depending on the vehicle used (Cosmetic Ingredient Review (CIR) Expert 
Panel, 2005).  
 
1.9.6. Dosages, adverse effects and toxicity 
Nicotinamide has a high safety profile and is generally well tolerated at doses of 1-
3g/day (Niren, 2006). Higher doses, up to 3.5 g/day, have been well tolerated in trials 
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of type I diabetes prevention (Visalli et al., 1999). Reported side effects, occurring 
mainly with much higher oral doses, include nausea (6g/day, given in combination 
with radiotherapy and carbogen) (Denekamp and Fowler, 1997) and liver toxicity 
(9g/day) (Winter and Boyer, 1973). Other potential side effects are rare (less than 5% 
overall frequency) including heartburn, vomiting, other gastrointestinal symptoms, 
dull headache, fatigue, and dizziness (Knip et al., 2000). Nicotinamide does not 
influence blood pressure, heart rate or body temperature (Stratford et al., 1992). 
Unlike niacin, nicotinamide is not a vasodilator, thus it rarely causes flushing 
(Ranchoff and Tomecki, 1986). Although nicotinamide crosses the placental barrier, 
it is not teratogenic in mice (Cosmetic Ingredient Review (CIR) Expert Panel, 2005). 
There is no reported teratogenecity data of nicotinamide in humans (Knip et al., 
2000). Lifelong administration of 1% nicotinamide in drinking water (300-fold 
above requirements) is not carcinogenic in mice (Toth, 1983), with no evidence of 
carcinogenicity in humans (Knip et al., 2000). Nicotinamide was shown to decrease 
insulin sensitivity at doses of 2g/day in adults at high risk for insulin-dependent type 
I diabetes (Greenbaum et al., 1996). Topical nicotinamide is available in 
concentrations of 0.001% to 4% in cosmetic, hair, and skin care preparations. 
Clinical testing reported no irritation up to the concentration of 5% to 10%. Also in 
this report, nicotinamide was not found to be a sensitiser nor a photosensitiser 
(Cosmetic Ingredient Review (CIR) Expert Panel, 2005). Therefore it is very safe 
over a wide concentration range.  
 
1.9.7. Contraindications and drug interactions 
Large doses of nicotinamide and niacin are contraindicated in patients with liver 
disease, gallbladder disease or a history of jaundice or liver disease, diabetes 
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mellitus, gout, active peptic ulcer, or hypersensitivity to nicotinamide (Drugdex Drug 
Evaluation: niacinamide, 2006).   Since nicotinamide was found to inhibit human 
P450 enzymes in vitro, it may decrease carbamazepine clearance, although its 
interactions with other drugs and oral contraceptives have not been reported 
(Gaudineau and Auclair, 2004).  
 
1.9.8. Cellular functions of nicotinamide 
Both nicotinamide and niacin are precursors for synthesis of NAD and its 
phosphorylated derivative NADP. Nicotinamide is the primary precursor for NAD in 
most tissues (Jacobson et al., 1995). NADPH, the reduced form of NADP, functions 
as a hydride ion donor in reductive biosyntheses including fatty acid synthesis, 
cholesterol synthesis, and hydroxylation. NAD serves as a coenzyme in energy 
metabolism including glycolysis, the citric acid (Krebs) cycle, and fatty acid 
oxidation. The transfer of electrons from NAD formed in these processes to oxygen 
is the source of adenosine triphosphate (ATP) production in aerobic metabolism. 
ATP is the major storage form of energy in cells. The bonds between the phosphate 
groups of ATP are called high-energy bonds because their hydrolysis can be used to 
drive energy-requiring reactions. The phosphate group in ATP can also be 
transferred to an enzyme in phosphorylation reactions to regulate the enzyme 
activity. Besides its role as coenzymes, NAD is the sole substrate for the nuclear 
enzyme poly(ADP-ribose) polymerase-1 (PARP-1). PARP-1 has been shown to have 
important roles in DNA damage responses (DDR) including DNA repair, regulation 
of p53 gene expression, control of cell cycle arrest and apoptosis, telomere stability 
regulation, and numerous other cellular functions (Satoh and Lindahl, 1992, 
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Jacobson and Jacobson, 1999, Oliver et al., 1999). Nicotinamide acts as PARP-1 
inhibitor at high concentration during PARP-1 overactivation, preventing necrotic 
and apoptotic brain injury in animal models of focal brain ischaemia-reperfusion 
(Yang et al., 2002). NAD was also found to be a substrate for NAD-dependent 
protein deacetylases (sirtuins), which are involved in stress responses, apoptosis, 
transcriptional regulation, cellular differentiation, and ageing (Vaziri et al., 2001, 
Motta et al., 2004, Denu, 2005). In addition, NAD can act as substrate for the 
synthesis of molecules involved in calcium signalling, including ADP-ribose 
(ADPR), cyclic ADP-ribose (cADPR), nicotinic acid adenine dinucleotide phosphate 
(NAADP) and 2’-phospho-cyclic ADP-ribose (P-cADPR) (Benavente et al., 2009).  
 
Nicotinamide anti-inflammatory and anti-tumour effects were proposed to be 
mediated by nicotinamide inhibition of NF-κB gene transcription, which leads to 
decreased TNF-α production and induction of apoptosis (Pero et al., 1999). 
Nicotinamide inhibits lipopolysaccharide (LPS)-induced TNF-α production in human 
peripheral blood mononuclear cells (Fukuzawa et al., 1997) and endotoxin-induced 
production of the proinflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α in human 
whole blood (Ungerstedt et al., 2003). Murine studies also demonstrated that oral 
nicotinamide prevented an increase in serum TNF-α following LPS administration 
(Fukuzawa et al., 1997, Pero et al., 1999). Nicotinamide has also been shown by 
various in vitro studies to inhibit inducible NO synthase (Andersen et al., 1994), 
suppress endothelial expressions of MCH class II (Otsuka et al., 1991) and 
intracellular adhesion molecular ICAM-1 (Hiromatsu et al., 1993), and act as a free 
radical scavenger (Burkart et al., 1992).  
 
  57
1.10. CLINICAL USE OF NICOTINAMIDE IN SKIN 
DISEASES 
1.10.1. Autoimmune blistering disorders 
Oral nicotinamide as monotherapy or in combination with oral antibiotics 
(tetracycline, doxycycline, or minocycline) has been shown to be effective in the 
treatment of various inflammatory conditions including autoimmune blistering skin 
diseases, granuloma annulare, and erythema elevatum diutinum (Niren, 2006). An 
open-labelled randomised trial comparing the efficacy of oral nicotinamide 
(1.5g/day) plus tetracycline (2g/day) to oral prednisone (40-80mg/day) in 20 patients 
with bullous pemphigoid (BP) showed that the combined therapy gave at least 
comparable efficacy (Fivenson et al., 1995). Multiple case reports have reported the 
efficacy of combined oral nicotinamide and tetracycline in the treatment of BP, 
pemphigus vulgaris (PV), linear IgA bullous dermatosis, lichen planus 
pemphigoides, dermatitis herpetiformis and cicatricial pemphigoid (Niren, 2006). 
However, there is only one case report on the efficacy of oral nicotinamide as 
monotherapy (1.5g/day) in a patient with localised BP (Honl and Elston, 1998). Oral 
nicotinamide in combination with minocycline has been reported to be effective in 7 
patients with BP (Kawahara et al., 1996) and isolated cases of therapy-resistant PV 
(Hausermann et al., 2002) and pemphigus vegetans with oral and oesophageal 
mucosal lesions (Sawai et al., 1995).  
 
Topical nicotinamide may also be a useful adjunctive therapy for pemphigus 
vulgaris. Eight pemphigus patients, all taking concomitant immunosuppressive 
therapy with prednisone and azathioprine, were randomized to apply either 4% 
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nicotinamide gel or vehicle gel once daily for 30 days. The percentage of re-
epithelialized area at day 30 was significantly greater with nicotinamide (Iraji and 
Banan, 2010).  
 
The efficacy of nicotinamide in these inflammatory dermatoses is probably mediated 
by its inhibition of proinflammatory cytokines production (Fukuzawa et al., 1997, 
Pero et al., 1999, Ungerstedt et al., 2003), neutrophil chemotaxis and B cell 
transformation from naïve to antibody producing B cells (Daniel et al., 2007) – all 
are involved in BP pathogenesis (Sitaru and Zillikens, 2005).  
 
1.10.2. Acne and rosacea 
A multicentre open label cohort study of 198 patients with moderate to severe acne 
vulgaris and /or rosacea found that oral nicotinamide (1.5g) given in combination 
with 50mg zinc and 1mg folic acid daily for 8 weeks significantly reduced 
inflammatory lesions compared to no treatment and no added benefit of concomitant 
oral antibiotics was found (Niren and Torok, 2006). Randomised double-blinded 
studies involving 76 (Shalita et al., 1995) and 80 (Khodaeiani et al., 2002) patients 
with inflammatory acne compared 4% nicotinamide gel to 1% clindamycin gel 
applied twice daily for 8 weeks. Comparable efficacy was found in reducing 
inflammatory acne lesion counts, acne severity rating and Physician’s Global 
Evaluation scale. Nicotinamide has an added benefit of avoiding antimicrobial 
resistance, which can be associated with antibiotic use (Shalita et al., 1995, 
Khodaeiani et al., 2002). A double blinded randomised controlled trial comparing 
4% nicotinamide gel and 4% erythromycin gel (twice daily for 8 weeks) in 160 
patients with inflammatory acne also found equivalent regression of inflammatory 
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lesions and a greater decrease in cystic lesions and seborrhoea scores in the 
nicotinamide arm (Weltert et al., 2004).  
 
Propionibacterium acnes, gram-positive human skin commensal bacteria, are 
involved in acne pathogenesis. IL-8 and other cytokines induced by P. acnes 
including TNF-α and IL-1β are potent chemoattractants for neutrophils, which 
contribute to the inflammation in acne (Kim, 2005). In human keratinocytes, 
nicotinamide has been shown to prevent Propionibacterium acnes-induced activation 
of toll-like receptor (TLR)-2 via inhibition of NF-κB and mitogen activated protein 
kinase (MAPK) pathways, resulting in down-regulation of proinflammatory IL-8 
production (Grange et al., 2009).  
 
Nicotinamide may also inhibit sebaceous lipogenesis (Niren, 2006). In an ex vivo 
study of human skin, nicotinamide has been shown to dose dependently inhibit 
sebaceous triglyceride and fatty acid synthesis, which when excessive are important 
contributors to acne pathogenesis (Biedermann et al., 2002, Niren, 2006). In a 
double-blinded placebo-controlled trial and a parallel randomized split face study, 
2% nicotinamide gel reduced facial sebum production in 130 volunteers (Draelos et 
al., 2006).  
  
1.10.3. Atopic dermatitis and dry skin  
Topical nicotinamide has been shown to improve skin barrier function and increase 
skin resistance to irritants such as sodium lauryl sulfate and dimethyl suflfoxide 
(Tanno et al., 2000, Bissett, 2002, Draelos et al., 2005). 2% nicotinamide was 
evaluated against its vehicle in a right/left comparison study in 12 male volunteers 
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with dry skin (Tanno et al., 2000). After twice daily application of nicotinamide or 
vehicle for 4 weeks, transepidermal water loss (TEWL) was measured and the 
stratum corneum was stripped for lipid analysis. Nicotinamide reduced TEWL by 
27% compared to its vehicle and increased stratum corneum free fatty acid and 
ceramide levels by 67% and 34% respectively (Tanno et al., 2000).  
 
Topical nicotinamide is potentially a useful adjunctive treatment for sensitive dry 
skin associated with rosacea and irritated and dry skin associated with retinoic acid 
treatment for photoaging. In a randomised, investigator blinded study of 50 women 
with rosacea, moisturizer containing 2% nicotinamide applied twice daily decreased 
facial erythema, dryness and peeling/scaling and inflammatory lesion counts and 
significantly improved stratum corneum barrier function and hydration as measured 
by TEWL and skin capacitance respectively (Draelos et al., 2005).  
 
An in vitro study with human keratinocytes showed that nicotinamide dose-
dependently increased ceramide and other sphingolipids by stimulating the activity 
and gene expression of serine palmitoyltransferase, the rate-limiting enzyme in de 
novo sphingolipid synthesis (Tanno et al., 2000). Nicotinamide may also improve 
skin barrier function by increasing involuncrin, filaggrin and keratin (Bissett, 2002). 
In 28 patients with atopic dermatitis, 2% nicotinamide cream was significantly more 
effective in decreasing TEWL and increasing stratum corneum hydration than white 
petrolatum (Soma et al., 2005). An in vitro study with human HaCaT keratinocytes 
provides further insight into the mechanism of nicotinamide prevention of TEWL 
(Song et al., 2008). Aquaporin 3 (AQP3) mediates keratinocyte water transport 
(Song et al., 2008) and increased expression of AQP3 has been associated with 
  61
increased TEWL in atopic skin (Olsson et al., 2006) and in normal skin treated with 
retinoic acid (Bellemere et al., 2008). In cultured human keratinoctyes, nicotinamide 
treatment dose-dependently prevented retinoid-induced AQP3 over-expression (Song 
et al., 2008).  
 
1.10.4. Photoaged skin 
The photodamage that contributes to the clinical manifestations of photoaging 
(wrinkles, roughness, mottled hyperpigmentation, and loss of skin elasticity) is 
largely an effect of UVA exposure (McCullough and Kelly, 2006). UVA induced-
reactive oxygen species (ROS) production has been implicated in skin photoaging 
via the activation of NF-κB and AP-1 which resulted in the upregulation of matrix 
metalloproteinases, decreasing procollagen and collagen production and increasing 
collagen breakdown (Zussman et al., 2010).   
 
Topical nicotinamide at concentrations of 2-5% has been evaluated for the treatment 
of photoaging, characterised by fine lines and wrinkles, poor texture and 
hyperpigmentation. In a split-face randomised, double-blinded, vehicle controlled 
study of 50 women, 5% nicotinamide cream applied twice daily for 12 weeks was 
more effective than vehicle in reducing facial wrinkles, red blotchiness, 
hyperpigmented spots and skin sallowness and in improving skin elasticity (Bissett et 
al., 2005). In 30 healthy Japanese women with periorbital wrinkles (randomized split 
face study), 4% nicotinamide cream applied twice daily for 8 weeks significantly 
reduced wrinkle grades compared to its vehicle (Kawada et al., 2008).  
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Nicotinamide’s effects on wrinkle reduction was hypothesized to be mediated by 
downregulation of ROS production (Benavente and Jacobson, 2008), stimulation of 
collagen production (Matts et al., 2002), and reduction in excess dermal 
glycosaminoglycans which are associated with redundant folds and rhytides in aging 
skin (Bissett et al., 2005). In vitro, nicotinamide inhibits melanosome transfer from 
melanocytes to keratinocytes; twice daily application for 8 weeks of 5% and 2% 
nicotinamide cream was significantly more effective than vehicle in reducing facial 
hyperpigmentation (Hakozaki et al., 2002). 
 
1.11. NICOTINAMIDE, NIACIN AND 
CARCINOGENESIS 
1.11.1. Epidemiological studies  
There is a lack of epidemiologic studies on the impact of nicotinamide intake on 
human carcinogenesis. In the early 1970s, it was observed that in many populations 
with a high incidence of oesophageal cancer, their staple foods consisted of wheat 
and corn, which are known to be relatively deficient in nicotinamide. It was 
suggested, therefore, that a deficiency in nicotinamide and other micronutrients in 
food including riboflavin, zinc and magnesium, possibly plays an aetiologic role in 
oesophageal cancer (Warwick and Harington, 1973, van Rensburg, 1981). 
Deficiency of nicotinamide and other micronutrients including riboflavin, zinc, and 
magnesium have been linked to the increased frequency of oesophageal cancer in 
certain populations in China and Italy (Franceschi et al., 1990, Blot et al., 1993). 
Low dietary niacin has also been associated with an increased frequency of oral, 
gastric and colon cancers, as well as oesophageal dysplasia (Franceschi et al., 1990, 
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Negri et al., 2000, Siassi et al., 2000). In the Linxian trial in China, involving nearly 
30,000 residents, 40 mg niacin and 3.2 mg riboflavin were supplemented in one of 
the treatment arms daily for over 5-years. It was shown that this combined 
supplementation decreased oesophageal cancer incidence and mortality by 14% and 
10% respectively (Blot et al., 1993). Most human studies have examined the dietary 
intake of or supplementation of niacin in combination with other micronutrients 
(Franceschi et al., 1990, Blot et al., 1993, Bosetti et al., 2007, Qu et al., 2007, Kabat 
et al., 2008, Zablotska et al., 2008, Pelucchi et al., 2009). The impact of niacin on 
human carcinogenesis is therefore confounded by the effect of other micronutrients.  
 
1.11.2. Effects of nicotinamide and NAD status on genomic 
stability and DNA repair 
In vitro studies 
A large number of in vitro studies reported that NAD status influences genomic 
stability and sensitivity to cytotoxic effects of DNA-damaging agents. Nicotinamide 
(50 – 500 µM) increased intracellular NAD and enhanced the repair of DNA damage 
induced by N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) in cultured primary 
human mammary epithelial cells (Jacobson et al., 1999). Preincubation with 74 µM 
nicotinamide prevented NAD depletion after dimethyl sulphate (DMS) exposure, and 
increased the strand break rejoining rate (Durkacz et al., 1980).  Increasing NAD 
status by the addition of nicotinamide thus improved the capacity of DNA repair. 
NAD is also an important determinant of skin cell survival following UV radiation. 
0.1 and 33 μM nicotinamide added to UV-irradiated cultured human skin fibroblasts 
increased cell survival 7-days post irradiation in a dose-dependent manner (Jacobson 
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et al., 2001). Even in the absence of genotoxic stress, NAD depletion increased 
spontaneous DNA damage in human HaCaT keratinocytes, which was reversible 
with the addition of nicotinamide (Benavente and Jacobson, 2008). NAD status is 
therefore critical in preserving genomic function of skin cells. Furthermore, it was 
shown that skin NAD levels are negatively correlated with malignant phenotype in 
human skin cancers.  Normal skin from patients with premalignant actinic keratoses 
had significantly higher NAD than normal skin from patients with cutaneous 
squamous cell cancers (Jacobson et al., 1999). 
 
Exposure of ex vivo human lymphocytes to oxygen radicals (Weitberg, 1989), UVB 
(Berger and Sikorski, 1980, Sims et al., 1981), γ-irradiation (Kjellen et al., 1986), 
N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (Berger and Sikorski, 1980, Sims et 
al., 1981), or dimethyl sulfate (DMS) (Berger and Sikorski, 1980), resulted in 
reduced intracellular NAD, with the numbers of DNA-strand breaks inversely 
correlated with NAD levels (Weitberg, 1989). Addition of 2-5mM nicotinamide 
prevented this lowering of NAD levels, stimulated unscheduled DNA synthesis 
(UDS), and increased DNA repair (Berger and Sikorski, 1980, Sims et al., 1981, 
Kjellen et al., 1986). The ability of nicotinamide to enhance DNA repair depends on 
the presence of functional repair mechanisms. Xeroderma pigmentosum (XP) is an 
autosomal recessive genetic disorder of DNA repair, in which the ability to repair 
DNA damage caused by UVR is deficient (Cleaver and Trosko, 1969).  In the 
presence of 2mM nicotinamide, lymphoctyes from XP patients exhibited increased 
UDS after MNNG treatment, but failed to show increased UDS after UVB 
irradiation. Normal lymphocytes incubated with the same dose of nicotinamide, in 
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contrast, showed increased UDS and enhancement of DNA repair after UVB or 
MNNG exposures (Miwa et al., 1981).  
 
In HaCaT cells (human keratinocyte cell line) NAD depletion upregulated NADPH 
oxidase activity with consequent increases in reactive oxygen species (ROS) 
production. NAD repletion with nicotinamide completely reversed the ROS 
accumulation (Benavente and Jacobson, 2008). In support of these findings, niacin 
deficiency, which results in intracellular NAD depletion in rats, also caused an 
increase in both protein carbonyls and 8-oxodG in bone marrow (Tang et al., 2008). 
ROS also damages other cellular components including cell membranes by 
peroxidation of fatty acids within the phospholipid bilayer and proteins by forming 
carbonyl derivatives (Svobodova et al., 2006). Lipid peroxidation increases 
production of prostaglandins (PG), including PGE2, which is known to play an 
important role in inflammation. Inflammation in premalignant actinic keratoses has 
been reported to be a marker of progression to squamous cell carcinoma (Halliday, 
2005). It was also postulated that ROS may cause gene mutations in actinic 
keratoses, driving their progression to squamous cell carcinoma (Halliday, 2005). 
Regulation of ROS levels by maintenance of intracellular NAD is therefore 
important in preventing oxidative DNA damage and gene mutation.  
 
In vivo studies 
Administration of 100mg/day niacin to two volunteers for 8 weeks protected against 
ex vivo lymphocyte DNA strand breaks induced by hypoxanthine/ xanthine oxidase. 
The supplementation increased NAD concentrations by nearly 5 times baseline levels 
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and significantly reduced oxygen radical-induced DNA stand breaks in the 
lymphocytes (Weitberg, 1989).  
 
The impact of niacin deficiency in rats has been extensively studied by the Kirkland 
group (Boyonoski et al., 2002, Spronck and Kirkland, 2002, Spronck et al., 2007, 
Kostecki et al., 2007, Tang et al., 2008, Kirkland, 2009a). Wenling Long-Evans rats 
were kept niacin-deficient or were pair-fed either normal dietary niacin or 
supplemental 4 mg/gram niacin (0.4% of diet). The DNA-alkylating agent 
ethylnitrosurea (ENU) or the topoisomerase II inhibitor etoposide (ETO) was then 
administered to these rats orally. Bone marrow is a good indicator of niacin intake. 
Niacin-deficient diets caused 72 - 80% (Boyonoski et al., 2002, Spronck et al., 2007) 
reduction in bone marrow NAD content, whereas niacin-supplemented diets 
produced a 240% increase (Spronck and Kirkland, 2002). Basal poly(ADP-ribose) 
levels were also significantly lower in niacin-deficient rats. After ENU- or ETO- 
treatment, poly(ADP-ribose) levels were not increased in bone marrow of niacin-
deficient rats, whereas niacin-supplemented rats, the level of bone marrow 
poly(ADP-ribose) rose significantly (Boyonoski et al., 2002, Spronck et al., 2007).  
Adequate NAD is therefore essential for the increase in ADP-ribose polymer 
metabolism activated by DNA damage. Niacin deficiency alone causes increased 
micronuclei formation (6.2-fold), sister chromatid exchange frequency (2.8-fold) 
(Spronck and Kirkland, 2002), chromosomes breaks (4-fold), and chromatid breaks 
(2-fold). With ENU- or ETO- treatment, there were much greater increases in 
micronuclei formation, sister chromatid exchange, and chromosomal aberrations in 
bone marrow of niacin-deficient rats (Spronck and Kirkland, 2002, Kostecki et al., 
2007). The increased genomic instability in niacin deficient rats is further evidenced 
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by the reduction in latency and the increase in the incidence of developing ENU-
induced leukemia (Boyonoski et al., 2002). Niacin deficiency significantly delayed 
DNA repair in bone marrow after ENU- or ETO- treatment (Spronck and Kirkland, 
2002, Kostecki et al., 2007) and was shown to alter p53 expression and impair ETO-
induced cell cycle arrest and apoptosis (Spronck et al., 2007).  
 
1.11.3. Animal models of nicotinamide or niacin 
supplementation 
Animal studies demonstrate that nicotinamide or niacin supplementation affects 
carcinogenesis in a dose-dependent and organ-specific manner (Table 1.4). 
Carcinogenic effects were not observed in 100 Swiss albino mice receiving 1% 
nicotinamide supplementation (> 300-fold above requirement) in the drinking water 
for their life span (Toth, 1983). Overall, low dose nicotinamide (dose range of 150 – 
200 µM topical; 0.25 – 2.5% oral; 30 mg/kg body weight (bw) intraperitoneal) 
appears to be protective in various chemical- and UVR-induced carcinogenesis 
models in animals. There are two reports which show the efficacy of nicotinamide 
and niacin in preventing UV-induced skin tumours (predominantly SCCs) in 
BALB/c mice (Gensler, 1997, Gensler et al., 1999). Topical 2.5% nicotinamide, 
applied twice weekly for two weeks prior to UVB irradiation (5 days/week for 17.5 
weeks; total dose 1.09 × 106 J/m2) reduced skin tumour incidence significantly by 
30% and average tumour counts almost 50% (Gensler, 1997). Supplementation with 
0.1%, 0.5%, or 1% dietary niacin in mice irradiated with UVB over 22 weeks (total 
dose of 1.41 × 106 J/m2) reduced tumour incidence (by 8, 20, and 40% respectively) 
and tumour counts (by 17, 33, and 44% respectively)(Gensler et al., 1999). However, 
supplementation with oral nicotinamide (250 mg/kg) daily for 4 weeks had no effect 
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on the development of skin tumours in mice in response to a single application of 
9,10-dimethyl-12-benzanthracene (DMBA) on skin, followed by weekly paintings 
with croton oil for 15 weeks (Roe, 1964).  
Nicotinamide at dietary concentrations of 0.25-2.5% is protective against urethane-
induced pulmonary adenoma in mice, whereas 0.25% niacin did not show the same 
protection (French, 1978, Gotoh et al., 1988). However, higher concentrations of 
dietary niacin (0.4%) caused a 6% reduction in the incidence of non-lymphocytic 
leukemia induced by ethylnitrosurea (ENU) in Weanling male Long-Evans rats 
(Bartleman et al., 2008). The effect of nicotinamide on diethylnitrosamine (DEN)-, 
streptozotocin-, and heliotrine- induced carcinogenesis seems to be organ-specific. 
Massive doses of nicotinamide (350 – 500 mg/kg, intraperitoneal, multiple dosing) 
inhibited DEN-induced liver tumours (34% reduction), but promoted DEN-induced 
kidney neoplasia (44% increase) in Wistar rats (Schoental, 1977). However, in 
another study of DEN-induced carcinogenesis, even low dose nicotinamide  (0.082% 
and 0.37% oral) increased the incidence of DEN-induced kidney tumours from 5% in 
controls (DEN only) to 28% and 59% respectively in male F344 rats (Rosenberg et 
al., 1985). 0.37% nicotinamide by itself had no effect on tumour formation 
(Rosenberg et al., 1985), suggesting the presence of carcinogen is required for the 
tumour promoting or inhibiting effect of nicotinamide. Intraperitoneal nicotinamide 
(350 mg/kg) increased the incidence of streptozotocin-induced pancreatic islet-cell 
tumours in male Holtzman rats from 4% in controls (streptozotocin only) to 64% 
(Rakieten et al., 1971), but it decreased the incidence of renal adenomas from 77 to 
18% (Rakieten et al., 1976). Nicotinamide at the dietary concentration of 5 mg/g 
given for up to 58 weeks to male and female albino rats fed the plant carcinogen 
bracken fern reduced the incidence of intestinal tumours by 48% and of urinary 
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bladder tumours by 37%. Nicotinamide by itself, given at the same dose for the same 
duration of study, did not produce any tumours (Pamukcu et al., 1981). Nicotinamide 
administered intraperitoneally at 500 mg/kg to white male weanling rats before and 
after administration of pyrrollizidine alkaloid heliotrine increased pancreatic islet cell 
tumours (Schoental, 1975). However, nicotinamide (30 mg/kg intraperitoneally) 
prevented pancreatic ductal adenomas and carcinomas by N-nitrosobis(2-
oxopropylamine) (BOP) in both male and female Syrian golden hamsters (Pour and 
Lawson, 1984). Nicotinamide has also been shown to inhibit the growth of 
transplanted murine breast adenocarcinoma in mice, although the doses required are 
higher (2.5% and 5% diet; 1000 mg/kg bw intraperitoneal) than those needed to 
suppress carcinogen-induced cancers (Gotoh et al., 1993, Horsman et al., 1995).  
 
1.11.4. Effect of topical nicotinamide on actinic keratoses 
In randomized double-blind placebo controlled clinical trials involving 41 patients 
with at least 4 AKs, 1% topical nicotinamide gel applied twice daily significantly 
reduced AKs by 22% from baseline AKs compared to a 10% reduction with placebo 
gel at 3 months assessment. However, the difference in AK reduction was not 
significant at 6 months (Moloney et al., 2010). 
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Table 1.4. Animal models of nicotinamide or niacin supplementation – effect on carcinogenesis. 
Animal Carcinogen Form Organ Effect on 
tumour 
Reference 
Mouse None Oral nicotinamide  All None (Toth, 1983) 
Mouse UVB Topical nicotinamide (200µM) Skin Inhibition  (Gensler, 1997) 
Mouse UVB Oral niacin (0.5%; 1% diet) Skin Inhibition  (Gensler et al., 1999) 
Mouse TPA1 Topical nicotinamide (150µM) Skin Inhibition (Ludwig et al., 1990) 
Mouse DMBA2 and 
Croton oil 
Oral nicotinamide (0.2% diet) Skin None (Roe, 1964) 
Mouse Urethane Oral nicotinamide (0.25%; 0.4% diet) 
Oral niacin (0.25% diet) 
Lung 
Lung 
Inhibition 
None 
(French, 1978) 
Mouse Urethane Oral nicotinamide (1%; 2.5% diet) Lung Inhibition (Gotoh et al., 1988) 
Rat ENU3 Oral niacin (0.4% diet) Bone marrow  
(haemopoeitic cells) 
Inhibition (Bartleman et al., 2008) 
Rat Bracken fern Oral nicotinamide (0.5% diet) Intestine 
Bladder 
Inhibition 
Inhibition 
(Pamukcu et al., 1981) 
Rat DEN4 Oral nicotinamide (0.082%; 0.37% diet) Kidney Increase (Rosenberg et al., 1985) 
Rat DEN4 Intraperitoneal nicotinamide  
(350-500mg/kg) 
Kidney 
Liver 
Increase 
Inhibition 
(Schoental, 1977) 
Rat Streptozotocin Introperitoneal nicotinamide (350mg/kg) Pancreas Increase (Rakieten et al., 1971) 
Rat Streptozotocin Intraperitoneal nicotinamide(350mg/kg) Kidney Inhibition (Rakieten et al., 1976) 
Rat Heliotrine Intraperitoneal nicotinamide (500mg/kg) Pancreas Increase (Schoental, 1975) 
Hamster BOB5 Intraperitoneal nicotinamide (30mg/kg) Pancreas Inhibition (Pour and Lawson, 1984) 
Mouse Transplanted 
murine breast 
adenocarcinoma 
Oral nicotinamide (2.5%; 5% diet) Recipient 
subcutaneous tissue 
Inhibition (Gotoh et al., 1993) 
Mouse Transplanted 
murine breast 
adenocarcinoma 
Intraperitoneal nicotinamide (1000mg/kg) Recipient 
subcutaneous tissue 
Inhibition (Horsman et al., 1995) 
1TPA: 12-O-tetradecanoylphorbol-13-acetate; 2DMBA: 9,10-dimethyl-12-benzathracene; 3ENU: ethylnitrosurea; 4DEN: diethylnitrosamine; 5BOB: N-nitrosobis(2-
oxopropylamine) 
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1.11.5. Effects of nicotinamide on UV-induced immune 
suppression  
Nicotinamide is protective against UV radiation-induced immune suppression in 
mice and humans. In BALB/c mice chronically irradiated with UVB, 2.5% topical 
nicotinamide (Gensler, 1997) and 0.5% and 1% dietary niacin (Gensler et al., 1999) 
prevented UV immune suppression as measured by passive transfer assay. In this 
assay, spleen cells from the mice receiving UVB irradiation were injected into naïve 
unirradiated mice receiving intradermal implantation of syngeneic SCC cells. In 
immune competent mice, the growth of transplanted tumours is suppressed. Injection 
of splenocytes from UV-irradiated mice transferred UV immune suppression and 
caused accelerated growth of transplanted tumours (Gensler, 1997, Gensler et al., 
1999). In healthy human volunteers, both topical (0.02% and 5%) and oral 
nicotinamide (500mg daily and 1500mg daily doses) prevented solar-simulated UV-
induced immune suppression as measured by the Mantoux model of delayed-type 
hypersensitivity (Damian et al., 2008, Yiasemides et al., 2009, Sivapirabu et al., 
2009). UV radiation suppresses Mantoux-induced induration and erythema in a dose-
dependent manner, and these reductions can be used to measure UV-immune 
suppression (Damian and Halliday, 2002). Topical 5% nicotinamide was also 
significantly immune protective when applied immediately after UV exposure, 
suggesting that nicotinamide does not act as a UV filter (Damian et al., 2008). 5% 
topical nicotinamide is protective against both UVA (385nm) and UVB (300nm), 
when tested separately, suggesting its broad-spectrum immune protective effect 
(Sivapirabu et al., 2009).   
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1.12. SUMMARY AND AIMS OF THIS PROJECT 
Nicotinamide, an amide form of vitamin B3 (niacin), is converted intracellularly into 
NAD, an essential coenzyme in glycolysis and oxidative phosphorylation for ATP 
production (Bogan and Brenner, 2008). Besides its redox function, NAD is also a 
substrate for covalent protein modification, including mono-/poly-(ADP-
ribosyl)ation and deacetylation by nuclear enzymes poly(ADP-ribose)polymerase 
(PARP) and sirtuin respectively. Both are involved in genomic maintainance during 
oxidative stress (Kirkland, 2009b). Nicotinamide is protective against UV-induced 
skin carcinogenesis in mice (Gensler, 1997) and UV-immune suppression in humans 
(Damian et al., 2008, Yiasemides et al., 2009, Sivapirabu et al., 2009). 
Nicotinamide’s role in cellular bioenergetics and NAD-dependent regulatory 
pathways is likely key to its observed photoprotection. UVR damages both 
mitochondrial and nuclear DNA (Melnikova and Ananthaswamy, 2005, Birch-
Machin and Swalwell, 2010). Mitochondria play an essential role in energy 
production and apoptotic cell death (Berneburg et al., 2006). The UV-induced 4977 
bp mitochondria DNA common deletion (mtDNA-CD) is a recognized biomarker for 
photodamaged skin (Birch-Machin and Swalwell, 2010). Although the contribution 
of mtDNA-CD to skin carcinogenesis is currently unclear, high levels of mtDNA-CD 
affect cellular energy production (Berneburg et al., 2006, Kamenisch et al., 2007). 
Directly induced DNA photolesions, cyclobutane pyrimidine dimers (CPDs), are 
mediators for UV-induced immune suppression (Kripke et al., 1992). Although there 
is no direct evidence that oxidative photolesions, 8-oxo-7,8-dihydro-2’-
deoxyguanine (8-oxodG) are responsible for UV-immune suppression, 8-oxodG is 
mutagenic and likely involved in UV-skin carcinogenesis (Halliday, 2005). 
Prevention from UV-immune suppression and skin carcinogenesis is therefore 
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partially dependent on effective repair of these photolesions. This project aims to 
examine the role of nicotinamide in the regulation of repair of UV-induced DNA 
damage. Firstly, the effect of nicotinamide on UVA-induced mtDNA-CD was 
examined in HaCaT human keratinocytes and primary human fibroblasts. Cellular 
viability following repetitive UVA irradiations was assessed in both cell lines. Real-
time (RT) and nested polymerase chain reaction (PCR) was utilized to detect 
mtDNA-CD.  Secondly, the effect of nicotinamide on nuclear DNA repair synthesis 
was investigated using an unscheduled DNA synthesis (UDS) assay in HaCaT cells 
exposed to solar simulated (ss)-UV.  Nicotinamide is a natural inhibitor of PARP, 
and this may mediate nicotinamide protection from cellular energy loss during UVR 
(Park et al., 2010).  The inhibitory concentration of nicotinamide on PARP-1 activity 
was therefore determined in a cell free system using purified human PARP-1 extract 
and chemiluminescent assay. UDS assesses the overall ability of nicotinamide to 
stimulate DNA repair. It does not reveal formation and repair of specific UV-induced 
photolesions. Using a comet assay, and lesion-specific enzymes T4 endonuclease V 
(T4N5) and human 8-oxoguanine DNA N-glycosylase 1 (hOGG1), which cleave 
CPDs and 8-oxodG respectively, formation and repair of the two photolesions on 
ssUV-induced HaCaT cells were analysed in time course studies. To confirm the 
comet assay findings, ex vivo whole human skin obtained from healthy volunteers 
who underwent plastic surgery, was irradiated with the same dose of ssUV and 
immunostained with specific antibodies against CPDs and 8-oxodG. Finally to 
determine whether nicotinamide has potential as an oral chemoprevention agent 
against skin cancer in humans, the effect of two doses of nicotinamide (500 mg twice 
daily or 500 mg once daily) administered over 4 months was assessed on 
precancerous skin lesions (actinic keratoses, [AKs]) in two phase II randomized 
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double blinded placebo controlled trials. The results of these trials will determine 
whether the given doses of nicotinamide are safe as daily supplements and whether 
larger phase III clinical trial is warranted to validate the findings and investigate 
further the effect of nicotinamide on NMSCs.  
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CHAPTER 2 MATERIALS AND METHODS 
 
2.1. EFFECT OF NICOTINAMIDE ON DNA REPAIR 
AND MITOCHONDRIA DNA COMMON DELETION 
 
2.1.1. HaCaT cell line 
The HaCaT cell line (Figure 2.1a) was a kind gift from Professor Rebecca Mason, 
Department of Physiology, the University of Sydney. The HaCaT is a spontaneously 
immortalised human keratinocyte cell line derived from histologically normal skin. It 
was isolated from the distant periphery of a melanoma on the upper back of a 62 
year-old male patient (Boukamp et al., 1988). HaCaT cells were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) medium (Gibco, Invitrogen, 
Calsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (FBS) 
(Hyclone, Logan, UT, USA) in a 37°C humidified incubator containing 5% CO2.  
 
2.1.2. Primary human fibroblasts  
Primary human dermal fibroblast cultures (Figure 2.1b) used in the mitochondria 
DNA damage study were a kind gift from Dr Xiao Xuan Huang, a postdoctoral 
fellow in my laboratory. These cells were isolated from healthy human adult skins 
(n=4) obtained from breast reduction surgeries. The cells were grown in DMEM 
medium with 10% FBS (v/v). Samples from passages 4-8 were used in this study. 
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          Figure 2.1. Phase-contrast microscopic views of (a) HaCaT cells and  
          (b) primary human fibroblasts.  A green filter was used to enhance image contrast.    
 
(a) 
(b) 
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2.1.3. Cell plating and nicotinamide treatment 
Cells were detached from a cell culture flask following 5 minutes (mins) incubation 
at 37°C in 0.05% trypsin-EDTA (v/v) in Phosphate-Buffered Saline (PBS) solution 
(Invitrogen, Carlsbad, CA, USA). HaCaT cells are known to be highly adherent, in 
particular following UV irradiation. To prevent prolonged trypsinization, HaCaT 
cells were pre-incubated with 0.02% EDTA (w/v; Sigma-Aldrich, St Louis, MO, 
USA) in PBS for 10 mins at 37°C. Depending on the studies, the cells were seeded 
onto 5.5 cm-diameter-petri dishes (BD Falcon, BD Biosciences, Bedford, MA, USA) 
or polystyrene 4-chamber-well slides (BD Falcon) containing DMEM medium with 
10% FBS (v/v). The sizes of petri dishes and chamber-well slides were chosen as 
they allow a uniform dose of UV radiation to be delivered within the 7.5cm2 area of 
the solar simulator output.  
 
When the cells reached approximately 40% confluence, the medium was replaced 
with fresh prewarmed media (DMEM with 10% FBS (v/v) for comet assay and 
mitochondrial common deletion experiments; DMEM with 0.5% FBS (v/v) for 
Unscheduled DNA Synthesis (UDS) experiments) with 50µM nicotinamide (Sigma-
Aldrich, St Louis, MO, USA) was added to the nicotinamide (Nic) treatment group 
and the cells were placed in a humidified incubator for 24 hours at 37°C with 5% 
CO2. The FBS concentration in DMEM for the UDS experiments was reduced to 
0.5% to minimize the number of cells in replicative DNA synthesis (S-phase) as 
previously described (Saffi et al., 2010).  
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2.1.4. Human skin explant and nicotinamide treatment 
Human skin was obtained from healthy volunteers who underwent abdominoplasty 
(n=2) or breast reduction (n=1) surgeries with Dr David Pennington and Dr Harvey 
Stern, plastic surgeons at Strathfield Private Hospital, Sydney. Volunteers were 
contacted prior to the surgeries for informed consent (approved by the Ethics 
Committee of the University of Sydney according to Declaration of Helsinki 
principles) and were requested to fill in a questionnaire (Appendix 1), which 
included information on background medical history, current medications (including 
intake of vitamins), and Fitzpatrick skin phototyping. All volunteers (n=3) were 
female of age range 30-40 and of skin phototypes III-IV. Volunteers who were 
pregnant, immune suppressed, currently taking vitamin B3, had active malignancy or 
had melanoma in the past were excluded from the study.  
 
Human skin specimens (measuring at least 60 cm2) were transported in normal saline 
from the operating theatres to the laboratory. Within 4 hours of collection, excess fat 
was trimmed with curved scissors. The skin specimens were then washed once with 
chlorhexidine solution, rinsed twice with PBS, cut into 4×4 mm2 pieces (Figure 
2.2), and transferred into 6 cm-diameter petri dishes containing RPMI 1640 medium 
(Gibco) supplemented with 10% (v/v) FBS and 1% (v/v) penicillin-streptomycin-
amphotericin B (10,000U/ml, 10,000µg/ml, and 25µg/ml, respectively; Gibco). 
50µM nicotinamide was added to the nicotinamide groups. All petri dishes were then 
incubated for 24 hours in a 37°C humidified atmosphere containing 5% CO2.  
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          Figure 2.2. Human skin explant cut into full-thickness 4 mm2  
          and immersed in RPMI medium.  
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2.1.5. Ultraviolet radiation source and measurement 
Solar simulator 
Irradiation of the cells and ex vivo skin was performed with a 1000-Watt xenon-arc 
Oriel solar simulator (Newport, Stratford, CT, USA) (Figure 2.3a, 2.4). It emits UV 
radiation that closely matches the solar spectrum (Figure 2.6) and allows consistency 
in the doses of UV radiation delivered. It consists of a high-pressure ozone-free 
xenon-arc lamp, lamp igniter, collimating optics, a light shutter, and light shutter 
power supply, all housed in an aluminium casing. Integral fans and filter blower 
provide air-cooling to optimize housing temperature for the optics and prevent lamp 
overheating (Figure 2.4). The lamp has negligible output below 260nm and is 
replaced after 600-900 hours of use or when the output decreases significantly. The 
solar simulator was run at 1000 Watts using an external power supply (Figure 2.3b). 
A digital timer (Figure 2.3b) allows precise irradiation time within 0.1-second 
intervals. When an electric current passes through the pressurized xenon gas within 
the lamp, electromagnetic radiation (UV, visible light, and infrared light) is 
generated. An ellipsoidal reflector surrounding the lamp (Figure 2.4) collect more 
than 70% of the UV radiation produced, and directs it towards the first dichroic 
mirror, which then reflects the UV radiation towards an optical integrator. This 
integrates the UV radiation to produce a divergent beam and directs it towards the 
second dichroic mirror, which then reflects the UV radiation towards a collimating 
quartz lens, producing a uniform final output beam of 7.5 cm2. The two dichroic 
mirrors remove visible and infrared components, allowing only UV radiation (280-
400nm) to pass through. An atmospheric attenuation filter (UVC blocking filter) is 
placed between the second dichroic mirror and the quartz (collimating) lens (Figure 
2.4) to modify the output spectrum so that it closely simulates natural sunlight (290-
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400nm) (Figure 2.6). A UVB/UVC blocking filter, in place of the UVC blocking 
filter, was used to produce a UVA only spectrum  (320-400nm) (Figure 2.7).  
 
               
 
                 
     Figure 2.3. (a) Oriel solar simulator, (b) external power supply  
                 and digital timer. 
 
 
Digital Timer 
 
 
 
 
Power Supply 
(a) 
(b) 
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\
 
 
Figure 2.4. A cross-sectional view of Oriel solar simulator. 
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Scanning spectroradiometer  
Spectral irradiance of the solar simulator was monitored 6-monthly by an OL 756 
scanning spectroradiometer (Optronic Laboratories Inc., Orlando, FL, USA) (Figure 
2.5), which was calibrated against a traceable standard Tungsten-Halogen lamp (OL 
752-10) over the wavelength of 250-800nm. It consists of an input optic (an 
integrating sphere), which conveys the radiation from the source into the double 
monochromators (two holographic gratings with peak efficiency at 300nm), whose 
function is to disperse the irradiance onto a detector (a high-sensitivity, 
thermoelectrically-cooled photomultiplier). The spectroradiometer is capable of 
measuring spectral irradiance over 200-800nm ranges of wavelengths at 1nm 
intervals. The area under the curve of the measured spectrum (290-400nm for solar 
simulated UV (ssUV) spectrum, obtained with UVC blocking filter (Figure 2.6); 
320-400nm for UVA spectrum, obtained with UVB/UVC blocking filter (Figure 
2.7) represents spectral absolute irradiance (integrated power output in Watt/cm2).  
 
  Figure 2.5. A cross-sectional view of Optronics OL 756 spectroradiometer. 
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Figure 2.6. Solar simulator output with UVC blocking filter (dashed line) 
compared to natural sunlight (solid line). The sunlight spectrum was measured on the roof 
of Gloucester House, Royal Prince Alfred Hospital, Sydney, Australia (34°S longitude, 151° latitude), 
on a cloudless summer day, 17 February 2011, 1 pm using the same monitoring equipment as used to 
monitor the experimental irradiation source. (a) Natural sunlight and solar simulator (UVC blocking 
filter) spectra were normalised to 1 at 320nm to enable comparison of spectral shapes. (b) Absolute 
spectral irradiance. Both spectra were measured at 1nm interval by the author using the Optronics OL 
756 spectroradiometer. 
(b) 
(a) 
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Figure 2.7. Experimental source output with UVB/UVC blocking filter 
generating a UVA spectrum. The spectra were normalised to 1 at 360nm for comparison with 
natural sunlight spectrum. Both spectra were measured at 1nm increment with the calibrated 
Optronics OL 756 spectroradiometer. 
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Broadband radiometer 
Fluctuation in the xenon-arc solar simulator output was monitored just before each 
irradiation with a portable IL-1700 broadband radiometer (Figure 2.8a) using SED 
038 (UVA) and SED 240 (UVB) probes (Figure 2.8b) (International Light, 
Newburyport, USA.  This step is essential to ensure consistency and accuracy in the 
UV dose delivered to the skin and cells. In order to calibrate the broadband 
radiometer measurements to the solar simulator output as measured with the 
spectroradiometer, a calibration factor (CF) was determined as: 
 
CF (UVA) = solar simulator output (area under the curve between 320-400nm) 
(Watt/cm2) / Broadband radiometer reading (UVA probe) (Watt/cm2) 
 
CF (UVB) = solar simulator output (area under the curve between 290-320nm) 
(Watt/cm2) / Broadband radiometer reading (UVB probe) (Watt/cm2) 
 
The UVA probe was used in all experiments to measure solar simulator output just 
before irradiation. The UVA portion of the dose was calculated by multiplying the 
dose by the percentage of UVA in the spectrum as measured by the 
spectroradiometer.  
 
The time of irradiation to achieve the required dose by the skin or cells was 
determined as:  
 
Time (UVA probe)  (sec) = Dose Required (UVA portion) (mJoule/cm2) / (Broadband reading 
(UVA probe) (mWatt/cm2) × CF (UVA)) 
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       Figure 2.8. (a) Broadband radiometer, (b) UVA and UVB probes. 
 
 
 
(a) 
(b) 
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2.1.6. Cells and ex vivo skin irradiation  
After 24 hours incubation (± nicotinamide) at 37°C, UV groups were exposed to UV 
radiation using the 1000-Watt xenon-arc Oriel solar simulator (ssUV or UVA 
depending on the studies, Table 2.1). Before irradiation culture media was discarded 
and the cells or skin specimens were washed twice with prewarmed PBS to prevent 
formation of medium derived toxic photoproducts during irradiation (Cho et al., 
2008). A small amount of PBS was left in the petri dishes (1ml/ petri dish) and 4 
chamber-well slides (200µl/well) to prevent drying of the cells or skin specimens. 
For the skin, the epidermal side of the samples was set at the air-liquid (PBS) 
interphase in the petri dish. The cells/ skin samples were placed at the same distance 
from the collimating quartz lens of the solar simulator, as per measurements of the 
UV output with the broadband and spectroradiometer. After irradiation, the PBS was 
removed and replaced with respective media containing vehicle or nicotinamide for 
various incubation times depending on the studies.  
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Table 2.1. Methods and irradiation protocols used in these studies. 
Study  (method) Sample Dose   Frequency 
DNA excision repair activity 
(UDS/ immunofluorescence) 
HaCaT cells 4 J/cm2 (ssUV) Single irradiation 
DNA photolesions repair  
(Comet Assay) 
HaCaT cells 4 J/cm2 (ssUV) Single irradiation 
DNA photolesions repair  
(Immunohistochemistry) 
Melanocytes  4 J/cm2 (ssUV) Single irradiation 
DNA photolesions repair  
(Immunohistochemistry) 
Skin explant 4 J/cm2 (ssUV) Single irradiation 
Mitochondria DNA damage 
(Polymerase Chain Reaction) 
HaCaT cells and primary 
human fibroblasts (obtained 
from human breast skin) 
8 J/cm2 (UVA) 3 times/day for 4 consecutive days per week, for 
3 weeks  
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2.1.7. Cell counting with Vicell 
In the comet assay and mitochondria common deletion experiments, the cell number 
and viability were assessed by a Beckman Coulter Vi-CELL automated viability 
analyser (Beckman Coulter Inc., California, USA), which is based on a trypan blue 
exclusion method to determine cell viability. Viable cells, due to their intact plasma 
membranes, exclude the trypan blue. Non-viable, membrane-permeable cells stain 
dark blue. Aliqout of cells were placed in the autosampler cups, automatically 
aspirated and mixed with 0.4% (v/v) trypan blue. The cells were then drawn through 
a flow cell and imaged with a camera in real time. The images are analysed based on 
specific parameters for viability, concentration and morphology (cell type).   
 
2.1.8. Quantification of mitochondria DNA common 
deletion 
DNA extraction 
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) was used to extract 
DNA 24 hours after the last irradiation protocol (after 12, 24, and 36 UVA 
irradiations). The cells were detached by trypsinization, resuspended in 200µl of PBS 
in a 1.5 ml eppendorf tube (Eppendorf AG), treated with 4µl of 100mg/ml RNAase 
A, 20µl protease, and 200µl lysis buffer. After a brief vortexing for 15 seconds 
(secs), the mixture was incubated at 56°C for 10 mins and centrifuged (all 
centrifugation was at 5900 g for 1 min, unless otherwise indicated). 200µl pure 
ethanol (Sigma) was added to the tube. After a brief vortexing the tube was 
centrifuged. The mixture was applied to the QIAamp Mini spin column in a 
collection tube and centrifuged. The filtrate in the collection tube was discarded and 
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the column was reattached onto a new collection tube. 500µl wash Buffer AW1 was 
added and the column was centrifuged, discarded the filtrate, and reattached onto a 
new collection tube. 500µl wash Buffer AW2 was added and the column was 
centrifuged at full speed for 3 mins. Lastly, the Qiagen spin column was placed onto 
a sterile 1.5ml microcentrifuge tube and 200µl TE buffer was added before final 
centrifugation. This method was used to extract total genomic DNA including 
nuclear and mitochondria DNA (mtDNA). DNA concentration and its purity were 
measured by NanoDrop® ND-1000 (Thermo Scientific, Wilmington, DE, USA), a 
full-spectrum (220-750nm) spectrophotometer, which measures DNA by absorbance 
at 280 and 260nm. The presence of protein in the sample is determined by 
absorbance at 280nm. A comparison of the 260nm and 280nm readings indicates the 
purity of the samples. DNA samples with limited protein contamination will give an 
expected 260:280nm ratio of ~1.8. Any cross contamination from proteins will result 
in a reduced 260:280nm ratio. DNAs were stored at -20°C until further use.  
 
Primer design 
Initially, real-time polymerase chain reaction (RT-PCR) using primers as described 
previously (Pogozelski et al., 2003) (Table 2.2) with some modifications (SYBR 
Green-I was used for detecting and quantitating PCR products rather than TaqMan 
fluorescent probes). The modification was done due to inability to obtain the 
specified probes as per (Pogozelski et al., 2003) and failure to detect any 
fluorescence with modified probes. The forward and reverse primers for mtDNA-CD 
span the mtDNA sequence flanking the deleted junctions and designed to amplify an 
amplicon of 127 bp. Internal control forward and reverse primers (mtDNA-IC) were 
designed to amplify a product of 127 base pairs in length, containing a 12S rRNA 
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gene of the heavy strand of the mtDNA (Table 2.2), which contains no reported 
mutations or UV-induced deletions (Pogozelski et al., 2003). This served a reference 
fragment (internal control) during quantification. Positive control for mtDNA-CD 
was obtained from purified plasmids containing 227 bp DNA sequences flanking the 
deleted junctions of mtDNA (Mr. Gene GmbH, Regensburg, Bavaria, Germany). 
The amplification products of the plasmid using forward and reverse primers for 
mtDNA-CD are the expected products obtained from mitochondria containing 
mtDNA-CD. The use of plasmids to create positive controls for mtDNA-CD and 
external quantification standards has been shown previously (Pogozelski et al., 
2003). Due to high non-specific products detected with the mtDNA-CD primers, 
nested-PCR with two pairs of primers (outside mtDNA-CD and inside mtDNA-CD) 
were designed to amplify the region spanning the common deletion junction 
(mtDNA-CD). These were used in two successive runs of polymerase chain reaction 
(PCR) with the second (inside) primer pair designed to amplify a target sequence 
within the first PCR run product amplified using the first (outside) primer pair. 
Positive control for nested mtDNA-CD was obtained from purified plasmids 
containing 418 bp DNA sequences flanking the deleted junctions of mtDNA (Mr. 
Gene GmbH, Regensburg, Bavaria, Germany). The positive control DNA sequence 
for nested mtDNA-CD is longer than the positive control for regular (non-nested) 
mtDNA-CD in order to match the designed outside and inside primers for the nested 
mtDNA-CD. SYBR Green-I detection method was used with the nested-PCR 
mtDNA-CD and mtDNA-IC detections.  
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Table 2.2. Primers sequence for detection of mtDNA harbouring common 
deletion (mtDNA-CD) and internal control (mtDNA-IC). 
Primers Name Sequence (5’  3’)* Amplicon 
(product) size 
mtDNA-CDŦ 
mtDNA-CD-forward  
mtDNA-CD-reverse  
 
CCTTACACTATTCCTCATCACC 
TGTGGTCTTTGGAGTAGAAACC 
 
127 base pairs 
Nested mtDNA-CD¥ 
Outside mtDNA-CD  
mtDNA-CD-forward  
mtDNA-CD-reverse  
Inside mtDNA-CD  
mtDNA-CD-forward  
mtDNA-CD-reverse  
  
 
 
TCTAGAGCCCACTGTAAAGC 
 
GCGATGAGAGTAATAGATAGGG 
 
 
 
ACCAACACCTCTTTACAGTG 
 
CTCAGGCGTTTGTGTATGAT 
 
 
318 base pairs 
 
 
240 base pairs 
mtDNA-ICŦ 
mtDNA-IC forward  
mtDNA-IC reverse  
 
GTACCCACGTAAAGACGTTAGG 
 
TACTGCTAAATCCACCTTCG 
 
127 base pairs 
ŦPrimer pairs for mtDNA-CD and mtDNA-IC were based on Pogozelski et al, 2003. ¥Primer pairs for 
nested mtDNA-CD were based on a revised Cambridge Reference human mitochondrial sequence 
(www.mitomap.org/MITOMAP/HumanMitoSeq) and were designed by Dr Jane Huang, a post 
doctoral fellow at Dermatology Research Laborary, Sydney University.  
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Real-time polymerase chain reaction 
Real-time PCR was performed using a Rotor-Gene 6000  (Corbett Life Sciences, 
Qiagen, Valencia, CA, USA) with mtDNA-CD and mtDNA-IC reactions in separate 
tubes. The reactions were performed as a 20µl volume in triplicate using 100ng of 
total genomic DNA as template, 2× Platinum®SYBR®Green qPCR supermix-UDG 
(containing 400µM of each dGTP, dATP, dCTP, dUTP) (Invitrogen) and 0.25µM of 
each forward and reverse primer.  PCR conditions were as follows: Detection of 
mtDNA-CD and mtDNA-IC: initial denaturation (94°C for 4 mins) was followed by 
40 cycles of denaturation (94°C for 1 min), annealing (60°C for 55 secs), and 
extension (72°C for 30 secs, 81°C for 30 secs). Detection of mtDNA-CD with nested 
PCR: outside primer pair – initial denaturation (94°C for 4 mins), then 35 cycles of 
denaturation (94°C for 1 min), annealing (58°C for 1 min), and extension (72°C for 
45 secs). A 2µl aliquot of the outside primer PCR reaction was entered into 
reamplification with inside primer pair – initial denaturation (94°C for 4 mins), then 
40 cycles of denaturation (94°C for 1 min), annealing (60°C for 1 min), and 
extension (72°C for 30 secs). A short extension time for detection of mtDNA-CD 
was chosen in order to make amplification of deleted mtDNA more efficient than 
that of wild type mtDNA. Amplification products were visualized by gel 
electrophoresis on a 2% agarose gel stained with 0.25% ethidium bromide.  
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2.1.9. Measurement of nuclear DNA repair by unscheduled 
DNA synthesis (UDS) assay 
Unscheduled DNA synthesis (UDS) is a method for evaluating DNA repair through 
the uptake of the thymidine analogue, 5-bromo-2’-deoxyuridine (BrdU) into the 
DNA of cells that are not in the normal phase of DNA synthesis (S-phase). This kind 
of DNA synthesis is termed unscheduled DNA synthesis and it can be quantified by 
immunofluorescence staining using monoclonal antibodies against the BrdU. UDS 
was performed as previously described with some modifications (Nakagawa et al., 
1998). 
  
Cell treatments for UDS assay 
Following exposure to 4 J/cm2 ssUV, HaCaT cells grown in chamber slides were 
incubated with 10µM BrdU (± 50µM nicotinamide) in a 37°C humidified incubator 
with 5% CO2 for 45 mins to allow incorporation of BrdU into the DNA during post-
irradiation repair. At the end of the incubation period, the cells were fixed with cold 
methanol:glacial acetic acid (3:1) for 20 mins at 4°C, washed with 100% ethanol and 
stored at -20°C  before immunostaining.    
 
Immunofluorescence staining of BrdU 
To denature DNA, the cells were incubated with a 4 N hydrochloric acid (HCl) for 
30 mins at room temperature (RT). After washing with PBS (3 times 3 mins), the 
cells were incubated for 30 mins at RT with 20% FBS in PBS to reduce non-specific 
antibody binding. The cells were then incubated with purified mouse anti-BrdU 
monoclonal antibody (IgG1,κ) (BD Pharmingen, San Diego, CA, USA) diluted 1:300 
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with antibody diluent containing background reducing components (Dako, Glostrup, 
Denmark) for 30 mins at 37°C . For isotype control staining, mouse IgG1 
(DakoCytomation, Glostrup, Denmark) was diluted to the same protein concentration 
as the primary antibody. Negative (method) control cells received the diluent only. 
After washing with PBS (3 times 3 mins), the cells were incubated with biotinylated 
F(ab’)2 fragment of goat anti-mouse IgG (Invitrogen)  at 1:100 dilution for 30 mins 
at RT. Following washes with PBS (3 times 3 mins), the visualisation of primary and 
secondary antibody bindings was achieved by incubation with alexa-fluor 594-
conjugated streptavidin at final concentration of 10µg/ml for 30 mins at RT in the 
dark. The cells were then washed with PBS (3 times 3 mins), incubated with RNase 
A (Invitrogen) 100µg/ml for 10 mins at RT, and finally washed with deionized water 
(3 times 3 mins). After removing the walls of the chamber slides, they were 
counterstained and mounted in 4’,6-diamidino-2-phenylindole (DAPI) (Invitrogen) at 
a final concentration of 50ng/ml in deionized water and coverslipped.  
 
Quantification of DNA repair activity 
The cells were visualized using a fluorescence microscope (Olympus BH-2, 
Olympus Optical Co. Ltd., Japan) connected to a high-resolution digital camera and 
computer. Image-Pro Plus v.7.0 (Media Cybernetics, Inc., Bethesda, USA) software 
was used to quantify unscheduled DNA synthesis from digital images, based on the 
appearance of punctate spots (grains) in the nuclei, in contrast to the uniformly 
intense staining of the nuclei which underwent ordinary DNA synthesis during S-
phase (replication). All slides had the treatment group labels covered with black tape 
by a third party to prevent bias occurring during data collection and analyses. The 
tapes were uncovered following completion of data analyses. The percentage of UDS 
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and S-phase nuclei was calculated in at least 10 fields (40× magnification) for every 
treatment group. The number of grains per nuclei, which represents the degree of 
DNA repair in individual cell (Li et al., 2008) was analysed in all nuclei that 
underwent UDS in all treatment groups.  
 
2.1.10.  Detection of DNA damage and repair in HaCaT 
cells using the comet assay 
Cell treatments for the comet assay 
Following exposure to 4 J/cm2 ssUV and further incubation for 0, 30, 60, 90, or 120 
mins (with or without 50µM nicotinamide supplementation), HaCaT cells were 
harvested for DNA damage evaluation by alkaline single cell gel electrophoresis 
(comet assay), as described by Singh et al (Singh et al., 1988). As previously 
described, HaCaT cells are highly adherent to the petri dish, in particular after UV 
radiation (Wischermann et al., 2007). Prolonged trypsinization or scraping of 
adherent cells to detach them has been shown to increase background DNA damage 
as measured by comet assay (Singh et al., 1991, Hill and Hill, 1991). Preincubation 
of the cells in 0.02% EDTA (w/v; Sigma) in PBS for 10 mins at 37°C reduced 
trypsinization time to 5 mins. Due to the additional 15 mins taken to harvest the cells 
at 37°C, repair kinetics of UV-induced DNA damage were recorded as 15, 45, 75, 
105, and 135 mins post UV irradiation (i.e. incubation time plus 15 mins).  
 
Single cell gel electrophoresis (comet assay) 
Following harvesting, cell suspensions were centrifuged at 306 g, 4°C, for 5 mins 
and the cell pellet was resuspended in cold PBS. The cold temperature prevented 
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further repair from occuring. The cells were then mixed at 1:10 with low melting 
agarose (Trevigen Inc., USA). 75µL of the mixture of cells and agarose was pipetted 
onto the FLARE slide wells (Trevigen Inc., USA) and kept at 4°C for 1 hour to allow 
the gel to solidify. The slides were immersed in a lysis buffer containing 2.5M 
sodium chloride, 100mM EDTA, pH 10, 10mM Tris base, 1% sodium lauryl 
sarcosinate and 1% Triton X-100 for 1 hour at 4°C. To neutralize lysis buffer, the 
slides were incubated in FLARE buffer containing 10mM HEPES-KOH, pH 7.4, 
100mM KCl, and 10mM EDTA for 15 mins at RT and the buffer was changed twice 
during this period. 1 unit of the DNA excision enzyme human 8-oxoguanine DNA 
N-glycosylase 1 (hOGG1) or 200 units of T4-Endonuclease V (T4N5) enzymes 
diluted in FLARE buffer, bovine serum albumin (BSA, Trevigen) and deionized 
water was added to the enzyme wells and incubated at 37° C for 45 mins. hOGG1 
nicks DNA as sites of 8-oxodG photolesions and DNA containing 
formamidopyrimidine moieties, while T4N5 nicks DNA at sites of CPD 
photolesions. T4N5 also cleaves apurinic and apyrimidic (AP) sites on double and 
single-stranded DNA. Control wells received diluents only without the enzyme. The 
control wells detect DNA strand breaks not associated with the specific photolesions. 
Slides were then incubated in an alkaline solution (pH 12.1) for 30 mins at RT and 
the solution was changed once during this period. The alkaline treatment allows 
DNA denaturation and unwinding. The slides were briefly immersed in TBE buffer 
containing 89mM Tris Base, 89mM boric acid and 2mM EDTA-disodium salt (all 
materials from Sigma) dissolved in deionized water and then transferred to an 
electrophoresis tray containing TBE buffer. Electrophoresis was performed at 20 V 
for 30 mins. After electrophoresis, the slides were dipped in 70% ethanol for 5 mins 
and then air dried overnight. To minimize background DNA damage from ambient 
  
 99 
UV radiation, all these steps were conducted in dimmed light using a yellow lamp 
(60 Watt Philips Bugglezzz Incandescent bulb) connected to a rheostat light dimmer 
to minimize the brightness of the lamp. As measured by the spectroradiometer, this 
lamp does not emit UV radiation (Figure 2.9). 
 
 
Figure 2.9. A 60 Watt Philips Buglezzz Incandescent yellow lamp spectrum. The 
spectrum demonstrates visible light spectrum (wavelength > 400nm) and the absence of UV spectrum 
(wavelength < 400nm), measured at 35cm  (lamp to spectroradiometer distance, the same distance as 
a working distance during the comet assay study) measured at 1nm intervals using the Optronics OL 
756 spectroradiometer. 
 
Quantification of DNA damage 
SYBR Green was used to stain DNA as it has higher sensitivity and resolution 
compared to other DNA stains (Ward and Marples, 2000). 100µL of SYBR Green I 
dye solution (1µL of SYBR Green I in 10ml of TE buffer: 10mM Tris-HCl, 1mM 
EDTA, pH 7.5) was added to each well and incubated for 5 mins. Excess SYBR 
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Green I solution was then gently drained off and the slides were air dried in the dark 
at room temperature for 2 hours. The cells were visualized using a fluorescence 
based digital imaging system connected to a microscope. The cells were visualized 
and photographs were taken from each well using a fluorescent microscope 
(Olympus BH-2, Olympus Optical Co. Ltd., Japan) connected to a high-resolution 
digital camera and computer. 50 randomly selected cells were analysed for each 
treatment group.  Cells with damaged DNA appeared as fluorescent comets, with the 
nicked DNA electrophoresed into a comet behind the cell body. CometScore™ v1.5 
(TriTek) software was used to calculate tail moment (tail length × tail intensity), 
which represents DNA damage as described previously (Olive et al., 1990).  
 
2.1.11. Detection of DNA damage and repair in ex vivo 
human skin by immunohistochemistry 
Skin treatments, frozen sections, and slide preparation 
Following exposure to 4 J/cm2 ssUV and incubation for 15, 45, 75, 105, and 135 
mins in RPMI media (Gibco) with 10% FBS (± 50µM nicotinamide) in a humidified 
37°C incubator with 5% CO2, the skin pieces (each approximately 4 mm2) were 
washed with PBS and immersed in O.C.T. compound (Tissue-Tek®, Sakura, 
Zoeterwoude, Netherland) in 25×20×5mm cryomolds and then immediately snap-
frozen in liquid nitrogen. All frozen samples were kept in a -70°C freezer. Using a 
cryostat, the frozen blocks were cut into 6µm sections, which were mounted onto 
SuperFrost® UltraPlus glass slides (Menzel-Gläser, Glasbearbeitungswerk GmbH & 
co., KG, Braunschweig, Germany). The slides were incubated in ice-cold acetone at 
4°C for 20 mins, air dried at RT for 30 mins, wrapped in aluminium foil and stored 
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in a -70°C freezer. On the day of staining, the sections were permeabilized with Tris-
buffered saline (TBS) containing 0.05% Tween-20 (Sigma) (TBST). Each skin 
section on the slides was outlined using a pap pen (Zymed, San Francisco, CA, USA) 
and then reimmersed in the TBST to keep the sections well hydrated.  
 
Skin section treatments for immunostaining of CPD and 8-oxodG  
The sections for staining of cyclobutane pyrimidine dimers (CPDs) and 8-oxo-7,8-
dihydro-2’-deoxyguanosine (8-oxodG) were incubated in 0.15N sodium hydroxide 
(NaOH) in 70% alcohol at room temperature (RT) for 4 mins to denature DNA and 
then rinsed in 100mM Tris-HCl (pH 7.5) in 70% alcohol at RT for 1 min to 
neutralize. 5µg/ml proteinase K in Tris-EDTA (pH 7.5) was applied to each skin 
section (100µl/section) for 10 mins at 37°C, which causes proteolytic digestion of 
histones, opening up antigenic sites on the DNA for antibody bindings. The slides 
were then washed in TBST (standard rinse 3 times 3 mins in all washes, unless 
otherwise mentioned).  
 
Protein blocking and primary antibody incubation 
Protein blocking was performed using a serum-free protein block solution 
(DakoCytomation, Glostrup, Denmark) at RT for 1 hour. Without washing, the 
sections were then incubated with either: 
 
(1) Mouse monoclonal anti-8-oxodG antibody (Trevigen®, Gaithersburg, MD, 
USA) at 1:250 dilution at RT for 1 hour , OR 
(2) Mouse monoclonal anti-thymine dimer (CPD) antibody (Kamiya Biomedical, 
Seattle, WA, USA) at 1:120 dilution at RT for 90 mins 
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For isotype controls, mouse IgG1 isotype (DakoCytomation) and Mouse IgG2b 
isotype (DakoCytomation) were used to replace anti-thymine dimer and anti-8-
oxodG antibodies respectively. All primary antibodies and isotype controls were 
diluted in antibody diluent with background reducing components 
(DakoCytomation). The isotypes were diluted to the same protein concentrations as 
the corresponding primary antibodies. No antibody negative controls (method 
controls) were also included by just adding the diluent. All the slides were washed in 
TBS at the end of primary antibodies or isotypes incubation.  
 
Secondary antibody, streptavidin-AP, and chromogen incubation 
Dako REALTM Detection System + AP/ RED, Rabbit/ Mouse (Dako, Glostrup, 
Denmark) was used for visualisation. Tissue sections were first incubated with 
biotinylated anti-rabbit, anti-mouse, goat secondary antibody diluted 1:2 with 
antibody diluent (Dako) for 15 mins at RT.  After rinsing with TBST, the samples 
were incubated with Streptavidin-AP, which is streptavidin conjugated to alkaline 
phosphatase in PBS, for 15 mins at RT. The samples were then rinsed in TBST. 
 
Substrate-chromogen solution was prepared within 15 mins before application: 1 
drop of levamisole (endogenous alkaline phosphatase blocker) was dissolved in 10ml 
alkaline phophatase substrate buffer (Dako) as per manufacturer instruction. 740µL 
of the solution was then mixed with 30µL each of chromogen RED 1, 2, and 3. 
About 100µL was used to cover each section and incubated for 20 mins at RT. The 
chromogen is a Fast Red-type chromogen, which produces a red end product at the 
site of the target antigen. At the end of the incubation, the samples were then rinsed 
with deionized water (3 times 3 mins). 
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Quantification of skin staining  
At the end of staining protocols, all slides were air-dried overnight, mounted in 
VectaMount™ (Vector Laboratories, Burlingame, CA, USA) and cover-slipped. To 
randomize the slides, a third party covered the slides labels with black tape and a 
numbering system was used to identify the slides. Photomicrography and analyses 
were done in a blinded fashion. Photomicrographs were taken at the same 
microscope setting in one sitting per skin donor in order to minimize variability in 
background light intensity. Images were captured along the entire epidermis with 
good morphology (folded or fragmented epidermis were excluded), and saved in .tif 
format. Image analyses were performed using ImageJ 1.42 software (Wayne 
Rasband, National Institutes of Health, USA). The epidermis was outlined freehand 
and the area was measured in pixels quantity. CPD and 8-oxodG positive staining 
were calculated as a percentage of the epidermal area stained red. Using a plugin of 
Image J (Plugins  Threshold Colour  Saturation), a saturation threshold was 
determined for positive (red) area. A fixed threshold which best-represented positive 
slides was chosen and applied to all slides. Using the same threshold, the percentage 
of epidermal area stained positive in pixels was determined and the value was 
exported into excel spreadsheet for each slide. The average percentage positive 
staining was calculated for each treatment group. Analyses of hOGG1 stainings were 
determined as an average intensity for positively stained epidermal area. Using HSB 
(Hue Saturation Brightness) segmentation of the image J, a saturation auto-threshold 
for positive areas was set for each epidermis. The mean intensity of the thresholded 
positive epidermal areas was then measured and exported to excel spreadsheets. 
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2.2. EFFECT OF NICOTINAMIDE ON PARP-1 ENZYME 
ACTIVITY 
A PARP-1 inhibition assay was performed with PARP-1 chemiluminescent assay kit 
(BPS Bioscience, San Diego, USA) in a white 96-well-plate. 50µL of histone 
solution was added to the wells and incubated at 4°C overnight. The plate was 
washed with PBST buffer (Phosphate Buffer Saline containing 0.05% Tween 20) 3 
times 3 mins. The reaction was carried out in a total volume of 50µL containing 
100ng PARP-1, 5µM biotinylated substrate (NAD), 1× PARP-1 buffer, and 
100µg/ml activated-DNA at RT for 1 hour. Increasing concentrations of 
nicotinamide (25, 50, 100, 250, 500, and 2500µM) were added. Controls were wells 
with assay substrate, PARP-1 buffer and MilliQ water (no PARP-1) and wells with 
no nicotinamide for determining the maximum or 100% PARP-1 activity value. The 
plate was washed with PBST and incubated for 30 mins with 50µL/well 
Streptavidin-Horseradish Peroxidase, diluted 1:500 with blocking buffer. The plate 
was washed with PBST in preparation of the addition of the HRP substrate. For the 
chemiluminescent readout, a two-component substrate was mixed together in equal 
proportions and 100µL was added per well. The chemiluminescence was 
immediately determined in a plate reader (FLUOstar Omega, Alexandria, USA). Any 
intrinsic chemiluminescence exhibited by the substrate (background) was substracted 
and the values obtained from the various concentrations of nicotinamide were 
converted to a percentage of PARP activity. 
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2.3. ORAL NICOTINAMIDE FOR TREATMENT AND 
PREVENTION OF ACTINIC KERATOSES – PHASE 2 
CLINICAL TRIALS  
Two double-blind, randomized, placebo-controlled trials were conducted to test the 
hypothesis that supplementation with oral nicotinamide (Study 1 – 500 mg twice 
daily; Study 2 – 500 mg once daily) for 4 months reduces the incidence of actinic 
keratoses (AKs) in patients at high risk of skin cancer.  
 
2.3.1. Participants and eligibility criteria 
35 adults were recruited to Study 1 between June and October 2009 and 41 adults 
were recruited to Study 2 between August and November 2010. All participants were 
recruited from Royal Prince Alfred Hospital Dermatology Clinics, Sydney, Australia 
(latitude 33°S). A target sample size of 36 and 40 subjects provided 78% and 82% 
power in studies 1 and 2 respectively to detect a standardised effect size of 0.4 at the 
two-sided 5% level of significance based on an analysis of covariance model 
assuming a correlation of at least 0.90 between the baseline and follow-up 
assessments (Borm et al., 2007). These studies were approved by the ethics 
committees of the Sydney South West Area Health Service and the University of 
Sydney. The study protocols were registered with the Australian New Zealand 
Clinical Trials Registry (http://www.anzctr.org.au) (ACTRN 12609000490279 and 
ACTRN12610000689077). All volunteers were provided with trial information 
(Appendix 2) and gave written informed consent (Appendix 3) prior to inclusion in 
these studies. 
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Inclusion Criteria: 
• Men and women aged more than 18 years old 
• Symmetrically distributed non-hyperkeratotic actinic keratoses (AK) on 
face / scalp/ upper limbs 
• Minimum of 4 AKs in one or more treatment areas 
• Patients have received no other treatments for AKs within the last month 
Exclusion criteria:   
• Currently Pregnant or lactating 
• Taking immunosuppressive or photosensitising medications  
• Taking nicotinamide or other vitamin supplements 
• Patients unable to attend for regular follow up 
• Patients with active dermatitis 
• Liver disease  
• Currently taking carbamazepine  
• Immune suppressed (e.g. HIV infection, haematological malignancy) 
 
 Volunteers with liver disease were excluded from the studies as abnormal liver 
function tests including elevated serum concentration of bilirubins, 
aminotransferases (AST), and alanine animotransferase (ALT) have been reported 
with 3 g daily dose of nicotinamide for 3 months (Haslam et al., 1984). There is one 
report of reversible liver toxicity with a daily dose of 9 g nicotinamide (Winter and 
Boyer, 1973). Nicotinamide has been reported to increase serum concentration of 
carbamazepine and this may occur due to inhibition of cytochrome P450 isoenzymes 
by nicotinamide (Bourgeois et al., 1982).  Although there is no report of 
nicotinamide interaction with oral contraceptives, women of childbearing potential 
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who were taking the oral contraceptive pill were advised to use additional, barrier 
contraception during these studies.  
 
2.3.2. Baseline assessment and randomization 
Each participant had a complete skin examination by a dermatologist or a 
dermatology trainee (registrar) before randomisation and commencement of the 
study. All the recruited participants completed baseline questionnaires including 
demographic information, Fitzpatrick’s skin type (Fitzpatrick, 1988) (Table 2.3), 
general medical history, skin cancer history and previous AK treatments (Appendix 
4). Volunteers of Fitzpatrick skin types I-III participated in these studies. All 
participants were advised to use SPF 30+ sunscreen each day during the study as well 
as general sun protective measures.  
 
Table 2.3. Fitzpatrick’s Skin Phototypes.  
Phototype Constitutive skin colour  
(unexposed skin) 
Sunburn and tanning history  
(defines the phototype) 
I Ivory white Burns easily, never tans 
II White Burns easily, tans minimally with difficulty 
III White Burns moderately, tans moderately and 
uniformly 
IV Beige-olive, lightly tanned Burns minimally, tans moderately and easily 
V Moderate brown or tanned Rarely burns, tans profusely 
VI Dark brown or black Never burns, tans profusely 
Adapted from Fitzpatrick’s Dermatology in General Medicine, McGraw-Hill Professional; 5th edition. 
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Participants were randomised in a double-blinded manner to receive placebo 
(microcrystalline cellulose and 1% magnesium stearate; Australian Custom 
Pharmaceuticals, Sydney) or nicotinamide 500mg tablets (Nature’s Own, Virginia, 
Queensland, Australia) twice daily (trial 1) or once daily (trial 2) for 4 months. The 
placebo tablets were manufactured to be of similar size, shape and colour to the 
active tablets and all tablets were contained in identical opaque plastic bottles. Each 
participant was instructed to return the tablet bottles at each visit and the remaining 
tablets were counted at the conclusion of the trial for compliance analysis.  
Consecutive patients were allocated to treatment based on a randomisation list, 
which was created by a third party with permuted blocks method (block size of 6). 
One person (the author) counted the numbers of AK in both studies. All patients and 
the author remained blinded to treatment allocation until study completion. 
 
2.3.3. Assessments of actinic keratoses and skin cancers 
Based on thickness, AKs can be classified into 3 grades: grade I – visible, grade II – 
visible and palpable, and grade III – very thick (hyperkeratotic) (Olsen et al., 1991) 
(Figure 2.10). In the two trials, all palpable AKs (grade II and III) were quantified 
into one group. Visible but not palpable AKs were not counted in these studies due to 
low precision and low inter- and intra-observer correlation experienced in a previous 
trial on AKs with topical nicotinamide (Moloney et al., 2010).  
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Figure 2.10. Hand of a volunteer showing multiple AK (indicated by arrows) of 
different grades.  
 
At baseline, 2-month and 4-month assessments, palpable AKs on the face, scalp and 
upper limbs were identified, counted and the precise location of each lesion was 
documented on a body grid chart (Appendix 5) and by photographs. At each follow 
up visit, participants were evaluated for any side effects, asked if they had seen their 
usual dermatologist since their last visit and had any biopsies or excisions for skin 
cancers. Skin cancers diagnosed before or during the study were recorded and 
confirmed by review of histopathology reports. During the study, AKs clinically 
suspicious for undergoing malignant transformation as indicated by increase in size, 
pain, itch or tenderness (MacKie and Quinn, 2004), were biopsied and referred for 
treatment as per standard clinical practice. All biopsied AKs were noted and not 
included in the AK counts. 
 
Visible AK 
 Palpable AK 
    
Hyperkeratotic AK 
     
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2.3.4. Blood collection and measurement 
At baseline and at 2-month assessments, blood specimens were collected for full 
blood count (FBC), serum electrolytes, urea, creatinine (EUC), liver function tests 
(LFT), and total NAD/NADP quantification. FBC, EUC and LFT were performed 
independently in the clinical laboratories at Royal Prince Alfred Hospital. The results 
were viewed before each participant’s next visit and any abnormalities were noted, 
notified to the participants, the treating dermatologists, and were followed up by the 
regular general practitioners (GPs). Whole blood specimens for NAD(H) and 
NADP(H) quantification were collected in purple top tube containing anticoagulant 
potassium-ethylenediaminetetraacetic acid (K2EDTA) (BD, New Jersey, USA), 
stored initially in the 4°C fridge (no longer than 3 hours) until  participants’ 
assessments were completed, transported to Dermatology Research Laboratory, the 
University of Sydney, divided into 4 samples of 500µl each into a 2 ml Eppendorf 
tubes (Eppendorf AG, Hamburg, Germany), and stored  at -20°C freezer prior to 
NAD/NADP extraction and analyses.   
 
2.3.5. Extraction of NAD(H) and NADP(H) from blood 
NAD+, NADP+, NADH and NADPH were extracted from the blood samples as 
described by Jacobson et al (Jacobson and Jacobson, 1997). All materials for the 
extraction were obtained from Sigma (St Louis, MO, USA). 500µl of frozen whole 
blood was homogenized in 5ml of 1M NaOH by vortexing and was immediately 
neutralized with 1.25ml of 2M of H3PO4. The vortexing was limited to less than 2 
mins to avoid loss of oxidized nucleotides in alkali solution. To precipitate the 
protein, 1.1ml of ice-cold 1M HClO4 was added and the mixture was incubated at 
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4°C for at least 10 mins before centrifugation at 1912 g for 10 mins at 4°C. 2ml of 
the supernatant was collected, neutralized with 1ml of 1M KOH, and incubated at 
4°C for 10 mins. Finally, the sample was centrifuged at 1912 g for 10 mins at 4°C 
and the supernatant was collected for NAD(H) and NADP(H) assay.  
 
2.3.6. NAD(H) and NADP(H) assay  
NAD(H) and NADP(H) were assayed as described previously (Jacobson and 
Jacobson, 1997, Creeke et al., 2007). The assay is based on the principle of 
enzymatic cycling between oxidized and reduced states of pyridine nucleotides. 
NAD(H) and NADP(H) are the rate limiting components that determine the amount 
of oxidation of thiozolyl blue (MTT) (colour is yellow in oxidized state and blue in 
reduced state), which can be quantified by absorption at 570 nm. The sample was 
mixed with NAD or NADP assay cocktails (all materials from Sigma) in a NUNC 
96-well microtiter plate (Thermo Scientific, Roskilde, Denmark). NAD cocktail 
consists of 5 vols of NAD premix (570mM ethanol, 114mM bicine, 0.48mM 3-(4,5-
dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide, 4.8mM 
ethylenediaminetetraacetic acid, 1mg/ml bovine serum albumin (BSA)), 1 vol of 1 
mg/ml alcohol dehydrogenase, and 1 vol of 40mM phenazine ethosulfate. NADP 
coctail is made up of 5 vols of NADP premix (7.1 mM isocitrate, 76 mM phosphate 
buffer pH 6.8, 0.48 mM 3-(4,5-dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium 
bromide, 7mM MgCl2, 1mg/ml BSA), 0.28 vol of 10mg/ml isocitrate dehydrogenase, 
and 1 vol of 40mM phenazine ethosulfate. The samples were incubated at 0.015 g on 
a rotary plate mixer at room temperature (RT) for 30 mins before NAD(H) and 
NADP(H) measurement. At the end of the incubation, the absorbance (optical 
density) was measured at 570 nm in a plate reader (FLUOstar Omega, Alexandria, 
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USA). The concentration of NAD(H) or NADP(H) was measured using Beer-
Lambert law, concentration (M) = absorbance at 570 nm / (absorption coefficient × 
length of light pathway), with absorption coefficient = 6.22 × 102 L/mol cm and 
length of light pathway = 0.662 cm (depth of well for 200 µl mixture).  
 
2.4. STATISTICAL ANALYSIS 
Statistical analyses for nicotinamide trials were performed using SAS/STAT® 
software (SAS Institute Inc., Cary, NC, USA). All randomized volunteers were 
included in the statistical analyses in accordance with the intention to treat analysis 
principle. The primary endpoint obtained for each patient was the AK count at 4 
months. Secondary endpoints included AK count at 2 months. A loge transformation 
was applied to AK count data to normalize the right-skewed data distribution. 
Treatment groups were compared on the loge(AK count) endpoints using an analysis 
of covariance (ANCOVA) with treatment group as a factor and the baseline loge(AK 
count) as the covariate (Bonate, 2000). The estimates from these models were back-
transformed by taking the antilog for reporting (the absolute difference between the 
groups on loge(AK count), corresponding to the relative difference between the 
groups on AK count). Logistic regression was used to compare the proportion of 
patients in each group that developed new skin cancers and Poisson regression was 
used to compare the rate of new cancers in each group. A covariate adjusting for the 
number of previous cancers was included in modelling approaches. The comparison 
of skin cancer rates was repeated using a negative binomial model as part of a 
sensitivity analysis to examine the impact of possible over-dispersion.  
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All statistical analyses for laboratory experiments data were performed using a 
Prism® software (GraphPad Software, Inc., La Jolla, CA, USA). In all studies, data 
were based on at least 3 independent experiments conducted on at least duplicate 
samples. Results are expressed as means±SEM. For time course studies, where 4 
different groups (‘UV’, ‘UV + Nic’, ‘No UV’, ‘No UV + Nic’) were compared in 5 
time points, significant differences were determined with repeated measured analysis 
of variance (ANOVA). When only one time point was chosen, significant differences 
between 2 groups (‘UV’ Vs ‘UV + Nic’ and ‘No UV’ Vs ‘No UV + Nic’) were 
determined with Student’s paired t tests. In all statistical analyses, a p value < 0.05 
was considered significant. 
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CHAPTER 3 NICOTINAMIDE ENHANCES 
REPAIR OF ULTRAVIOLET RADIATION-
INDUCED DNA DAMAGE 
 
3.1. INTRODUCTION 
Nuclear DNA packed in chromosomes within the nucleus of a cell forms the basis of 
our genetic make-up, controlling cellular functions. A small amount of DNA is also 
found in the mitochondria (mtDNA), which contains 37 genes that are essential for 
normal mitochondrial function. 13 of these genes encode protein of the 
mitochondrial respiratory chain, 22 genes encode transfer RNA (tRNA) and 2 genes 
encode ribosomal RNA (rRNA), which both help to assemble the amino acids into 
the protein of the respiratory chain (Anderson et al., 1981).  
 
The effects of ultraviolet (UV) radiation on nuclear DNA in the skin are well 
recognized. These include DNA photodamage, immunosuppression, and the 
resulting induction of mutations and skin carcinogenesis. UV radiation has also been 
shown to induce mitochondrial DNA deletions (Berneburg et al., 1999, Koch et al., 
2001, Berneburg et al., 2004, Krishnan et al., 2004), although the significance of this 
in the induction of skin carcinogenesis is still unclear. One of the most studied 
mtDNA deletions is a 4977 bp deletion of mtDNA, also known as mt common 
deletion (mtDNA-CD). mtDNA-CD has been suggested to be a biomarker of skin 
photoageing (Yang et al., 1995, Berneburg et al., 1997, Birch-Machin et al., 1998) 
and may lead to a reduction in mitochondrial function and energy production 
(Berneburg et al., 2005). Furthermore, mitochondria play important roles in the 
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regulation of programmed cell death or apoptosis (Birch-Machin, 2006). Induction of 
apoptosis is central in preventing accumulation of genetic damage and progression to 
cancer.  
 
Nicotinamide is a water-soluble amide form of vitamin B3 or niacin. Both 
nicotinamide and niacin are dietary precursors for synthesis of coenzymes 
nicotinamide adenine dinucleotide (NAD), and its phosphorylated derivative NADP. 
NAD has a central role in cellular metabolism and energy production as a hydride-
accepting and hydride-donating coenzyme. NAD also functions as a substrate for 
NAD-consuming enzymes, including ADP-ribose transferases, poly(ADP-ribose) 
polymerases, cADP-ribose synthase and sirtuins (Belenky et al., 2007, Benavente et 
al., 2009). Nicotinamide is also an endogenous inhibitor of poly(ADP-ribose) 
polymerase (PARP) (Pero et al., 1999). PARP is a DNA damage-sensing nuclear 
enzyme, which cleaves NAD into nicotinamide and ADP-ribose (De Murcia et al., 
1994). Polymers of ADP-ribose (pADPr) covalently bind to nuclear proteins and this 
process was suggested to have a role in cellular responses following DNA damage 
(Satoh et al., 1994, Skaper, 2003, Kim et al., 2004).  
 
The first part of these studies aims to investigate the effect of nicotinamide on 
mitochondrial DNA mutations (mtDNA common deletion) in repetitively UVA-
irradiated HaCaT human keratinocytes and primary human fibroblasts. The second 
part of these studies examined the effect of nicotinamide on nuclear DNA repair 
activity in HaCaT keratinocytes after exposure to ssUV. Lastly, the inhibitory 
concentration of nicotinamide on PARP-1 activity was determined in purified human 
PARP-1, using a chemiluminescence activity assay.  
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3.2. RESULTS 
3.2.1. Quantification of mtDNA common deletion (mtDNA-
CD) by polymerase chain reaction (PCR) 
As previously described in Materials and Methods (Section 2.1), HaCaT cells and 
primary human fibroblasts (isolated from human breast skin) were incubated with 
50µM nicotinamide (Nic) for 24 hours before they were exposed to 8 J/cm2 UVA 
three times daily for four consecutive days for 3 weeks. In between irradiation 
periods, the cells in the nicotinamide treated groups (‘No UV + Nic’ and ‘UV + 
Nic’) were also incubated with 50µM nicotinamide. Total nuclear and mitochondrial 
DNA was extracted from the cells at the end of irradiation protocol (after 12, 24, and 
36 UVA irradiations) using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, 
USA). DNA concentration and purity was then measured with a NanoDrop® ND-
1000 Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). RT-PCR and 
then nested PCR designs were utilized to amplify mtDNA-CD. 12S rRNA gene of 
the heavy strand of mtDNA, known to be free from mutation or deletion (Pogozelski 
et al., 2003), was amplified as an internal control gene (mtDNA-IC).  
 
Effect of repetitive UVA doses on HaCaT and primary human 
fibroblast viability 
To investigate the effect of repetitive UVA irradiations (8 J/cm2) and 50µM 
nicotinamide on HaCaT cells and primary human fibroblasts survival, cell viability 
was assessed after 12, 24, and 36 UVA irradiations. There were no differences in 
viability between the groups treated with and without UVA or nicotinamide after 12 
or 24 UVA irradiations (one-way ANOVA). Viability exceeded 80% in all groups 
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soon after 12 and 24 UVA irradiations (Table 3.1, 3.2). However, cell deaths were 
apparent at and above 30 UVA irradiations, with most of the cells lost during media 
changes during the irradiation protocol. Hence these HaCaTs and fibroblasts could 
not be further irradiated and used for DNA extraction.  
 
Table 3.1. Percentage of viable HaCaT cells after repetitive UVA 
irradiations. 
  
No UV 
 
No UV + Nic 
       
    UV 
 
UV + Nic 
UVA 12 × 89.6 ± 0.6 90.2 ± 0.5 87.4 ± 2.8 83.4 ± 0.8 
UVA 24 × 94.0 ± 0.6 87.2 ± 4.3 92.7 ± 1.1 91.4 ± 2.4 
HaCaT cells were incubated with 50µM nicotinamide (Nic) for 24 hours at 37°C and then irradiated 
with 8 J/cm2 UVA (UV) three times a day for four consecutive days in each week.  At the fourth day 
each week, the cells were harvested, half of the cells were recultured for further irradiation in 
subsequent weeks, the half of the cells was collected for DNA extraction and PCR. Viable cell 
numbers were determined (Vi-CELL automated cell counter). The values shown are the mean ± SEM 
of 2 independent experiments, each performed in duplicate. No significant difference in cell viability 
in all groups at 12 × and 24 × repetitive UVA irradiation (p = 0.11 and p = 0.37 respectively; one-way 
ANOVA).  
 
 
 
Table 3.2. Percentage of viable primary human fibroblast cells after 
repetitive UVA irradiations. 
  
No UV 
 
No UV + Nic 
       
    UV 
 
UV + Nic 
UVA 12 × 97.7 ± 1.2 97.8 ± 0.9 96.2 ± 1.6 98.3 ± 1.0 
UVA 24 × 100 ± 0 98.7 ± 1.3 100 ± 0 99.3 ± 0.7 
Primary human fibroblasts isolated from human breast skin were incubated with 50µM nicotinamide 
(Nic) for 24 hours at 37°C and then irradiated with 8 J/cm2 UVA (UV) three times a day for four 
consecutive days. At the fourth day each week, the cells were harvested, half of the cells were 
recultured for further irradiation in subsequent week, the half of the cells was collected for DNA 
extraction and PCR. Viable cell numbers was determined (Vi-CELL automated cell counter). The 
values shown are the mean ± SEM of 2 independent experiments, each performed in duplicate. No 
significant difference in cell viability in all groups at 12 × and 24 × repetitive UVA irradiation (p = 
0.65 and p = 0.49 respectively; one-way ANOVA).  
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Measurement of purity of DNA samples 
Both quantity and quality of the total DNA isolated following extraction after 12 and 
24 UVA irradiations were measured with the Nanodrop® ND-1000 
Spectrophotometer.  As previously explained (Materials and Methods, Section 2.1.8), 
a ratio of absorbance at 260nm and 280nm (260:280nm ratio) was used to assess the 
purity of DNA samples. All isolated samples showed 260:280nm ratios between 1.8 
and 2, indicative the relatively high purity of the total DNA sample obtained.  
 
Both real-time PCR and nested PCR failed to detect mitochondrial 
common deletions in repetitively UVA-irradiated HaCaT cells and 
primary human fibroblasts  
Real-time PCR (RT-PCR) using primer oligonucleotides as described previously 
(Pogozelski et al., 2003) (Materials and Methods, Section 2.7.2) and SYBR Green-I 
for detection was performed. Plasmids containing 227 bp DNA sequences flanking 
the deleted junctions of mtDNA (Mr. Gene GmbH, Regensburg, Bavaria, Germany) 
were used to create positive controls and standard curves for real-time quantification. 
Despite multiple RT-PCR attempts, mtDNA-CD could not be detected in all the 
samples (HaCaT and primary human fibroblasts, 12 and 24 UVA irradiations) 
(Figure 3.1). mtDNA-IC and control plasmids for mtDNA-CD were amplified with 
the same RT-PCR conditions and visualized in a 2% agarose gel stained with 0.25% 
ethidium bromide (Figure 3.2). A nested PCR method was then developed to 
increase the specificity of amplified mtDNA-CD. Outside primers (outside mtDNA-
CD) were designed to anneal outside the 4977 bp common deletion, amplyifing 
primary fragments of 318 bp, which spans the deletion junction. To increase 
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sensitivity and specificity of secondary fragments, inside primers (inside mtDNA-
CD) were designed to amplify fragments of 240 bp, which are located “inside” the 
primary fragments. As a reference fragment for quantification, mtDNA-IC primers 
were designed to amplify a product of 127 bp, which represents a region of the 12S 
rRNA gene of the heavy strand, known to contain no reported mutations (Pogozelski 
et al., 2003). Despite multiple RT-PCR runs, no mtDNA-CD was detected. There 
were no primary products detected on the 2% agarose gel stained with 0.25% 
ethidium bromide in the first round of amplification with outside mtDNA-CD 
primers. Assuming that the yield was too low for detection on the agarose gel for the 
first round of amplifications with outside mtDNA-CD, a diluted aliquot (1:80 for 
primary human fibroblasts; 1:160 for HaCaTs) of the first round PCR product was 
entered into the second round of RT-PCR with inside mtDNA-CD primers. Again, 
no mtDNA-CD was amplified that was convincingly detectable above reliable 
threshold levels, and no mtDNA-CD could be visualized on the agarose gel. 
Therefore the detection assays appears to specifically detect the mtDNA-CD. 
However the photolesion could not be detected even after extensive UVA irradiation 
in these cells. It is possible that the photolesion was too rare to be detected, or that 
cells with this deletion died and therefore were not present in the final cell 
suspension used for analysis. Many attempts were made with variations on the UV 
irradiation protocol and spectra (including solar-simulated UV) but all without 
success. These are not presented as they just show, similarly to the presented data, an 
absence of detectable mtDNA-CD. Hence effects of nicotinamide on mitochondrial 
DNA damage were not pursued further. 
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Figure 3.1. Amplification of plots of standard plasmids for mtDNA-CD (positive 
control) and samples of extracted DNA from irradiated cells. Samples in these plots 
contained total DNA isolated from HaCaT cells irradiated 12 and 24 times with UVA are shown here. 
Similar amplification plots were shown for total DNA isolated from repetitively UVA irradiated 
primary human fibroblasts.  
 
     
Figure 3.2. Representative agarose gel of RT-PCR amplifications of the internal 
control (IC) and positive control (CD) from plasmid (both are 127 bp in size). 
   CD                                           IC      Hyperladder 
II 
127 bp 
 
 Size 
 
 
 
 
 
 2000 
 
 
 
 1000 
 
 
 
 
 
 
 500 
 
 
 
 
 300 
 
 
 
 200 
 
 
 
 
 100 
 
 
 
 50 
 
 
 
127 bp 
Standards 
(amplified 
from plasmid 
positive 
control) 
All samples 
below 
threshold for 
reliable 
detection 
  
 121 
3.2.2. Measurement of nuclear DNA repair activity by 
unscheduled DNA synthesis (UDS) assay 
Considering the inability to detect UV-induced damage to mitochondrial DNA, 
damage to nuclear DNA was explored. HaCaT keratinocytes, pre-incubated with 
50µM nicotinamide for 24 hours, were irradiated with a single dose of 4 J/cm2 solar-
simulated UV (ssUV) as per the protocol described in Material and Methods (Section 
2.1). After ssUV irradiation, repair of photodamage to nuclear DNA was measured 
via unscheduled DNA Synthesis (UDS).  This assay is based on the incorporation of 
the thymidine analogue Bromodeoxyuridine (BrdU) into a stretch of DNA being 
synthesized during repair of the photodamage (Beisker and Hittelman, 1988). BrdU 
detection was performed with immunofluorescence staining using an Alexa-Fluor-
594 (stains nuclei fluorescent red) detection system. Nuclei from all cells were 
counterstained by DAPI (4’-6-diamidio-2-phenylindole) (which stains nuclei blue 
upon UV visualisation). The percentage of nuclei undergoing UDS was quantified by 
numbers of BrdU-Alexa-Fluor594 labelled UDS nuclei compared to total numbers of 
nuclei labeled with DAPI only. A measure of DNA excision repair in each individual 
cell was further quantified by grain counts per nuclei (Li et al., 2008).  
 
Low dose ssUV and nicotinamide had no effect on HaCaT cell viability 
To investigate the effect of the low dose of ssUV (4 J/cm2) used in these studies and 
incubation with 50µM nicotinamide on HaCaT cell survival, cell viability was 
assessed at 15, 45, 75, 105 and 135 mins after ssUV irradiation. There were no 
differences in viability between groups treated with and without ssUV or 
nicotinamide at any time points after ssUV irradiation (repeated measures ANOVA). 
Viability exceeded 88% in all group at all times (Table 3.3) indicating that this dose 
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of ssUV was too low to cause substantial cell death and nicotinamide had no effect on 
HaCaT cell viability.  
 
Table 3.3. Percentage of viable HaCaT cells at various time points after 
irradiation. 
  
No UV 
 
No UV + Nic 
       
    UV 
 
UV + Nic 
15 minutes 92.6 ± 3.8 94.1 ± 2.1 86.9 ± 3.8 92.1 ± 4.1 
45 minutes 90.6 ± 5.3 91.2 ± 9.4 96.1 ± 3.4 92.9 ± 1.7 
75 minutes 93.8 ± 3.8 94.4 ± 3.4 92.9 ± 8.6 92.6 ± 4.1 
105 minutes 95.5 ± 1.0 91.4 ± 6.8 91.3 ± 6.3 88.9 ± 6.6 
135 minutes 93.9 ± 2.5 90.7 ± 0.6 92.3 ± 6.7 92.3 ± 3.9  
HaCaT cells were incubated with 50µM nicotinamide (Nic) for 24 hours at 37°C and then irradiated 
with 4 J/cm2 ssUV (UV).  Following further incubation, at various time points as previously 
described, the cells were detached from petri dishes and viable cell numbers was determined (Vi-
CELL automated cell counter). The values shown are the mean ± SEM of 3 independent experiments, 
each performed in duplicate. No significant difference in cell viability in all groups at all time points 
(P = 0.89; two-way repeated measured ANOVA). 
 
 
Nicotinamide enhanced unscheduled (repair), but not scheduled (cell 
division) DNA synthesis, in ssUV irradiated HaCaT keratinocytes  
In contrast to uniformly BrdU labelled nuclei undergoing replicative S-phase 
scheduled DNA synthesis, unscheduled DNA synthesis occurs in discrete foci 
throughout the nuclei (punctate nuclei) (Nakagawa et al., 1998) (Figure 3.3). 
Compared with unirradiated control cells (‘no UV’), the cells exposed to UV 
radiation demonstrate punctate nuclear staining, indicative of UDS (Figure 3.4). 
Treating the cells with nicotinamide increased the number of cells with punctate 
nuclei.  
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Figure 3.3. S-phase nuclei compared to UDS.  
Arrowheads point toward S-phase nuclei (scheduled DNA synthesis occurring before cell division). 
The nuclei show uniform staining. In contrast, UDS can be seen as punctate or granular staining of 
nuclei (stars). Magnification 20×. 
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                       DAPI                                BrdU (Alexa-Fluor-595)                           Merge 
 
 No UV 
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 UV 
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Figure 3.4. Nicotinamide stimulated unscheduled DNA synthesis in HaCaT 
cells irradiated with 4J/cm2 ssUV. DAPI and BrdU labeled HaCaTs visualized by 
fluorescence microscopy (20× magnification). The left panels show DAPI counterstaining of all 
nuclei (blue). The center panels demonstrate anti-BrdU binding to nuclei, which undergo DNA 
excision repair or cell division (red). The right panels merge the DAPI and anti-BrdU stainings.  
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Using Image-Pro v.7.0 image analysis software, the percentage of nuclei 
undergoing UDS was calculated in each treatment group. UV radiation increased 
the percentage of UDS nuclei (‘No UV’, 6.9% vs ‘UV’, 20.5%; p<0.0001) (Figure 
3.5a). This was expected as UV-induced genetic damage stimulates DNA repair. 
Nicotinamide (Nic) treatment by itself did not induce DNA damage as shown by 
the lack of any difference in the percentage of UDS nuclei in the unirradiated 
groups (‘No UV’, 6.9% vs ‘No UV + Nic’, 7.2%; p=0.73). However, in the 
presence of DNA damage induced by UV radiation, nicotinamide significantly 
increased the percentage of UDS nuclei (‘UV’, 20.5% vs ‘UV + Nic’, 25.2%; p = 
0.01). This indicates nicotinamide enhancement of the number of cells undergoing 
repair of UV-induced DNA damage.  
 
There was no significant difference in the percentage of S-phase cells in any 
treatment group.  Thus this low dose of ssUV was not sufficient to cause cell cycle 
arrest and treatment of HaCaT cells with 4 J/cm2 ssUV and/ or 50µM nicotinamide 
did not affect cell division (Figure 3.5b).  
 
The number of BrdU stained grains in each nuclei represents the number of DNA 
foci that are undergoing repair. The number of grains per nucleus was counted and 
found to increase after ssUV (‘No UV’, 46.3 grains/nucleus vs ‘UV’, 53.7 
grains/nucleus; p=0.0089) (Figure 3.5c). Nicotinamide was shown to further 
significantly increase the number of grains per nuclei (‘UV’, 53.7 grains/ nucleus 
vs ‘UV + Nic’, 62.1 grains/ nucleus; p=0.049), indicating that nicotinamide 
enhances the rate of repair in each cell in addition to the number of cells 
undergoing DNA repair.   
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Figure 3.5. Nicotinamide increased UDS, but not replicative (S-phase) 
DNA synthesis after UV irradiation. HaCaT cells were incubated with 50µM 
nicotinamide (Nic) for 24 hours and then exposed to 4 J/cm2 ssUV (UV) followed by 
incubation at 37oC. Repair was stopped 45 minutes after irradiation. The percentage of cells 
with (a) UDS and (b) S-phase nuclei in each group were counted in at least 10 microscopic 
fields (40× magnification) with each field containing at least 100 cells. (c) Number of grains 
per cell were counted and shown as UDS foci per nucleus. There were significant increases in 
the percentage of cells with UDS and in the population density per nucleus in irradiated, 
nicotinamide-treated cells (‘UV + Nic’) compared with UV alone (‘UV’) groups (paired 
Student’s t-test; mean + SEM of 4 independent experiments. 3 experiments with duplicate 
samples in each group and 1 experiment with one sample per group, i.e. total of n = 9 replicate 
experiments).  
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3.2.3. Effect of nicotinamide on PARP-1 enzyme activity  
PARP-1 is a DNA repair enzyme that uses NAD as a substrate but is inhibited by 
nicotinamide. It was examined whether the activity of this enzyme could be involved 
in responses stimulated by the low nicotinamide doses studied in these experiments. 
 
PARP-1 activity was measured using purified human PARP-1 (BPS bioscience, San 
Diego, USA) as described in Materials and Methods (Section 2.2). Briefly, histone 
proteins were immobilized on 96-well plates by overnight incubation. Biotinylated 
NAD, PARP-1, activated DNA and nicotinamide (0, 25, 50, 100, 250, 500 and 
2500µM) were added to the wells. PARP-1 catalyzes DNA-histone ribosylation, 
using biotinylated NAD as a substrate, forming DNA-histone-linked-ADP-ribose 
polymers. It was examined whether nicotinamide dose-dependently inhibits these 
reactions. Addition of Streptavidine-Horse Radish Peroxidase (Strep-HRP) enzyme 
and Strep-HRP chemilumisence substrate enables measurement of PARP-1 enzyme 
activity by chemiluminescence (FLUOstar omega reader, Alexandria, USA). 
 
Nicotinamide at concentrations of 50µM and larger significantly (all p < 0.05, one-
way ANOVA) inhibited PARP-1 activity (Figure 3.6). Addition of 50µM of 
nicotinamide resulted in approximately 66% reduction from maximum PARP-1 
activity whereas 500µM and higher nicotinamide caused more than 95% reduction in 
PARP-1 activity. 25µM nicotinamide did not significantly inhibit PARP-1.  
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Figure 3.6. Nicotinamide inhibits poly-ADP-ribose polymerase (PARP) activity 
at concentrations of 50µM and higher. Purified human PARP enzyme activity was 
measured by chemiluminescent assay. n = 8 for no (0) nicotinamide positive control; n=12, 12, 4, 6, 5 
and 6 for nicotinamide at concentrations from 25 to 2500µM respectively; *p < 0.01; **p < 0.001; 
one-way ANOVA compared with control.  
 
 
 
3.3. DISCUSSION 
 
The aim of these experiments was to commence investigation into regulation of UV-
induced DNA damage by nicotinamide. In this chapter it was determined whether 
nicotinamide could enhance repair of mitochondrial or genomic DNA and as NAD is 
the sole substrate of PARP-1 whether increased activity of this DNA repair enzyme 
could be involved. These studies show that the low dose of UV radiation used in 
these studies was not able to induce detectable levels of mitochondrial DNA damage 
but could cause damage to nuclear DNA. Nicotinamide increased repair of UV 
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damaged nuclear DNA but did not augment activity of PARP-1. Nicotinamide 
effects on repair of nuclear DNA are explored in more detail in the next chapter.  
 
Quantification of mtDNA-CD is a difficult task as the deletions are frequently 
present in very low copies, especially in tissues and cultured cells with high turnover 
rate, such as skin (Pogozelski et al., 2003). Selective growth disadvantage in the cells 
with large-scale mtDNA deletions may further decrease the number of cells 
harboring mtDNA-CD (Bourgeron et al., 1993, Gattermann et al., 1995). There are 
three possible reasons for the failure to detect mtDNA-CD in these studies. First, 
while the UV irradiation protocol was low and did not increase the rate of cell death 
above unirradiated cells, the cells with mtDNA-CD, while few in number, may have 
preferentially died.  Hence they would have been washed off during the media 
change and their DNA not available for analysis. HaCaT keratinocytes have been 
shown to have a dysfunctional constitutive NF-κB signaling pathway, resulting in 
increased sensitivity of these cells to UV-induced apoptosis (Qin et al., 1999). If the 
mtDNA-CD was induced in a small number of HaCaT cells that were more prone to 
death, then this small increase in cell death would not have been detected in the 
viability assessment. Secondly, the detection system may not have been sufficiently 
sensitive. The primers and PCR conditions used, although able to successfully 
amplify the positive control derived from a commercial plasmid, may not have been 
sufficiently sensitive for amplification of the small copies of mtDNA-CD present in 
the samples. A large number of studies were conducted (mostly not presented) with 
gradual increases in UVA dosages and higher frequencies of DNA extractions and 
different spectra to determine the optimal irradiation protocols to give detectable 
mtDNA-CD. However none of these were successful. Thirdly, the most probably 
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explanation is that the low doses of UV radiation used in these studies were 
insufficient to cause the mtDNA-CD in cultured cells.  
 
Previous studies in normal human fibroblasts showed that repetitive 16 J/cm2 UVA 
irradiations resulted in cell deaths, while repetitive UVA irradiations with the lower 
dosages 4 J/cm2 and 8 J/cm2 had no effect on cell viability (Berneburg et al., 1999, 
Berneburg and Krutmann, 2000, Berneburg et al., 2005). In the same studies, 
exposure to 8 J/cm2 UVA for 12 times failed to cause detectable mtCD-DNA, 
whereas 24 and 36 times 8 J/cm2 UVA irradiations resulted in detectable and 
maximal induction of mtDNA-CD respectively (Berneburg et al., 1999, Berneburg 
and Krutmann, 2000, Berneburg et al., 2005). In my study, irradiation of primary 
human fibroblasts with 8 J/cm2 UVA for 12 and 24 times had no effect on cell 
viability. Irradiation of the cells with 8 J/cm2 UVA for 30 times and higher resulted 
in excessive cell death. While in these studies the threshold dose for mtCD-DNA 
detection is 24 times of 8 J/cm2 UVA irradiations, no mtCD-DNA was detectable 
with the method used in my study. However, these studies used a different irradiation 
source (UVASUN5000 Biomed irradiation device, filtered to consist of wavelengths 
greater than 340nm) from the one used in my study (1000 W xenon-arc Oriel solar 
simulator, filtered to consist of wavelengths between 320 and 400nm). Furthermore, 
no previous studies using repetitive doses of UVA to induce mtDNA-CD have been 
reported in HaCaT keratinocytes. Hence it is likely that the doses used in these 
studies, designed to mimic the exposures received by humans during normal daily 
activities, are not able to induce mtDNA-CD in cultured HaCaT cells. Hence 
nicotinamide could not be examined in this system. 
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Nicotinamide treatment caused an increase in nuclear DNA repair in HaCaT human 
keratinocytes exposed to a low dose of ssUV (4 J/cm2). The ssUV used in this study 
consists of 90.43% UVA and 9.57% UVB (as measured by an Optronics OL 756 
spectroradiometer; Materials and Methods, Section 2.1.5) and was found to be 
suberythemal in our previous in vivo studies in humans (Damian et al., 2008). This 
dose mimics low dose incidental daily sunlight exposure rather than high dose 
erythemal recreational exposure. The effect of 4 J/cm2 ssUV on HaCaT cell viability 
was assessed at various time points up to 135 mins after UV irradiation, which is 
many times longer than the time period over which UDS was determined. The 
Dulbecco’s Modified Eagle’s (DMEM) medium (Gibco, Invitrogen, Calsbad, CA, 
USA) used in this study is known to contain 32.8µM nicotinamide. Hence, after 
50µM nicotinamide supplementation, the total nicotinamide concentration in the 
media was 82.8µM. The dose of nicotinamide and ssUV used in this study had no 
effect on cellular survival, which is consistent with previous findings from my 
laboratory at similar ssUV doses (Park et al., 2010). Furthermore, the ssUV dose 
used in this study is not sufficient to decrease cell viability or induce cell cycle arrest 
as demonstrated by the lack of effect on cells entering division. Hence, loss of UV 
damaged cells or arrest of cell division did not appear to be able to complicate 
interpretation of our assays for detection of DNA repair. This low dose ssUV 
irradiation however resulted in an almost threefold increase in the proportion of cells 
undergoing UDS within 45 mins of irradiation, showing that it damaged DNA and 
initiated DNA repair. Nicotinamide treatment for 24 hours before irradiation and 
during the 45 mins incubation time after irradiation, caused a further significant 
23.3% relative increase in the number of cells showing UDS. The number of grains 
within cells reflects the amount of incorporated thymidine per cell during excision 
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repair and this also increased with nicotinamide treatment, suggesting an increased 
rate of DNA repair synthesis in UV damaged cells. Hence, nicotinamide stimulates 
not only the proportion of cells undergoing repair of UV-induced DNA damage, but 
also the repair rate in each cell.  
 
The mechanism involved in nicotinamide enhancement of UDS is not completely 
understood. Nicotinamide is a precursor for NAD, a substrate for the synthesis of 
poly(ADP-riboses) polymers. This is a product of the activity of the nuclear DNA 
damage sensing enzyme poly(ADP-ribose) polymerase (PARP). In a different study, 
stimulation of UDS has been reported to occur in association with poly(ADP-ribose) 
synthesis and both processes increased in a dose-dependent manner with increasing 
UV doses (Berger et al., 1979). UV irradiation of cultured human fibroblasts and 
mouse skin in vivo depletes intracellular and epidermal NAD respectively and these 
were found to be associated with activation of PARP-1 and an accumulation of its 
metabolites poly(ADP-riboses) (Jacobson et al., 1983, Balard and Giacomoni, 1989, 
Jacobson et al., 2001). Addition of nicotinamide into a cell culture medium 
containing primary human mammary epithelial cells (HMEC) increased intracellular 
NAD content and prevented lowering of NAD following the cells treatment with the 
DNA damaging agent, N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) (Jacobson et 
al., 1999). Hence, it was examined whether nicotinamide functions in the DNA 
damage response by replenishing cellular NAD and thereby activating PARP, 
resulting in enhancement of UDS. However the concentration of nicotinamide used 
in these studies did not enhance PARP activity suggesting that nicotinamide did not 
enhance UDS via this mechanism. PARP-1 is a complex DNA damage sensing 
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enzyme and it remains possible that it is involved in some way, but it is unlikely that 
an inhibition of this enzyme can explain enhancement of UDS. 
 
This is the first study showing nicotinamide stimulation of UDS after solar simulated 
UV irradiation in HaCaT human keratinocytes. It seems that nicotinamide’s effect on 
UDS stimulation is not species- and /or tissue-specific. Previous studies on the effect 
of nicotinamide on UDS in human cells were conducted in ex vivo normal human 
lymphocytes, exposed to various DNA-damaging agents including UVB, MNNG, 
dimethyl sulphate (DMS) (Berger and Sikorski, 1980, Sims et al., 1981, Miwa et al., 
1981) and γ-radiation (Kjellen et al., 1986). Nicotinamide supplementation to the 
media prevented lowering of intracellular NAD associated with exposure to DNA 
damaging agents, and at the concentration range between 2-5mM nicotinamide 
increased UDS in these cells (Berger and Sikorski, 1980, Sims et al., 1981, Miwa et 
al., 1981, Kjellen et al., 1986). Nicotinamide’s effect on UDS is dependent on 
functional DNA repair mechanisms as shown by the lack of effect of nicotinamide 
on UDS in human fibroblasts derived from patients with xerodermal pigmentosum, a 
rare genetic disease characterized by a defect in nucleotide excision repair (Riklis et 
al., 1990). Nicotinamide also stimulated UDS in murine studies in vitro. Addition of 
25µM nicotinamide in the culture medium increased UDS in cultured rat hepatocytes 
exposed to a carcinogen, methyl methanesulfonate and a procarcinogen, 2-
acetylaminofluorene (Althaus et al., 1980). In a tumour cell line, K-1735 mouse 
melanoma non-metastatic C1-11 cells exposed to gamma and UVC irradiation, 3mM 
nicotinamide increased UDS (Riklis et al., 1990).  
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Previous studies in my laboratory showed that the concentration of nicotinamide used 
here prevented depletion of cellular energy (ATP) during irradiation of HaCaT 
keratinocytes using the same ssUV source and dose (Park et al., 2010). Hence, it is 
more likely that 50µM nicotinamide, at least at a cellular level in the presence of UV-
induced DNA damage, enables the supply of larger amounts of ATP, thus leading to 
stimulation of UDS. Further details of nicotinamide augmentation of nuclear DNA 
repair are explored in the next chapter of this thesis.  
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CHAPTER 4 NICOTINAMIDE ENHANCES 
REPAIR OF ULTRAVIOLET RADIATION-
INDUCED CYLOBUTANE PYRIMIDINE 
DIMERS AND 8-OXO-7,8-DIHYDRO-2’-
DEOXYGUANOSINE 
 
4.1. INTRODUCTION 
UVB (290-320nm) damages DNA directly resulting in the formation of cyclobutane 
pyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone photoproducts (6-4PPs) 
(Sutherland and Griffin, 1981, Young et al., 1996). Both CPDs and 6-4PPs induce 
UV-signature CT and CCTT transitions at dipyrimidines (Yoon et al., 2000), the 
most commonly found hotspot mutations in the p53 gene of non-melanoma skin 
cancers (NMSC) (Brash et al., 1991, Ziegler et al., 1993). However, CPDs are 
thought to be the major mutation contributors in mammalian cells as 6-4PPs are 
formed at levels that are significantly lower (Mitchell and Nairn, 1989, Yoon et al., 
2000) and are repaired at much faster rates (Mitchell and Nairn, 1989), than that of 
CPDs. UVA can also cause the formation of CPDs by unknown mechanisms (Tewari 
et al., 2012). Nucleotide excision repair (NER) removes helix distorting lesions 
including CPDs and 6-4PPs (Hoeijmakers, 2001). DNA repair has an important role 
in preventing mutation and cancer. NER-deficient xeroderma pigmentosum (XP) 
patients developed 2000-fold increased frequency of skin cancers (Kraemer et al., 
1984) and the majority of the tumours from these patients harboured UV signature 
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mutations in the p53 genes (Dumaz et al., 1993, Sato et al., 1993, Spatz et al., 2001). 
Moreover, repair efficiency may play an important role in preventing skin cancer. In 
UV-irradiated human fibroblasts, sites of mutational hotspots on the p53 gene 
coincide with the nucleotide positions where repair of pyrimidine dimers was 
particularly slow (Tornaletti and Pfeifer, 1994).  
UVA (320-400 nm) induces CPDs but also causes singlet oxygen photosensitization-
induced DNA photolesions such as 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) 
and 4,6-diamino-5-formamidopyrimidine (FapyG)  (Pfeifer et al., 2005). UVB can 
also cause this oxidative damage to DNA (Besaratinia et al., 2005).  The base 
excision repair (BER) pathway is the primary mechanism for repair of these oxidative 
base lesions. The initial step in BER involves DNA glycosylases cleaving N-glycosyl 
bonds between the sugar and the base, releasing the damaged base to form an abasic 
(apurinic/ apyrimidic (AP) site. Human 8-oxoguanine-DNA N-glycosylase 1 
(hOGG1) cleaves 8-oxodG and FapyG lesions (Maynard et al., 2009). Efficient 
removal of 8-oxodG plays an important role in preventing skin carcinogenesis. 8-
oxodG is the major cause of  G:CA:T transversions (Kim et al., 2007, Besaratinia 
et al., 2008) and failure to remove 8-oxodG in Ogg1 knockout mice makes them more 
susceptible to skin carcinogenesis (Kunisada et al., 2005). Recently it has been shown 
that basal cell carcinomas are deficient in hOGG1 and have a correspondingly high 
level of unrepaired 8-oxodG (Huang et al., 2012).  
In the previous Chapter, nicotinamide was shown to stimulate unscheduled DNA 
synthesis (UDS). Although UDS measures the amount of DNA repair synthesis, its 
correlation with repair of specific DNA photolesions is not completely understood. In 
the following studies in this Chapter, formation and repair of UV-induced CPDs and 
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8-oxodG photolesions and the effect of nicotinamide on these were investigated. In 
the first part of these studies, the comet assay was utilized to examine the effect of 
nicotinamide on formation and repair of CPDs and 8-oxodG respectively at a single 
cell level in HaCaT keratinocytes. In the second part of the studies, immunostaining 
of whole human skin with antibodies against CPDs and 8-oxodG was used to analyse 
photolesion formation and repair in the upper and lower epidermis of whole human 
skin. Lastly, the effect of nicotinamide on hOGG1 expression was examined in ex 
vivo human skin through immunostaining of the hOOG1 proteins.  
 
 
4.2. RESULTS 
4.2.1. Detection of CPDs and 8-oxodG in HaCaT cells by 
comet assay 
HaCaT human keratinocytes were incubated with or without 50µM nicotinamide 
supplementation in DMEM media (containing a basal level of 32.8µM nicotinamide; 
hence total nicotinamide concentration after nicotinamide supplementation was 
82.8µM) for 24 hours before exposure to 4 J/cm2 ssUV. The media was changed to 
PBS for the irradiations. Following irradiation, the cells were incubated for 0, 30, 60, 
90, or 120 mins to enable DNA repair, with or without 50µM nicotinamide 
supplementation at 37°C. Cells were then detached from culture flasks for 
measurement of DNA damage using the comet assay. A further 15 mins’ incubation 
at 37°C (10 mins in 0.02% EDTA (w/v) [Sigma-Aldrich] and 5 mins in 0.05% (v/v) 
Trypsin-EDTA solution [Invitrogen]) were undertaken to detach the cells gently, 
avoiding unwanted DNA damage. DNA repair would have occurred during this 
additional incubation time. Hence, the comet assay time course was reported as 15, 
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45, 75, 105, and 135 mins following irradiation. The comet assay was performed as 
previously described in Materials and Methods (Section 2.1.10). DNA damage was 
evaluated using the tail moment parameter, which is defined as the product of the 
amount of DNA in the comet tail and the mean distance of migration in the tail (Olive 
et al., 1990). This was calculated using CometScore™ v1.5 (TriTek) software. The 
standard alkaline comet assay detects DNA strand breaks and alkali-labile sites 
(apurinic and pyrimidic (AP) sites) (Collins et al., 2008). T4-Endonuclease V (T4N5) 
recognizes CPDs and AP sites on double and single-stranded DNA, whereas hOGG1 
catalyzes the removal of 8-oxodG and DNA-containing formamidopyrimidine 
moieties (Smith et al., 2006). These enzymes were therefore used to detect the 
relevant specific photolesion. In parallel with the enzyme incubation, no-enzyme 
control slides were incubated with buffer alone, and the tail moment scores from 
these control slides were subtracted from the ‘+ enzyme’ tail moment scores to give 
the ‘net T4N5- or hOGG1-sensitive sites’ tail moment scores. Three separate 
experiments were performed for each group and each time point. At least 50 cells 
were analyzed for each treatment group.  
 
Nicotinamide enhanced repair of CPDs in HaCaT keratinocytes 
Unirradiated cells with or without nicotinamide did not have elongated tails (Figure 
4.1. ‘No UV’ and ‘No UV + Nic’ panels) and showed undetectable tail moments 
(Figure 4.2). This is consistent with the UDS data that nicotinamide alone did not 
cause DNA damage. Exposure to 4 J/cm2 ssUV induced formation of T4N5-sensitive 
sites (CPDs and AP sites), which were repaired to baseline within the duration of 
these experiments. At 45 and 75 mins respectively after irradiation, there were 19.9% 
and 38.6% relative reductions in T4N5-tail moments in ‘UV + Nic’ treated cells 
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compared to ‘UV’ treated cells (Figure 4.2). Using repeated measures ANOVA to 
compare tail moment values over the repair time course, nicotinamide was found to 
significantly enhance the repair of CPDs (p=0.0001, ‘UV’ vs ‘UV + Nic’), consistent 
with the UDS data on nicotinamide stimulation of DNA repair.  
 
 
   
 
 
 
Figure 4.1. Nicotinamide (Nic) decreased ssUV-induced T4N5-sensitive sites            
(represented as comet tails) in HaCaT keratinocytes as determined by comet 
assay.  HaCaT cells were exposed to 4J/cm2 ssUV or were unexposed (‘No UV’). They were further 
incubated for the times as indicated, and then harvested for comet assay. The tail of the comet was 
visualized by microscopy. Photomicrographs of representative fields are shown (20× magnification). 
Single cells can be seen with their “comet” of damaged DNA extending to the right of the cell body. 
The maximal reduction in tail moment is seen at 45 minutes after UV.  
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Figure 4.2.  Nicotinamide increased repair of T4N5 sensitive sites induced by 4 
J/cm2 ssUV in HaCaT keratinocyte cells as measured by comet assay. HaCaT cells 
were irradiated with 4 J/cm2 ssUV, further incubated for various times as shown, and finally detached 
for quantification of T4N5-sensitive sites using the comet assay with T4N5 enzymes. Tail moments 
(tail length × fluorescent intensity) were measured in at least 50 cells in each treatment group using 
image analysis. Each time point represents the mean ± SEM from 3 independent experiments. 
Nicotinamide significantly enhanced repair of T4N5-sensitive sites in irradiated HaCaT keratinocytes 
(p=0.0001; ‘UV’ vs ‘UV + Nic’, repeated measures ANOVA).  
 
Nicotinamide enhanced repair of 8-oxodG in HaCaT keratinocytes 
8-oxodG is a ubiquitous type of oxidative DNA damage formed by various 
endogenous and exogenous biochemical processes (Evans et al., 2004). It was 
therefore found as expected in unirradiated keratinocytes (Figure 4.4, 4.5). 8-oxodG 
was significantly increased by 4 J/cm2 ssUV, detected at 15 and 45 mins after 
irradiation (p<0.0001; ‘UV’ vs ‘No UV’, repeated measures ANOVA). In UV 
irradiated cells, a 45.6% relative reduction in 8-oxodG at 45 mins after irradiation 
was observed in cells pretreated with nicotinamide. At 75 mins after ssUV, most 8-
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oxodG had been removed by excision repair.  Nicotinamide significantly reduced the 
number of 8-oxodG photolesions over the time course studied (p<0.0001; ‘UV’ vs 
‘UV + Nic’, repeated measures ANOVA), showing that nicotinamide increased repair 
of this photolesion. 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Nicotinamide (Nic) decreased ssUV-induced hOGG1- sensitive sites 
(represented as comet tails) in HaCaT keratinocytes as determined by comet 
assay.  HaCaT cells were exposed to 4J/cm2 ssUV or were unirradiated (‘No UV’). They were 
incubated for various times with or without nicotinamide as shown. They were then harvested for 
comet assay. The tail of the comet was visualized by microscopy. Photomicrographs of representative 
fields are shown (20× magnification). Single cells can be seen with their “comet” of damaged DNA 
extending to the right of the cell body. The maximal reduction in tail moment is seen at 45 minutes 
after UV. 
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Figure 4.5.  Nicotinamide increased repair of 8-oxodG induced by 4 J/cm2 ssUV 
in HaCaT keratinocyte cells as measured by comet assay. HaCaT cells were irradiated 
with 4 J/cm2 ssUV or were unirradiated (‘No UV’). The cells were further incubated with (Nic) or 
without nicotinamide for various times as indicated. The cells were finally detached for quantification 
of hOGG1-sensitive sites using the comet assay with hOGG1 enzymes. Tail moments (tail length × 
fluorescent intensity) were measured in at least 50 cells in each treatment group using image analysis. 
Each time point tail moment represents the mean ± SEM from 3 independent experiments. 
Nicotinamide significantly enhanced repair of hOGG1-sensitive sites in irradiated HaCaT 
keratinocytes (p<0.0001; ‘UV’ vs ‘UV + Nic’, repeated measures ANOVA). UV significantly 
increased the hOGG1 tail moment compared to the No UV group (p<0.0001; ‘UV’ vs ‘No UV’, 
repeated measures ANOVA). 
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Nicotinamide did not have a significant effect on repair of UV-induced 
DNA strand breaks in HaCaT keratinocytes 
As previously described, in the absence of specific enzymes, which cleave specific 
photolesions, the comet assay detects DNA strand breaks and AP sites.  The ‘no 
enzyme’ controls (buffer only) slides in both T4N5 and hOGG1 comet assay 
experiments were analyzed to investigate the effect of nicotinamide on DNA strand 
breaks (DSB). The tail moment in ‘UV’ irradiated group was not significantly higher 
than the tail moment in the ‘No UV’ group (p=0.08; repeated measures ANOVA), 
indicating that UV at the dose used in this study did not cause significant DSB.  At 
each time point after UV irradiation, DSB tail moment was lower in the ‘UV + Nic’ 
group, compared to ‘UV’ group.  However, repeated measures ANOVA analysis of 
the ‘UV’ compared to the ‘UV + Nic’ groups did not show any significant difference 
in DSB over the time course studied (p=0.71). The number of DSB was however very 
low, as can be seen by comparing this figure to the CPD and 8-oxodG data in the 
figures above. It is therefore possible that this lack of significant increase in repair 
may be due to the low level of photolesions making the repair data difficult to 
quantitate. 
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Figure 4.6.  Nicotinamide did not have a significant effect on repair of DNA 
breaks induced by 4 J/cm2 ssUV in HaCaT keratinocyte cells as measured by 
comet assay. HaCaT cells were unirradiated (‘No UV’) or irradiated with 4 J/cm2 ssUV (‘UV’). 
They were further incubated for various times as shown with or without nicotinamide (Nic). The cells 
were finally detached for quantification of DNA strand breaks (DSB) using the comet assay without 
additional excision enzymes. Tail moments (tail length × fluorescent intensity) were measured in at 
least 50 cells in each treatment group using image analysis. Each time point tail moment represents 
mean ± SEM from 6 independent experiments. Nicotinamide did not have any significant effect on 
DNA strand breaks in irradiated HaCaT keratinocytes (p=0.71; ‘UV’ vs ‘UV + Nic’, repeated 
measures ANOVA). 4 J/cm2 ssUV did not cause significant increase in DSB (p=0.08; ‘UV’ vs ‘No 
UV’, repeated measures ANOVA). 
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4.2.2 Detection of CPDs and 8-oxodG in ex vivo human skin 
by immunohistochemistry 
Ex vivo skin from three healthy female volunteers (age range 30-40, skin phototypes 
III-IV) who underwent abdominoplasty (n=2) or breast reduction (n=1) was cut into 
4mm2 pieces and incubated with or without 50µM nicotinamide supplementation in 
RPMI 1640 media (containing basal levels of 8.2µM nicotinamide in unsupplemented 
media; hence total nicotinamide concentration after nicotinamide supplementation 
was 58.2µM) for 24 hours in a 37°C 5% CO2-in-air incubator. Following exposure to 
4 J/cm2 ssUV, the skin sections were further incubated with or without 50µM 
nicotinamide supplementation for 0, 30, 60, 90, and 120 mins to enable DNA repair 
before being snapped frozen. As previously described in Material and Methods 
(Section 2.1.4), 6µm thick-tissue sections were prepared. They were stained using 
mouse monoclonal anti-thymine dimer (CPD) antibody or mouse monoclonal anti-8-
oxodG antibody depending on the studies. Biotinylated link antibody (mouse/rabbit), 
streptavidin conjugated with alkaline-phosphatase, and a RED chromogen were used 
for visualization of the antibody binding. Staining was visualized by light microscopy 
and digital images were captured. Quantification of staining (percentage of epidermal 
area positively stained for CPD or 8-oxodG) was performed using ImageJ 1.42 image 
analysis software (National Institute of Health, Bethesda, USA). This method uses an 
intensity threshold to calculate percentage staining, allowing comparison of relative 
photolesion intensity in nicotinamide versus control-treated cells. To compare repair 
of 8-oxodG photolesions in upper and lower epidermis, photomicrograph images of 
the 8-oxodG staining were outlined freehand to identify each epidermal area. The 
epidermis was divided 50:50 into upper and lower epidermis. The same image 
analysis (calculates an intensity threshold to calculate percentage staining) used to 
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measure whole epidermal 8-oxodG repair, was utilized to analyze 8-oxodG repair 
kinetics in upper and lower epidermal regions separately.  
 
Nicotinamide enhanced repair of CPDs in ex vivo human skin 
Exposure of ex vivo skin to 4 J/cm2 ssUV resulted in significant formation of CPDs in 
the epidermis (p<0.0001; ‘UV’ vs ‘No UV’, repeated measures ANOVA; Figure 4.7, 
4.8). These were repaired over the time course of these experiments but did not come 
all of the way back to unirradiated levels. There were no detectable CPD lesions in 
unirradiated skin, consistent with CPDs being specifically UV-induced.  
Nicotinamide alone did not increase the levels of CPDs in unirradiated skin (repeated 
measures ANOVA) consistent with previous findings that it did not cause DNA 
damage. CPDs were first detected at 15 mins after irradiation and nicotinamide 
treatment did not prevent the initial formation of CPDs induced by ssUV in the 
epidermis (Figure 4.8). The lack of effect of nicotinamide at this early time point also 
excludes a nicotinamide ssUV radiation filtering effect. Nicotinamide caused 26.5% 
and 34.9% relative reductions in CPDs in irradiated epidermis at 45 and 75 mins 
respectively, and significantly reduced CPDs over the time course studied (p=0.05; 
‘UV’ vs ‘UV + Nic’, repeated measures ANOVA), indicating enhancement of repair, 
consistent with the UDS data.  
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Figure 4.7. Nicotinamide reduced CPDs in ex-vivo human skin exposed to 4 
J/cm2 ssUV. Representative photomicrographs taken at 45 min time point (bar = 200 µm). After 
irradiation, ex vivo human skin pieces were further incubated at various time points as described, and 
then sectioned and stained for CPDs (red chromogen staining) by immunohistochemistry. CPDs were 
only present in irradiated skin. The maximal relative reduction in photolesions by nicotinamide is seen 
at 45 mins after UV. Human skin can be divided to epidermal (e) and dermal (d) layers. The uppermost 
layer of the epidermis is stratum corneum (s.c), which consists of anucleated corneocytes embedded in 
extracellular lipid-ladden matrix.  
 
d 
e 
s.c 
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Figure 4.8.  Nicotinamide enhanced repair of CPDs in ex vivo human skin 
exposed to 4 J/cm2 ssUV. Ex vivo skin was treated with 50µM nicotinamide (Nic) for 24 hours 
before ssUV. Some skin sections were not irradiated (‘No UV’). The skin was further incubated with 
nicotinamide for various time points as shown before being snap-frozen for immunostaining. 
Determination of percentage epidermal cells positive for photolesions was performed using image 
analysis from digital images of the skin. Mean ± SEM from 3 independent experiments shown. 
Nicotinamide significantly enhanced repair of CPD photolesions in human skin (p=0.05; ‘UV’ vs ‘UV 
+ Nic’, repeated measures ANOVA). 4 J/cm2 ssUV caused significant increase in CPDs in ex vivo 
epidermal human skin (p<0.0001; ‘UV’ vs ‘No UV’, repeated measures ANOVA). No CPDs were 
present in unirradiated skin, indicating that CPDs are specific DNA lesions induced by UVR.  
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Nicotinamide enhanced repair of 8-oxodG in ex vivo human skin 
Exposure of ex vivo skin to 4 J/cm2 ssUV resulted in a significant increase in 8-oxodG 
above baseline levels in the epidermis (Figure 4.9, 4.10). Nicotinamide alone did not 
increase levels of 8-oxodG above the background levels in unirradiated skin (p=0.51; 
‘No UV’ vs ‘No UV + Nic’, repeated measures ANOVA) consistent with previous 
findings that it did not cause DNA damage. 4 J/cm2 ssUV induced 8-oxodG 
photolesions significantly above baseline values, reaching a maximum level 45 mins 
after irradiation (p=0.021; ‘UV’ vs ‘No UV’, repeated measures ANOVA). These 
photolesions were repaired within the time frame of these experiments to baseline 
levels (Figure 4.10).  Pretreatment with nicotinamide decreased 8-oxodG to levels 
equivalent to those in unirradiated epidermis at all time points (p=0.0023, repeated 
measures ANOVA), suggesting that nicotinamide also accelerates repair of ssUV-
induced 8-oxodG photolesions in human skin. 
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Figure 4.9. Nicotinamide reduced 8-oxodG in ex vivo human skin exposed to 4 
J/cm2 ssUV. Representative photomicrographs taken 45 mins time point (bar = 200 µm). After 
irradiation, ex vivo human skin pieces were further incubated at various time points as described, and 
then sectioned and stained for 8-oxodG (red chromogen staining) by immunohistochemistry. 8-oxodG 
photolesions were also found in unirradiated skin as a result of normal skin metabolism. The maximal 
relative reduction in photolesions by nicotinamide is seen at 45 mins after UV.  
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Figure 4.10.  Nicotinamide enhanced repair of 8-oxodG in ex vivo human skin 
exposed to 4 J/cm2 ssUV. Ex vivo skin was treated with 50µM nicotinamide for 24 hours before 
ssUV. The skin was further incubated with nicotinamide for various time points before being snap- 
frozen for immunostaining. Determination of percentage epidermal cells positive for photolesions was 
performed using image analysis. 4 J/cm2 ssUV increased 8-oxodG significantly above the background 
level in human epidermis (p=0.021; ‘UV’ vs ‘No UV’, repeated measures ANOVA). Nicotinamide 
significantly enhanced repair of 8-oxodG photolesions in irradiated human skin (mean ± SEM from 3 
independent experiments; p=0.0023; ‘UV’ vs ‘UV + Nic’, repeated measures ANOVA). In the absence 
of UV radiation, nicotinamide did not alter the background 8-oxodG levels in epidermis (p=0.51; ‘No 
UV’ vs ‘No UV + Nic’, repeated measures ANOVA).  
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Nicotinamide enhanced repair of  8-oxodG in both upper and lower 
epidermis of ex vivo human skin  
Nicotinamide enhanced repair of ssUV-induced CPDs and 8-oxodG in ex vivo human 
skin. The ssUV used in this study closely simulates the solar spectrum and consists of 
90.43% UVA (320-400 nm) and 9.57% UVB (290-320 nm) (as measured by an 
Optronics OL 756 spectroradiometer; Materials and Methods, Section 2.1.5). UVA is 
therefore approximately 10-fold more abundant than UVB in our spectrum. Due to its 
long wavelength, more UVA than UVB would be expected to reach basal layers of 
epidermis. In human skin ex vivo, less than 10% of UVB and more than 20% of UVA 
was found to reach the basal germinative layers (Bruls et al., 1984). 8-oxodG is the 
most commonly used biomarker to evaluate UVA oxidative damage in human skin 
cancer (Zhang et al., 1997). UVA-induced mutations at epidermal basal layers are 
particularly important as these layers contains actively dividing stem cells which are 
thought to give rise to skin cancers (Morris, 2000). It is therefore important to 
investigate whether nicotinamide enhanced repair in these critical basal layers as 
repair in the upper layers only may not prevent mutations and consequently skin 
cancers. 4 J/cm2 ssUV induced 8-oxodG levels that were significantly above baseline 
values, reaching a maximum level 45 mins after irradiation in both upper and lower 
epidermis (Figure 4.11a,b) (p=0.029 and p=0.035 for upper and lower epidermis 
respectively; ‘UV’ vs ‘No UV’, repeated measures ANOVA). There was more 8-
oxodG present in the lower epidermis particularly at 15 and 45 mins after 4J/cm2 
ssUV exposure, than in the upper epidermis (p=0.0014; ‘UV upper epidermis’ vs ‘UV 
lower epidermis, repeated measures ANOVA). In the absence of UVR, nicotinamide 
did not reduce 8-oxodG in either upper or lower epidermis (p=0.72 and p=0.59 for 
upper and lower epidermis respectively; ‘No UV’ vs ‘No UV + Nic’, repeated 
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measures ANOVA). In UV-irradiated skin, pretreatment with nicotinamide 
significantly decreased 8-oxodG in both upper and lower layers of epidermis 
(p=0.017 and p=0.0028 for upper and lower epidermis respectively; ‘UV’ vs ‘UV + 
Nic’, repeated measures ANOVA). Furthermore, in irradiated skin nicotinamide 
reduced 8-oxodG to levels equivalent to those unirradiated samples in both upper and 
lower layers of epidermis (p=0.69 and p=0.68 for upper and lower epidermis 
respectively; ‘UV + Nic’ vs ‘No UV’, repeated measures ANOVA), indicating 
complete repair with nicotinamide in both upper and lower epidermis.  
 
 
(a) 
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(b) 
 
 
Figure 4.11.  Nicotinamide enhanced repair of  8-oxodG in both (a) upper and 
(b) lower epidermis of ex vivo human skin exposed to 4 J/cm2 ssUV. Ex vivo skin was 
treated with 50µM nicotinamide for 24 hours before exposure to ssUV. The skin was further incubated 
with nicotinamide for various time points as indicated to enable repair of DNA to occur before being 
snap-frozen for immunostaining. Determination of percentage of upper and lower epidermis positive 
for photolesions was performed using image analysis with epidermis divided evenly into upper and 
lower portions. Mean ± SEM from 3 independent experiments shown. Nicotinamide significantly 
enhanced repair of UV-induced 8-oxodG photolesions in both upper and lower epidermis (p=0.0172 
and p=0.0028 respectively; ‘UV’ vs ‘UV + Nic’, repeated measures ANOVA). In unirradiated skin, no 
reduction in 8-oxodG with nicotinamide was seen in either upper or lower epidermis (p=0.72 and 
p=0.59 for upper and lower epidermis respectively; ‘No UV’ vs ‘No UV + Nic’, repeated measures 
ANOVA). In irradiated skin, nicotinamide caused complete repair in both upper and lower layers of 
epidermis with 8-oxodG levels approximating background 8-oxodG in unexposed skin (p=0.69 and 
p=0.68 for upper and lower epidermis respectively; ‘UV + Nic’ vs ‘No UV’, repeated measures 
ANOVA).  
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4.3. DISCUSSION 
In the previous chapter, using UDS, it was shown that nicotinamide enhanced 
repair of ssUV-induced DNA photolesions. In this chapter, the identity of some 
of the photolesions was determined by detecting CPDs and 8-oxodG by comet 
assay in HaCaT keratinocytes and immunohistochemistry in ex vivo human skin. 
A single dose of 4 J/cm2 ssUV induced formation of CPDs and 8-oxodG in both 
HaCaT cells and human epidermis. There was no reduction in CPDs with 
nicotinamide detected by either system or 8-oxodG photolesions detected by the 
comet assay at 15 mins after irradiation. This indicates that nicotinamide did not 
affect the formation of these photolesions.  It is also consistent with nicotinamide 
not having any UV filtering effect.  Previous studies in human volunteers showed 
a lack of nicotinamide effect on sunburn threshold (minimal erythema dose) 
(Damian et al., 2008, Yiasemides et al., 2009), which suggests that it could not 
act as a UV filter. In HaCaT cells, both T4N5 and hOGG1 sensitive sites reached 
maximum levels at 45 mins post ssUV. Similarly in ex vivo human skin, there 
were delays of 15 and 45 mins for CPDs and 8-oxodG respectively to reach their 
maximum detected levels.  Using the comet assay in HaCaT cells, Javeri et al 
reported a 1 hour delay for both CPDs and 8-oxodG to reach maximum levels 
after a single dose of either 3 J/cm2 UVA or 150 mJ/cm2 UVB (Javeri et al., 
2011). Gupta et al found a longer 6 hour delay for maximum CPD formation 
following UV irradiation (consisting of 1.17 J/cm2 UVA and 200 mJ/cm2 UVB) 
in primary human keratinocytes derived from neonatal foreskins, as measured by 
immunostaining with anti-thymidine dimer (CPD) antibodies (Gupta et al., 
2007). The delay likely reflects changes in the targeted substrate such as DNA 
relaxation and increasing accessibility in the context of repair (Snopov et al., 
  
 156
2004) and recruitment of NER proteins including proliferating cell nuclear 
antigen (PCNA) into the sites of DNA repair (Katsumi et al., 2001).  
 
In HaCaT keratinocytes, more than 80% of T4N5 and all of hOGG1 sensitive sites 
were repaired within 135 and 75 minutes respectively. Repair was slower in whole 
human skin than in HaCaT cells, with a decrease of 60.9% in CPDs and 70.4% in 8-
oxodG from the maximum levels at 135 minutes after irradiation. Mouret et al 
similarly reported slower repair of DNA photoproducts in skin biopsies than in 
cultured primary human keratinocytes and fibroblasts (Mouret et al., 2008). Repair of 
8-oxodG was faster than CPDs in both HaCaT cells and ex vivo human skin and the 
8-oxodG kinetic was consistent with previous studies utilizing similar UV dosage and 
experimental methods and conditions (Javeri et al., 2008, Frost et al., 2011). Using 
T4N5 enzyme and alkaline sucrose sedimentation, D’Ambrosio et al and Reusch et al 
found biphasic repair kinetics of epidermal CPDs. About 40-50% of the dimers were 
removed rapidly within approximately 60 mins, and the remaining dimers were 
removed more slowly within 24 hours after UV irradiation of human volunteers in 
vivo (D'Ambrosio et al., 1981, Reusch et al., 1988). Biphasic repair kinetics of UV 
photoproducts were confirmed in another study utilizing quantitative polymerase 
chain reaction (QPCR) in a human SL89 fibroblast cell line. This assay was based on 
the blockage of DNA synthesis activity of the Thermus aquaticus (Taq) polymerase 
by UV photoproducts or other heat stable DNA adducts. The amount of PCR product 
was proportional to the amount of intact, non-adducted DNA template. 
Approximately 65% of UV photoproducts were removed within the first 4 hours after 
15 J/m2 UVC irradiation (254 nm), and the remaining 35% of the adducts were 
removed during the second slower phase of repair in 20 hours (McCarthy et al., 
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1997). Repair of UV-induced DNA damage also prolonged with UVB only exposure 
(Lehmann et al., 1998, Greinert et al., 2000) and reached a saturation point at UVB 
dosage more than 800 J/m2 (Greinert et al., 2000). Therefore, the kinetics of 
formation and repair of CPDs and 8-oxodG are likely to vary in different studies 
depending on UV dose and subsequent damage to repair processes, experimental 
conditions and measurement methods. 
 
Furthermore, significant inter-individual variability in removal of UVB-induced 
CPDs has been reported (Freeman, 1988, Bruze et al., 1989, Sutherland et al., 2002). 
Some studies showed that older individuals (Bykov et al., 1999, Goukassian et al., 
2000, Yamada et al., 2006) and those with skin phototypes I and II (Young et al., 
1996) removed CPDs more slowly than younger individuals and those with skin 
phototypes III and IV. Goukassiani et al found slower removal of UV-induced CPDs 
and (6-4)PPs in dermal human fibroblasts derived from older donors. There was also 
an age-associated decrease in levels of the NER proteins excision repair cross-
complementing (ERCC)-3, anti-proliferating cell nuclear antigen (PCNA), replication 
protein A (RPA), xeroderma pigmentosum group A (XPA), and p53. Furthermore, 
there was a decrease in the level of p53 induced after UV irradiation with increasing 
age (Goukassian et al., 2000). Age-associated decreases in the oxidative repair 
enzyme hOGG1 were also shown in peripheral human lymphocytes derived from 78 
subjects of various ages ranging from newborn to 91 years old (Chen et al., 2003). 
The relatively rapid repair of CPDs observed in these studies compared to other in 
vivo studies in humans may be attributed to the relatively young volunteers (age range 
of 30-40) and their skin phototypes III-IV, from which the ex vivo skin were obtained. 
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However, the small numbers of volunteers (n=3) in these studies limit further 
interpretation of repair kinetics according to age, gender, and skin phototype.  
 
hOGG1 protein and gene are expressed more abundantly in the superficial than basal 
layer of human epidermis (Javeri et al., 2008). This may lead to a lack of repair in the 
basal layer of the epidermis and therefore accumulation of mutations due to 8-oxodG. 
My studies were consistent with this, showing higher levels of unrepaired 8-oxodG in 
the basal compared to superficial epidermal layers. Nicotinamide significantly 
enhanced repair of 8-oxodG in both upper and lower parts of the epidermis, with both 
layers returning to unirradiated control levels at about the same time. Repair of 8-
oxodG by nicotinamide in the stem cell basal layer of the skin is important as this is 
the layer where dividing stem or transit amplifying cells reside which are thought to 
give rise to skin cancer. Therefore nicotinamide enhancement of 8-oxodG in the basal 
layer may help reduce transformation into mutations and skin carcinogenesis.  
 
Two enzyme systems were incorporated into in vitro comet assay studies, T4N5 
which recognizes CPDs and abasic sites, and hOGG1 which cleaves 8-oxodG and 
DNA-containing formamidopyrimidine moieties. The data showed that nicotinamide 
enhances excision repair of both T4N5- and hOGG1-sensitive sites. This specificity 
issue with the enzymes was addressed, along with confirmation of the repair 
enhancing capacity of nicotinamide in human skin rather than a cell line, by 
immunostaining of whole human skin with specific anti-thymine dimer (Besaratinia 
et al., 2011) and anti-8-oxodG monoclonal antibodies (Soultanakis et al., 2000).  
Immunostaining of whole human skin also allowed localization of CPDs and 8-
oxodG photolesions in the epidermis and reduced the potential for artefactual DNA 
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damage induced during cell harvesting and lysis during DNA isolation in the comet 
assay. The use of normal human skin also demonstrates that nicotinamide 
enhancement of repair occurs in normal keratinoctyes in their usual physiological and 
architectural relationship to other cells. The comet assay is however a better 
quantitative method than immunohistochemistry as used in whole human skin. The 
combination of the in vitro and ex vivo systems used in these studies provides 
evidence that nicotinamide enhances repair of different UV-induced photolesions and 
therefore acts on a number of pathways. Nicotinamide enhancement of DNA repair is 
likely to extend beyond the photolesions studied in these experiments.  
 
It is unclear as to how nicotinamide stimulates an increase in at least two pathways of 
DNA excision repair after UV irradiation. Nicotinamide is a precursor for the 
intracellular synthesis of nicotinamide adenine nucleotide (NAD) (Jacob, 2001). 
NAD is an essential cofactor in glycolysis and NAD depletion inhibits glycolysis and 
in effect ATP production (Jacobson et al., 2001). 4 J/cm2 ssUV radiation caused 
significant intracellular ATP depletion within 2 hours (Park et al., 2010). DNA repair 
is highly energy dependent. Both nucleotide excision repair (NER) and double-strand 
break repair involves remodelling of the chromatin structure to allow access of DNA 
repair enzymes. This chromatin modification is highly ATP dependent (Halliday et 
al., 2009). 50µM nicotinamide prevented ssUV-induced depletion of intracellular 
ATP and glycolytic blockade in HaCaT cells (Park et al., 2010). It is likely that the 
nicotinamide stimulation of DNA excision repair shown in the present study is 
mediated by its ability to prevent UV-induced ATP decline, making higher amounts 
of ATP available for DNA repair and other cellular processes. In HaCaT human 
keratinocytes, nicotinamide restriction decreased cell viability and increased DNA 
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single-strand breaks and alkali labile sites as measured by comet assay (Benavente 
and Jacobson, 2008). In the same study, NAD depletion was shown to upregulate 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase which resulted in 
increased ROS production. NAD repletion with nicotinamide completely reversed the 
ROS accumulation (Benavente and Jacobson, 2008). Prevention of ROS 
accumulation by nicotinamide may contribute to the reduction in 8-oxodG observed 
in this study. Furthermore, besides functioning as an NAD coenzyme for cellular 
energy metabolism, NAD is also a substrate for a nuclear enzyme poly(ADP)ribose 
polymerase (PARP). Nicotinamide at certain higher concentrations also acts as a 
PARP inhibitor, as shown in Chapter 3, Section 3.2.3. PARP, which is known to be 
physically attached to chromatin (Kim et al., 2004), is activated by DNA strand 
breaks and was hypothesized to be involved in DNA repair through facilitating the 
opening of the condensed chromatin structure, allowing recruitment of DNA repair 
complexes (Shall and de Murcia, 2001, Virag and Szabo, 2002). PARP was reported 
to be involved in both NER (Stierum et al., 1994), BER (through interaction with 
BER protein X-ray repair cross-complementing (XRCC)-1) (Molinete et al., 1993, 
Ding and Smulson, 1994, Dantzer et al., 1998, Trucco et al., 1998), and maintenance 
of chromosomal integrity by preventing damaged DNA from inadvertent homologous 
recombination during DNA repair and replication (Satoh et al., 1994, Chatterjee et al., 
1999). It was proposed that activation of PARP by DNA strand breaks stimulates 
three cellular pathways depending on the intensity of DNA damage (Virag and Szabo, 
2002). With minor damage in DNA, PARP activation facilitates DNA repair through 
its interaction with p53 protein which signals cell-cycle arrest, and allows access of 
DNA repair enzymes into the site of DNA damage (Virag and Szabo, 2002). When 
DNA damage is moderate but is irreparable, PARP activation leads to apoptotic cell 
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death due to induction of nuclear factor (NF)-κΒ and prevention of ATP depletion 
through caspase-mediated PARP cleavage (Rolli et al., 2000, Virag and Szabo, 2002). 
Extensive DNA damage leads to PARP overactivation with depletion of NAD and 
ATP, which then leads to necrotic cell death (Rolli et al., 2000). As apotosis is an 
energy-dependent process, severely energy-deficient cells are prevented from 
undergoing apoptosis (Kass et al., 1996, Richter et al., 1996, Ferrari et al., 1998). 
Although PARP inhibition by nicotinamide has been reported by some in vitro 
studies to have a detrimental effect on DNA repair (Kjellen et al., 1986, Riklis et al., 
1990, Zheng and Olive, 1996, Tronov et al., 2002), application of the topical PARP 
inhibitor, O-(3-pyperidino-2-hydroxy-1-propyl) pyridine-3-carboxyclic acid 
amidoxime monohydrochloride (BGP-15M) to hairless mouse skin prior to UVB 
irradiation decreased single strand DNA breaks and sunburn (apoptotic) cell 
formation, prevented clinical and histological signs of sunburn, reduced PARP 
activation (as measured by a decrease in ADP-ribosylation) and UVB-induced TNF-α 
and IL-10 production (both are implicated in UV-induced immune suppression) 
(Farkas et al., 2002). Furthermore, it was shown in this study that despite suppression 
of PARP activity by BGP-15M, the level of PARP activity was still significantly 
higher than that in UV-exposed control skin, suggesting that inhibition of PARP 
overactivation can occur without negative consequences to DNA repair (Farkas et al., 
2002). 
 
In summary, these studies show that nicotinamide enhanced repair of UV-induced 
photolesions CPDs and 8-oxodG both in vitro in HaCaT human keratinocytes and in 
ex vivo whole human skin. Repair of 8-oxodG in basal layer of epidermis is 
particularly crucial in preventing skin carcinogenesis as this layer contains actively 
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dividing stem cells. Nicotinamide was shown to enhance repair of UV-induced 8-
oxodG in both basal and upper layers of epidermis. Nicotinamide enhancement of 
DNA repair after UV radiation may be a key mechanism of nicotinamide’s 
demonstrated protective effects against photoimmunosuppression in humans and 
against skin carcinogenesis in previous murine studies. Nicotinamide is therefore a 
promising agent for skin cancer chemoprevention in humans. The next Chapter 
investigates the effect of nicotinamide on precancerous skin lesions (actinic 
keratoses) in humans.  
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CHAPTER 5 EFFECT OF ORAL NICOTINAMIDE 
ON ACTINIC KERATOSES AND  
NON-MELANOMA SKIN CANCER INCIDENCE 
 
5.1. INTRODUCTION 
Non-melanoma skin cancers (NMSCs), mostly composed of basal cell carcinomas 
(BCCs) and squamous cell carcinomas (SCCs), are the most common malignancy in 
fair-skinned populations (Lomas et al., 2012). Solar or actinic keratoses (AKs) are 
premalignant skin lesions arising from a focal proliferation of atypical epidermal 
keratinocytes (de Berker et al., 2007). Some authors believe that AKs should be 
considered early in situ SCCs as the same p53 mutation and histological features 
exist in both AKs and SCCs (Fu and Cockerell, 2003). The reported rates of 
progression of AKs to SCCs vary considerably, from 0.025% to 16% per year 
(Glogau, 2000), but the presence of AKs strongly predicts the occurrence of NMSCs 
(Green and Battistutta, 1990, Frost et al., 2000). Hence, AKs are often used as 
surrogate endpoint biomarkers in skin cancer chemoprevention trials.  
 
Cumulative ultraviolet radiation (UVR) exposure is the most significance 
contributing factor in the development of AKs, as it is in NMSCs (Leffell, 2000). 
UVR causes skin cancer by inducing genetic mutations in the skin as well as by 
profoundly suppressing cutaneous immunity (Halliday, 2010). Intact immunity is a 
key defence against skin cancer, as evidenced by the hugely increased skin cancer 
risk in immune suppressed transplant recipients (Carroll et al., 2003). Therefore, the 
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use of agents that abrogate UV-induced immune suppression and steps involved in 
carcinogenesis will be an important strategy in skin cancer prevention.  
 
Nicotinamide, the amide form of vitamin B3 (niacin), prevents skin cancer in mice 
(Gensler, 1997, Gensler et al., 1999) and UV-induced immunosuppression in humans  
(Damian et al., 2008). Unlike nicotinic acid (niacin), nicotinamide does not cause 
headaches or flushing and is well tolerated even at high doses (Knip et al., 2000). It 
was recently reported that 1% nicotinamide lotion applied twice daily by an elderly 
population at high risk of skin cancers accelerates seasonal regression of AKs 
(Moloney et al., 2010). The current studies aimed to determine whether oral 
nicotinamide, at different daily doses, reduced AKs in heavily sun-damaged 
individuals, and whether it reduced new skin cancers in this high-risk group.  
 
 
5.2. STUDY PARTICIPANTS AND PROTOCOL 
5.2.1. Study design  
 
Between June and October 2009, 35 adults were recruited to Study 1 from Royal 
Prince Alfred Hospital Dermatology Clinics, Sydney, Australia (latitude 33°S). For 
Study 2, 41 adults were recruited from the same centre between August and 
November 2010. As previously described in Materials and Methods (Section 2.3.1), 
eligibility criteria included an age of at least 18 years and the presence of at least 4 
discrete palpable AKs in one or more observed areas (face, scalp, upper limbs). All 
volunteers had not received other AK treatments including cryotherapy, topical 5-
fluorouracil, imiquimod cream, or photodynamic therapy within the last month. The 
study protocols were approved by the ethics committees of the Sydney South West 
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Area Health Service and the University of Sydney. All volunteers were provided 
written informed consent.  
 
Exclusion criteria included pregnancy or lactation, concurrent intake of nicotinamide 
supplements, immunosuppressive and/or photosensitizing agents, active dermatitis, 
liver disease, concurrent intake of carbamazepine, which may interact with 
nicotinamide (Bourgeois et al., 1982), and the presence of immunosuppression. Due 
to the unknown effect of nicotinamide on oral contraceptive pills (OCPs), sexually 
active women of child-bearing age were required to use additional barrier 
contraception during the studies. 
          
All participants were randomly assigned to take tablets containing either 
nicotinamide 500mg (Nature’s Own, Virginia, Queensland, Australia) or matched 
placebo (microcrystalline cellulose and 1% magnesium stearate; Australian Custom 
Pharmaceuticals, Sydney) twice daily (Study 1) or once daily (Study 2) for 4 months. 
All tablets were provided in identical opaque containers. The treatment allocation 
sequence for consecutive patients was determined according to a randomisation list 
that had been prepared using a permuted blocks method (with a block size of 6) by 
an investigator who was not involved the assessment of AK outcomes. All patients 
and the AK assessor (the author) remained blinded to treatment allocation until study 
completion. Recruited participants completed baseline questionnaires including 
demographic information, Fitzpatrick’s skin type, general medical history, skin 
cancer history and previous AK treatments (Appendix 4). All participants were 
advised to use SPF 30+ sunscreen each day during the study as well as general sun 
protective measures.  
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5.2.2. Study assessments 
All randomised patients were eligible for inclusion in the efficacy analysis in 
accordance with the intention to treat analysis principle. The primary endpoint 
obtained for each patient was the AK counts at 4-month-assessment. Secondary 
endpoints included AK count at 2-month-assessement. Skin cancers diagnosed 
before or during the study were also counted, histologically confirmed and treated as 
per usual clinical practice.  
 
At baseline, 2-month and 4-month assessments, palpable AKs on the face, scalp and 
upper limbs were identified visually and by touch, counted and the precise location 
of each lesion was documented on a body grid chart and by photographs. At baseline 
and at 2-month assessments, full blood count (FBC), serum electrolytes, urea, 
creatinine (EUC), and liver function tests (LFT) were performed independently in the 
Royal Prince Alfred Hospital. In addition, blood specimens were also collected at 
baseline and at 2-month assessments for total NAD(H)/NADP(H) quantification. 
Each participant was instructed to return the tablet containers at each visit and the 
remaining tablets were counted at the conclusion of the trial for compliance analysis.  
 
Independent assessment of the nicotinamide tablet content uniformity was conducted 
by Phoenix Analytical Services, Underwood, Queensland, using a Hewlett Packard 
Agilent 1100 HPLC system (Agilent, Forest Hill, Victoria Australia). Analysis of 
twenty tablets from two batches showed a good uniformity with mean nicotinamide 
content per tablet of 501.3 ± 9.1mg (range 483.6-520.7 mg).  
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5.2.3. Statistical analysis 
As previously explained in the Materials and Methods (Section 2.13), the right-
skewed distribution of the AK count data was normalized by applying loge 
transformation. Analysis of covariance (ANCOVA; treatment group as a factor and 
baseline loge(AK count) as a covariate) was utilized to compare the relative 
difference in loge(AK count) between placebo and nicotinamide groups. The 
estimates from the ANCOVA results were back-transformed by taking the antilog for 
reporting.  Poisson regression and negative binomial models were utilized to 
compare the rate of new skin cancers in each group whereas the odds ratio was 
calculated using logistic regression model.  
 
 
5.3. STUDY 1 – NICOTINAMIDE 500 MG TWICE DAILY 
5.3.1. Study participants and baseline characteristics 
Thirty-five patients were enrolled in Study 1. One patient in the nicotinamide group 
withdrew from treatment after the 2-month assessment because of the development 
of invasive SCC on the right ear, but returned for his 4-month AK count. There were 
17 patients (10 men and 7 women) in the placebo group and 18 patients (15 men and 
3 women) in the nicotinamide group (Table 5.1). Most patients reported some 
sunscreen use at the baseline assessment; 37.1% reported that they “always used 
sunscreen,” 45.7% “sometimes used sunscreen” and 17% “never used sunscreen” 
(Table 5.1). Twenty-six (74.3%) of the study participants had previous, 
histologically confirmed skin cancers [11/17 (64.7%) patients in placebo group; 
14/18 (77.8%) patients in nicotinamide group] (Table 5.1). 4 of 17 patients in the 
placebo group took regular NSAIDs (oral ibuprofen or naproxen; voltaren gel) for 
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osteoarthritic pain relief. None reported NSAIDs intake in the nicotinamide group. 
One patient from the placebo group and 4 patients from the nicotinamide group took 
low-dose daily aspirin.  
 
 
           Table 5.1. Baseline characteristics of participants (Study 1). 
 Placebo Nicotinamide 
Patients enrolled 17 18 
Mean age  (years; range) 71.7 (52-90) 71.1 (59-82) 
Men:women   10:7  15:3  
Sunscreen use (%) 
    Always 
    Sometimes 
    Never 
 
7 (41.2) 
8 (47) 
2 (11.8) 
 
6 (33.3) 
8 (44.4) 
4 (22.2) 
Fitzpatrick skin type (%) 
   I 
   II 
   III  
 
8 (47) 
7 (41.2) 
2 (11.8) 
 
8 (44.4) 
5 (27.8) 
5 (27.8) 
Skin cancer history*       
NMSCs  
 
 
Melanoma (in situ) 
12 / 17 
11 patients  
26 BCCs 
6 SCCs 
1 patient 
17 / 18 
14 patients 
 23 BCCs  
14 SCCs    
5 patients 
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Total AKs 
Mean (SD) 
Range (median) 
 
31.5 (21.13) 
9-92 (23) 
 
29.3 (23.46) 
6-89 (19) 
Face AKs 
     Mean (SD) 
     Range (median) 
 
11 (8.04) 
2-27 (8) 
 
9.3 (5.99) 
1-23 (8) 
Scalp AKs 
     Mean (SD) 
     Range (median) 
 
1.8 (3.73) 
0-14 (0) 
 
2.3 (3.71) 
0-12 (0) 
Forearms, hands AKs 
     Mean (SD) 
     Range (median) 
 
18.7 (15.51) 
1-60 (18) 
 
17.7 (18.11) 
1-64 (9.5) 
  *Some patients had multiple previous skin cancers 
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5.3.2. Nicotinamide 500 mg twice daily significantly reduced 
actinic keratoses at 2- and 4-month assessments 
The average total AK count (±SD) at baseline was 29.3±23.46 for the nicotinamide 
 group and 31.5±21.13 for the placebo group, with AKs located mainly on the face 
and forearms (Table 5.1). The least-squares (LS) mean AK count at 4 months from 
the ANCOVA model was 12.9 (95% CI: 11.0-15.2) for the nicotinamide group 
compared to 19.9 (95% CI: 16.9-23.4) for the placebo group (Table 5.2). This 
corresponded to a highly significant 35% relative reduction (95% CI: 18-48%; 
p=0.0006). Similar results were obtained for the analysis of AK count at 2 months 
(Table 5.2). The mean reduction in total AK count (±SD) at 4 months was 4.5±6.57 
in the placebo group, compared to 12.7±13.98 for the nicotinamide group. Similarly 
at 2 months, the mean reduction in total AK count was 3.3±2.71 in the placebo 
group, compared to 11.2±11.28 in the nicotinamide group (Figure 5.1). The 
reductions in AKs were observed across body sites. In the placebo group, mean 
reductions at 4 months in AK counts (±SD) for lesions located on the scalp/face and 
forearms and hands were 1.8±4.16 and 2.6±4.11 respectively, whereas in the 
nicotinamide group AKs on the scalp/face and forearms and hands were reduced at 4 
months by 4.2±5.09, and 8.6±10.34 (Table 5.3). There was no evidence that the 
relative effect of nicotinamide was modified by baseline AK count (treatment-by-
baseline interaction p-value was non-significant) (Figure 5.2).  
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Table 5.2. Total actinic keratoses during treatment with nicotinamide 500mg 
twice daily or placebo (Study 1). 
LS = Least Squares, CI=Confidence Interval 
* Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at 
the time point indicated with treatment group included as a factor and the baseline loge(AK count) as a 
covariate. 
Table 5.3. Reduction in actinic keratoses during treatment with nicotinamide 
500mg twice daily or placebo (Study 1). 
 
Placebo 
N=17 
Nicotinamide 
N=18 
Relative 
Reduction 
(95% CI)* 
P value 
2 months 
Mean (SD) 
Range (median) 
LS Mean    (95% CI)* 
 
28.2 (20.73) 
6-91 (20) 
20.9 (18.5-23.5) 
 
18.1 (16.83) 
3-65 (11) 
13.6 (12.1-15.3) 
 
 
 
 
 
35% (23-45%) 
 
 
 
 
 
p<0.0001 
4 months 
Mean (SD) 
Range (median) 
LS Mean    (95% CI)* 
 
27.1 (19.92) 
6-89 (20) 
19.9 (16.9-23.4) 
 
16.6 (13.85) 
2-54 (10) 
12.9 (11.0-15.2) 
 
 
 
 
 
35% (18-48%) 
 
 
 
 
 
p=0.0006 
 Placebo 
N=17 
Nicotinamide 
N=18 
2 months 
Mean total AK reduction (SD) 
 
3.3 (2.71) 
 
11.2 (11.28) 
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Mean scalp AK reduction (SD) 
Mean face AK reduction (SD) 
Mean scalp and face AK reduction (SD) 
Mean left forearm and hand reduction (SD) 
Mean right forearm and hand reduction (SD)  
Mean left and right forearms and hands reduction (SD) 
0.4 (1.11) 
      1.5 (1.94) 
1.8 (2.07) 
0.6 (2.00) 
0.9 (1.83) 
1.5 (2.74) 
0.6 (1.42) 
3.0 (3.74) 
3.6 (4.16) 
3.8 (3.78) 
3.7 (4.36) 
7.6 (7.81) 
4 months 
Mean total AK reduction (SD) 
Mean scalp AK reduction (SD) 
Mean face AK reduction (SD) 
Mean scalp and face AK reduction (SD) 
Mean left forearm and hand reduction (SD) 
Mean right forearm and hand reduction (SD)  
Mean left and right forearms and hands reduction (SD) 
 
 
4.5 (6.57) 
0 (0.61) 
1.8 (4.19) 
1.8 (4.16) 
1.1 (2.89) 
1.5 (2.43) 
2.6 (4.11) 
 
 
12.7 (13.98) 
0.8 (1.73) 
3.4 (4.15) 
4.2 (5.09) 
4.4 (5.40) 
4.2 (5.27) 
8.6 (10.34) 
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Figure 5.1. Oral nicotinamide 500mg twice daily reduced the number of actinic 
keratoses (AKs) in sun-damaged individuals. In the placebo group, total AK mean 
reductions (±SD) of 3.3±2.71 and 4.5±6.57 were observed at 2 months and 4 months respectively. 
Whereas in the nicotinamide group, the total AK mean reductions were greater at 11.2±11.28 and 
12.7±13.98 at 2 months and 4 months respectively.  
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(a) 
(b) 
 
Figure 5.2. AK count at baseline is plotted against the AK count at 2 (a) and 4 
(b) months follow-up for patients in the nicotinamide 500mg twice daily (Study 
1).  There was 35% reduction in AK count for the nicotinamide group compared to placebo at 2 
months (95% CI: 23-45%; p<0.0001) and 4 months (95% CI: 18-48%; p=0.0006). There was no 
evidence that the relative effect of nicotinamide was modified by baseline AK count (treatment-by-
baseline interaction p-value was 0.70 at 2 months and 0.95 at 4 months) 
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5.3.3. Study 1 – compliance and safety 
Compliance, measured by counts of returned tablets, was excellent in both groups. 
Participants receiving placebo or nicotinamide took 94% and 95% of dispensed 
tablets respectively over the 4-month period. No side effects related to oral 
nicotinamide intake were reported during the entire period of the study and no 
clinically significant changes in blood profiles (FBC, EUC, LFT) were observed at 2-
month compared to baseline.  
 
5.4. STUDY 2 – NICOTINAMIDE 500 MG ONCE DAILY 
5.4.1. Study participants and baseline Characteristics 
41 patients were enrolled into Study 2. One man and one woman in the placebo 
group withdrew from treatment soon after their baseline AK counts because of frailty 
and nursing home placement. These patients agreed to follow-up and had AK counts 
repeated at 2 and 4 months. A man and a woman in the nicotinamide group withdrew 
from treatment soon after their baseline AK count; one declined further participation 
and follow-up, and the other travelled overseas for several months and was lost to 
follow-up. These patients had their baseline AK count carried forward and were 
included in the primary analysis. There were 20 patients (14 men and 6 women) in 
the placebo group and 21 patients (14 men and 7 women) in the nicotinamide group 
(Table 5.4). Again, most patients reported some sunscreen use at the baseline 
assessment (Table 5.4). Thirty-six (87.8%) of Study 2 participants had previous, 
histologically confirmed skin cancers (Table 5.4). 1 of 20 patients in placebo group 
regularly had oral NSAIDs (meloxicam) whereas 3 of 21 patients in the nicotinamide 
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group took regular oral NSAIDs (ibuprofen, meloxicam). 4 patients from the placebo 
group and 3 patients from the nicotinamide group took daily low dose aspirin.  
 
 
   Table 5.4. Baseline characteristics of participants (Study 2). 
 Placebo Nicotinamide 
Patients enrolled 20 21 
Mean age (years; range) 71.6 (48-89) 66.9 (52-80) 
Men:women   14:6 14:7 
Sunscreen use (%) 
    Always 
    Sometimes 
    Never 
 
4 (20) 
10 (50) 
6 (30) 
 
6 (28.6) 
13 (61.9) 
2 (9.5) 
Fitzpatrick skin type (%) 
   I 
   II 
   III  
 
9 (45) 
7 (35) 
4 (20) 
 
11 (52.4%) 
5 (23.8%) 
5 (23.8%) 
Skin cancer history*        
NMSCs  
 
 
Melanoma (in situ) 
19 / 20 
19 patients 
74 BCCs 
43 SCCs 
3 patients 
17 / 21 
17 patients 
63 BCCs 
18 SCCs 
4 patients 
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Total AKs 
Mean (SD) 
Range (median) 
 
40.3 (26.51) 
7-101 (37) 
 
30.6 (16.27) 
12-73 (27) 
Face AKs 
     Mean (SD) 
     Range (median) 
 
11.4 (7.19) 
2-26 (11.5) 
 
9.9 (5.17) 
4-21 (8) 
Scalp AKs 
     Mean (SD) 
     Range (median) 
 
3.5 (6.13) 
0-20 (0) 
 
1.2 (1.99) 
0-7 (0) 
Forearms, hands AKs 
     Mean (SD) 
     Range (median) 
 
25.3 (23.16) 
0-75 (19) 
 
19.5 (12.85) 
3-51 (16) 
  *Some patients had multiple previous skin cancers 
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5.4.2. Nicotinamide 500mg once daily significantly reduced 
actinic keratoses at 2- and 4- months assessments 
The average total AK count (±SD) at baseline was 30.6±16.27 for the nicotinamide 
group and 40.3±26.51 for the placebo group (NS, p= 0.35), with AKs located mainly 
on the face and forearms (Table 5.4). The least-squares (LS) mean AK count at 4 
months from the ANCOVA model was 18.3 (95% CI: 15.6-21.6) for the 
nicotinamide group compared to 25.9 (95% CI: 21.9-30.6) for the placebo group 
(Table 5.5). This corresponded to a significant 29% relative reduction (95% CI: 11-
44%; p=0.005). Smaller but still significant relative reductions were obtained for the 
analysis of AK count at 2 months with the lower daily nicotinamide dose in this trial 
compared to the first (Table 5.5). In the placebo group, the mean reductions in total 
AK count (±SD) were 4.8(±8.38) and 5.5(±9.16) at 2 months and 4 months 
respectively. In the nicotinamide group, the mean reductions in total AK count were 
6.3(±7.20) and 9.0(±10.39) at 2 months and 4 months respectively (Figure 5.3). The 
reductions in AKs were observed across body sites. In the placebo group, we 
observed mean reductions at 4 months in AK counts (±SD) for lesions located on the 
scalp/face and forearms and hands of 1.2 ±4.36 and 4.2±6.73 respectively, whereas 
in the nicotinamide group AKs on the scalp/face and forearms and hands were 
reduced at 4 months by 2.6±4.59, and 6.4±6.84 (Table 5.6). There was no evidence 
that the relative effect of nicotinamide was modified by baseline AK count 
(treatment-by-baseline interaction p-value was non-significant) (Figure 5.4).  
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Table 5.5. Total actinic keratoses during treatment with nicotinamide 500mg 
once daily or placebo (Study 2). 
LS = Least Squares, CI=Confidence Interval 
* Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at 
the time point indicated with treatment group included as a factor and the baseline loge(AK count) as a 
covariate. 
Table 5.6. Reduction in actinic keratoses during treatment with nicotinamide 
500mg once daily or placebo (Study 2). 
 
Placebo 
N=20 
Nicotinamide 
N=21 
Relative 
Reduction 
(95% CI)* 
P value 
2 months 
Mean (SD) 
Range (median) 
LS Mean    (95% CI)* 
 
35.5 (23.09) 
5-99 (34) 
26.1 (23.2-29.4) 
 
24.3 (14.56) 
4-60 (21) 
22.1 (19.7-24.8) 
 
 
 
 
 
15% (0-28%) 
 
 
 
 
 
    p=0.046 
4 months 
Mean (SD) 
Range (median) 
LS Mean    (95% CI)* 
 
34.8 (20.9) 
5-89 (32) 
25.9 (21.9-30.6) 
 
21.6 (14.73) 
3-60 (18) 
18.3 (15.6-21.6) 
 
 
 
 
 
29% (11-44%) 
 
 
 
 
 
p=0.005 
 Placebo 
N=20 
Nicotinamide 
N=21 
2 months 
Mean total AK reduction (SD) 
Mean scalp AK reduction (SD) 
 
4.8 (8.38) 
0.4 (2.01) 
 
6.3 (7.20) 
0.3 (0.56) 
  
 180
 
 
 
 
 
 
Mean face AK reduction (SD) 
Mean scalp and face AK reduction (SD) 
Mean left forearm and hand reduction (SD) 
Mean right forearm and hand reduction (SD)  
Mean left and right forearms and hands reduction (SD) 
    1.6 (4.23) 
2.1 (5.12) 
1.4 (3.25) 
1.3 (2.49) 
2.7 (4.69) 
1.6 (2.92) 
1.9 (3.01) 
2.3 (2.88) 
2.1 (2.98) 
4.4 (5.20) 
4 months 
Mean total AK reduction (SD) 
Mean scalp AK reduction (SD) 
Mean face AK reduction (SD) 
Mean scalp and face AK reduction (SD) 
Mean left forearm and hand reduction (SD) 
Mean right forearm and hand reduction (SD)  
Mean left and right forearms and hands reduction (SD) 
 
 
5.5 (9.16) 
0 (1.60) 
1.2 (3.90) 
1.2 (4.36) 
2.2 (3.38) 
2.0 (4.17) 
4.2 (6.73) 
 
 
9.0 (10.39) 
0.3 (1.43) 
2.3 (3.87) 
2.6 (4.59) 
3.8 (3.83) 
2.6 (3.71) 
6.4 (6.84) 
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Figure 5.3. Oral nicotinamide 500mg once daily reduced the number of actinic 
keratoses (AKs) in sun-damaged individuals. In the placebo group, total AK mean 
reductions (±SD) of 4.8±8.38 and 5.5±9.16 were observed at 2 months and 4 months respectively. 
Whereas in the nicotinamide group, the total AK mean reductions were greater at 6.3±7.20 and 
9.0±10.39 at 2 months and 4 months respectively.  
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(a)    
(b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. AK count at baseline is plotted against the AK count at 2 (a) and 4 
(b) months follow-up for patients in the nicotinamide 500mg once daily (Study 
2).  Compared to the reduction observed in placebo treated patients, nicotinamide treated patients 
experienced an additional 15% and 29% reduction in AK count at 2 months and 4 months (**p= 0.005 
and *p=0.046 respectively). There was no evidence that the relative effect of nicotinamide was 
modified by baseline AK count (treatment-by-baseline interaction p-value was 0.32 at 2 months and 
0.10 at 4 months) 
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5.4.3. Study 2 – compliance and safety 
Compliance, measured by counts of returned tablets, was excellent in both groups. 
Participants receiving placebo or nicotinamide took 98% and 97.7% of dispensed 
tablets respectively over the 4-month period. One patient, who was taking a range of 
medications including aspirin, described nausea whilst taking nicotinamide and 
declined further participation. It was unclear whether this symptom resolved when 
nicotinamide was ceased or continued due to other pathologies. No other potential 
side effects related to oral nicotinamide intake were reported and no clinically 
significant changes in blood profiles (FBC, EUC, LFT) were observed at 2-months 
compared to baseline. 
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5.5. Pooled analysis of studies 1 and 2 – nicotinamide 
reduced AK and non-melanoma skin cancer incidence 
 
The estimated relative reduction in AK counts at 4 months from a pooled analysis of 
both studies was 0.32 (95% CI: 0.20-0.42, p<0.0001) (Table 5.7). A study-by-
treatment-group interaction was not significant at 4 months (p=0.57). 
 
Table 5.7. Pooled analysis of total actinic keratoses during treatment with 
nicotinamide or placebo (Study 1 and Study 2 combined AK count). 
LS = Least Squares, CI=Confidence Interval 
Ŧ = Wilcoxon Rank Sum test 
* Back-transformed estimates from an analysis of covariance performed on the loge(AK count) data at 
the time point indicated with treatment group included as a factor and the baseline loge(AK count) as a 
covariate. 
 
 
 
 
 
Placebo 
N=37 
Nicotinamide 
N=39 
Relative 
Reduction 
(95% CI)* 
P valueŦ 
4 months 
Mean (SD) 
Range (median) 
LS Mean    (95% CI)* 
 
31.2 (20.55) 
5-89 (26) 
22.8 (20.4-25.6) 
 
19.3 (14.73) 
2-60 (14) 
15.5 (13.9-17.4) 
 
 
 
 
 
32% (20-42%) 
 
 
 
 
 
P<0.0001 
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For Study 1, in the placebo group, there were 6 new histologically confirmed skin 
cancers in 6 patients during the 4 months of the study (4 SCCs, 2 BCCs), compared 
to one new SCC in the nicotinamide group. For Study 2, in the placebo group, there 
were 14 new histologically confirmed skin cancers in 7 patients during the 4 months 
of the study (4 SCCs, 10 BCCs), compared to one new SCC in situ and 2 new BCCs 
in one patient in the nicotinamide group. Combining Studies 1 and 2, a total of 37 
patients were randomised to placebo and 37 randomised to nicotinamide.  11 placebo 
patients developed 20 new skin cancers (12 BCC, 8 SCC), and 2 nicotinamide 
patients developed 4 cancers (2 BCC, 2 SCC) (Figure 5.5). The odds of developing 
at least one new skin cancer were significantly lower for the nicotinamide arm 
adjusted for the number of previous skin cancers (odds ratio=0.14; 95% CI: 0.03-
0.73, p=0.019) using logistic regression model. The relative rate of new cancers for 
the nicotinamide arm adjusted for the number of previous cancers was 0.24 (95% CI: 
0.08-0.71, p=0.0099) as estimated by Poisson regression model. The treatment effect 
on skin cancer rates remained statistically significant (relative rate=0.24), when the 
comparison was repeated using a negative binomial model (95% CI: 0.06-0.92, 
p=0.038). 
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(a) 
 
(b) 
 
Figure 5.5. Numbers of NMSCs (a) and percentage of patients who developed 
new skin cancers (b) in the placebo and nicotinamide groups. Adjusted for the 
number of previous skin cancers, nicotinamide significantly reduced the rate of new skin cancers by 
76%, as estimated by both Poisson regression and negative binomial models (RR=0.24; 95% CI:0.08-
0.71;  p=0.0099) and negative binomial models (RR=0.24; 95% CI:0.06-0.92; p=0.038). The odds of 
developing at least one skin cancer was 86% lower with nicotinamide (OR=0.14; 95%CI:0.03-0.73; 
p=0.019) as estimated with logistic regression model.  
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5.6. NAD(H) AND NADP(H) QUANTIFICATION 
Whole blood for NAD(H) and NADP(H) analysis was collected in anticoagulant 
potassium-ethylenediaminetetraacetic acid (K2EDTA) containing tube (BD, New 
Jersey, USA) and stored frozen at -20°C within 3 hours of collection.  NAD(H) and 
NADP(H) were extracted and quantified following method described by Jacobson et 
al (Jacobson et al., 1999) and detailed in Materials and Methods (Section 2.3.5 and 
2.3.6).  
 
5.6.1. No significant increase in niacin status was able to be 
detected with nicotinamide supplementation 
Fu et al showed that erythrocyte NAD(H) content decreased within 5 weeks of 
depletion in dietary niacin equivalent (nicotinamide, nicotinic acid, tryptophan), 
whereas the NADP(H) content was relatively unchanged (Fu et al., 1989). Hence, the 
ratio of NAD(H)/NADP(H) is linearly associated with niacin status and this can be 
quantified in term of niacin number (erythrocyte NAD(H)/NADP(H) × 100) 
(Jacobson et al., 1999). There was no significance difference in baseline niacin 
number between placebo and nicotinamide groups (mean±SEM baseline placebo 
niacin number = 7.24±0.714 vs. mean±SEM baseline nicotinamide niacin number = 
6.89±0.734; p=0.73, unpaired student t-test). Nicotinamide 500mg twice-daily 
supplementation for 2 months did not significantly increase niacin number compared 
to baseline (2-month nicotinamide mean niacin number = 13.45±3.865; baseline 
nicotinamide mean niacin number = 6.89±0.734; mean±SEM; p=0.13, paired 
Student’s t-test). However, there were large inter-individual variations in NAD(H) 
and the corresponding niacin numbers in nicotinamide group at both baseline and 2 
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months (baseline nicotinamide range NAD(H): 2.47-11.34, niacin number: 3.31-
15.14; 2-month nicotinamide range NAD(H): 3.38-20.93, niacin number: 5.20-
73.96). Comparison of medians niacin numbers at baseline and 2 months shows 
closer values (baseline nicotinamide median niacin number = 5.87; 2-month 
nicotinamide median niacin number = 8.21). The difference in median niacin 
numbers is statistically non-significant (p=0.10), when comparison was calculated 
using Wilcoxon matched-pairs signed rank test. At 2 months, there was no 
significant difference in niacin number in the nicotinamide group compared to the 
placebo group (2-month nicotinamide niacin number = 13.45±3.865 vs. 2-month 
niacin number in placebo group = 8.04±0.594; mean±SEM; p=0.20, unpaired 
Student’s t-test). Large inter-individual variations in NAD(H) and the corresponding 
niacin numbers were also noted at 2 months, both without (placebo) and with 
nicotinamide supplementation (2-month placebo range NAD(H): 3.45-8.68, niacin 
number: 4.73-13.07; 2-month nicotinamide range NAD(H): 3.38-20.93, niacin 
number: 5.20-73.96). Comparison of medians niacin numbers at 2 months between 
placebo and nicotinamide groups shows no statistical significance (2-month placebo 
median niacin number = 7.64; 2-month nicotinamide median niacin number = 8.21; 
p=0.40, Mann-Whitney U test).  Similarly, no significant changes in niacin number 
was observed between nicotinamide and placebo groups either at baseline and after 
nicotinamide 500mg once-daily for 2 months. 
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5.7. DISCUSSION 
 
Patients in these trials were elderly Australians with an average of more than 30 AKs 
each and more than 80% had previous skin cancers. In this high-risk, heavily sun-
damaged population, nicotinamide 500mg twice and once daily reduced AKs by 35% 
and 29% respectively, relative to placebo within 4 months (p=0.0006 and p=0.005), 
and was equally effective in individuals with higher and lower baseline AK counts. 
Furthermore, the reduction in AKs was also observed within 2 months of daily 
nicotinamide supplementation. At 2 months, AKs reductions relative to placebo were 
35% and 15% for twice and once daily 500 mg nicotinamide respectively (p<0.0001 
and p=0.046). There is only one other in vivo study, investigating the effect of 
nicotinamide on AKs. In this randomized, double blind placebo controlled study of 
26 patients, topical 1% nicotinamide applied twice daily for 3 months significantly 
reduced AKs by 21.8%. In the vehicle (placebo) group the reduction at 3 months was 
only 10% and the difference was statistically significant (p=0.04). However, the 
difference in AK reduction between nicotinamide and placebo groups was not 
sustained after 6 months of application (Moloney et al., 2010). There is one ex vivo 
study investigating the relationship between Nicotinamide Adenine Dinucleotide 
(NAD) concentration in the skin and the incidence of AKs and SCCs (Jacobson et 
al., 1999). Both nicotinamide and niacin are converted to NAD and its 
phosphorylated form, NADP (Jacob, 2001). In that study, normal skin from 
individuals with AKs had significantly higher NAD than the normal skin of patients 
with a history of cutaneous SCC (p=0.0006) (Jacobson et al., 1999).  
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Previous in vivo studies were conducted in BALB/cAnNTacfBR mice. Topical 2.5% 
nicotinamide prevented UVB-induced immunosuppression and skin tumour 
(predominantly SCCs) formation in the mice (Gensler, 1997). Oral niacin (0.5% and 
1% in the diet), which like nicotinamide is a precursor for NAD and NADP, 
significantly prevented UVB-induced immunosuppression and markedly reduced 
skin SCCs incidence and multiplicity in these mice (Gensler et al., 1999). Studies of 
nicotinamide in humans have also investigated its effect on UV-induced 
immunosuppression (Damian et al., 2008, Yiasemides et al., 2009, Sivapirabu et al., 
2009). Topical 5% nicotinamide applied before or after exposure of human skin to 
solar simulated UV (ssUV) significantly prevented UV-induced immunosuppression 
(Damian et al., 2008). Subsequent studies revealed that both UVA- and UVB- 
immunosuppression were prevented by topical 5% nicotinamide applied immediately 
to the skin of human volunteers after the irradiations (Sivapirabu et al., 2009). Oral 
nicotinamide at the dose of 500 mg or 1500 mg once daily administered for 1 week 
before exposure to suberythemal doses of ssUV for 3 days, also significantly reduced 
UV- induced immunosuppression (Yiasemides et al., 2009). Neither topical nor oral 
nicotinamide reduced susceptibility to sunburn, suggesting its lack of sunscreening 
property or capacity to prevent sunburn (Damian et al., 2008, Yiasemides et al., 
2009).  
 
This is the first study showing a protective effect of nicotinamide on the incidence of 
NMSCs in humans. During this brief study in a relatively small sample size, a 
significant reduction in skin cancers was observed in the nicotinamide group, whilst 
in the placebo group a trend towards increased incidence was seen [11 placebo 
patients developed 20 new skin cancers (12 BCCs, 8 SCCs), and 2 nicotinamide 
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patients developed 4 cancers (2 BCCs, 2 SCCs)]. These trials did not have numbers 
of new NMSCs as a defined primary endpoint, as any detectable reduction in skin 
cancers was not anticipated within the 4-month study periods. Further studies, with 
larger sample sizes and longer follow-up times, will be needed to confirm the 
findings in these trials.  
 
Current approaches to the treatment of AKs are lesion-directed therapies 
(cryotherapy, shave excision, and curettage and electrodessication) which physically 
destroy the target AKs, and field directed therapies (5-fluorouracil (5-FU), 
imiquimod, photodynamic therapy, laser resurfacing, chemical peels, and ingenol 
mebutate) which treat clinically apparent AKs as well as perilesional skin and hence 
target both visible lesions as well as subclinical pre-neoplastic sun-damaged 
surrounding skin (field cancerization) (Braakhuis et al., 2003). These approaches all 
significantly reduce AKs compared with placebo, although comparisons among them 
are difficult due to varying end points (proportion of patients with total clearance, 
proportion of patients with more than 75% clearance, percentage reduction in target 
lesions, assessment of clinical or histological clearance) reported in different studies. 
Cryotherapy, 5-FU, imiquimod, ingenol mebutate, and photodynamic therapy are 
often associated with significant local skin reactions including pain, erythema, 
oedema and/or erosions. Some of these topical therapies can also be complicated by 
hypopigmentation and/or scarring. Surgical interventions (shave, curettage and 
electrodessication), laser and dermabrasion and chemical peels are associated with 
reported complications such as bacterial and viral skin infections, hypo- and hyper-
pigmentation, and scarring (Berman and Amini, 2012).  
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Previous studies of AK and/ or skin cancer chemoprevention in humans (see Chapter 
1, Section 1.8.2 for details of individual studies and efficacy) have included topical 
DL-α-tocopherol (vitamin E) (Foote et al., 2009), oral betacarotene (Greenberg et al., 
1990, Green et al., 1999, Frieling et al., 2000, Darlington et al., 2003), and oral 
selenium (Clark et al., 1996). None of these agents were shown to significantly 
reduce AKs or skin cancers. Oral and topical retinoids (Kraemer et al., 1988, Alirezai 
et al., 1994, Bavinck et al., 1995, Moon et al., 1997, Gibson et al., 1998, McKenna 
and Murphy, 1999) and DNA repair enzymes (T4 endonuclease V [T4N5] in 
liposomes) (Yarosh et al., 2001, DeBoyes et al., 2010) have been shown to be 
effective in reducing AKs and/ or skin cancers. These agents are however limited by 
toxicity (dry mucous membrane and skin, cheilitis, photosensitivity, hyperlipidaemia, 
hepatotoxicity, rarely raised intracranial pressure) and high cost respectively. Twice 
daily administration of celecoxib was reported to reduce the rate of new NMSCs in 
240 sun-damaged patients treated for 9 months (Elmets et al., 2010). A rate ratio of 
0.43 for new skin cancers was reported, despite no significant reduction in AKs. 
Nonsteroidal anti-inflammatory agents such as celecoxib do however carry a range 
of potential toxicities including gastritis, hypersensitivity, hypertension and 
gastrointestinal haemorrhage. The incidence of nonsteroidal side effects is higher in 
elderly patients, who are more likely to have reduced renal function and take a range 
of potentially interacting medications (Barkin et al., 2010).  Diclofenac gel, generally 
used for at least 3 months, has also shown efficacy against AKs on the face and scalp 
of individuals with baseline AK counts of ~8-12 (Gebauer et al., 2003, Nelson and 
Rigel, 2009) but is relatively costly and carries the compliance issues of topical 
therapy. Several dietary agents including resveratrol (found in grapes, red wines, 
berries, peanuts), proanthocyanidins (grape seeds), (-)-epigallocatechin-3-gallate 
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(green tea) have been shown to have antitumor effects by modulation of immune 
response in carcinogenesis (Zheng et al., 2012). However, these agents have not been 
shown to be effective in skin cancer prevention in humans. Sunscreen has been 
shown to reduce UV-induced immunosuppression (Damian et al., 1997) and the 
incidence of AKs and SCCs by almost 40% (Thompson et al., 1993, van der Pols et 
al., 2006). However, there is not yet clear evidence that it prevents BCCs (van der 
Pols et al., 2006) or melanoma (Dennis et al., 2003), although the incidence of 
melanoma may be reduced after prolonged follow-up (Green et al., 2011). Moreover, 
sunscreen effectiveness is limited by poor compliance, even in individuals at greatest 
skin cancer risk (Neale et al., 2002). Despite their extremely high risk for skin 
cancer, less than half of the participants in these studies regularly used sunscreen, 
although both nicotinamide and placebo groups showed excellent compliance with 
twice daily intake of oral nicotinamide. Most of the patients involved in the trials 
were elderly and take regular medications for chronic medical conditions. Additional 
intake of vitamin supplement therefore is easily added to the usual intake of other 
regular medications.  
 
The strengths of these trials were their prospective designs and the randomized and 
double-blinded nature of the protocols. AKs in both trials were counted by the same 
investigator (the author), who was not involved in the randomization process. All 
NMSCs were diagnosed by dermatologists who normally cared for the patients 
during their routine follow-up in the outpatient clinics separate from the trials 
appointments. All NMSCs were histologically confirmed by pathologists who 
worked at Royal Prince Alfred Hospital Pathology Department and they are not 
associated with the studies. Baseline AKs and previous NMSCs were accounted for 
in the analyses and we further assessed the robustness of the findings by conducting 
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pooled analysis of skin cancer data using three different models and the nicotinamide 
effect was consistently significant. Another strength of the study was the inclusion of 
extremely sun-damaged patients with very large numbers of AKs, reflecting the 
Australian dermatology clinic population. Nicotinamide was as effective in the most 
heavily sun-damaged patients as in those with much lower AK counts. AKs are 
useful surrogate markers for skin cancer risk and skin cancer reduction, but can 
sometimes be subtle lesions, with potential for inter-observer variation in AK counts 
especially in patients with large numbers of lesions (Weinstock et al., 2001). In both 
trials, all AKs were counted by in a blinded manner by the author, and any intra-
observer variation in AK counts was addressed by the double-blinded, randomised 
design with relative reduction in AK, rather than absolute AK counts, as the primary 
endpoint. Further, the findings of similar relative AK reductions in a separate, second 
study confirm the reliability of the AK data.  
 
Spontaneous seasonal fluctuation in AK counts has been previously reported 
(Criscione et al., 2009, Moloney et al., 2010), and the 13-15% reduction from 
baseline observed in the placebo groups is consistent with this. Although the 
majority of patients did use sunscreen “always” or “sometimes,” it is possible that 
some participants may have modified their sun protective behaviours during the 
study in response to their regular clinic appointments. The randomised, double-
blinded trial design enabled detection of significant reductions in AKs with 
nicotinamide relative to any background variations in AKs due to seasonal and 
personal fluctuations in UV doses. 
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No significant increase in niacin number (NAD(H)/NADP(H) × 100) with 
nicotinamide supplementation was detected in this study. Large variability in 
baseline whole blood NAD(H) up to 3 folds was observed in a large Western 
population (n=1300) within The Malmö Diet and Cancer Study (Jacobson, 1993), 
consistent the wide range of NAD(H) observed at baseline in this study. The 
relatively small numbers of patients and the large inter-individual variations in niacin 
numbers observed in nicotinamide group at baseline and 2 months; and in placebo 
and nicotinamide groups at 2 months may have contributed to the non-significant 
increase found after nicotinamide supplementation in this study. The randomised 
nature of the trial design nevertheless demonstrated significant reductions in AKs 
compared to placebo, with a trend to dose-responsiveness of this effect over the two 
daily doses used, regardless of likely inter-individual variation in tissue status or 
dietary intake.  
 
In this study, AK reduction was observed within 2 months and nicotinamide 
reduction on NMSCs incidence was apparent within 4 months of treatment. In some 
chemoprevention studies, where AK count reductions were the study end point, 
efficacy can be seen within few months of treatment (Moriarty et al., 1982, Alirezai 
et al., 1994, Alberts et al., 2000, DeBoyes et al., 2010, Moloney et al., 2010). Most 
NMSC chemoprevention studies are designed with longer durations of follow-up 
ranging from 11 months to 12 years (Kraemer et al., 1988, Greenberg et al., 1990, 
Tangrea et al., 1992, Naylor et al., 1995, Clark et al., 1996, Levine et al., 1997, 
Elmets et al., 2010, Moon et al., 1997, Green et al., 1999, McKenna and Murphy, 
1999, Frieling et al., 2000, Yarosh et al., 2001, Grau et al., 2006, Hughes et al., 2006, 
van der Pols et al., 2006, Ibiebele et al., 2007, Ulrich et al., 2009, Bailey et al., 2010, 
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Weinstock et al., 2012). Retinoid reductions of NMSCs in immunosuppressed renal 
transplant recipients were shown to occur within 3 to 6 months of oral administration 
in two studies (Bavinck et al., 1995, Gibson et al., 1998). Administration of acitretin 
30 mg daily for 6 months significantly reduced both the number of patients with 
NMSCs and the number of NMSCs in renal transplant recipients with at least 10 
AKs at the commencement of the study (Bavinck et al., 1995). In renal transplant 
patients with at least 2 NMSCs (total numbers of NMSCs at the baseline ranged from 
2 to 23), significant reduction in NMSCs incidence with oral etretinate 0.3mg/kg 
body weight per day was observed at 3- and 6- months treatment intervals and 
NMSCs incidence continued to decline in this study after 12- and 18- months of 
treatment although, the decrease in the incidence was not statistically significant at 
the later time points (Gibson et al., 1998). Similar to these studies, nicotinamide 
study participants had severe solar damage (average AKs count 30 at baseline, and 
more than 80% of patients have had NMSCs prior to enrolment in the study). In this 
high-risk group, the rate of AK transformation into SCCs was possibly higher than 
estimated in most studies (0.075 to 20% per AK (Marks et al., 1986, Marks et al., 
1988, Callen et al., 1997)). 20 NMSCs in 13 patients (out of total 37 patients in 
placebo groups from both studies) were diagnosed within 4 months. This may partly 
explain that nicotinamide reduction on NMSCs was observed within the short time 
frame of the study.   
 
Solar UV radiation causes skin cancer by both inducing DNA damage and 
suppressing cutaneous anti-tumour immunity (Halliday, 2010). Nicotinamide is an 
endogenous substrate of the nuclear enzyme poly-ADP-ribose polymerase (PARP), 
which is central in the maintenance of genomic stability and DNA repair process 
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(Virag and Szabo, 2002). As a precursor of nicotinamide adenine dinucleotide 
(NAD(H)), nicotinamide prevents the decline in cellular energy observed after UV 
exposure (Park et al., 2010), and could in this way enhance DNA repair, as observed 
in previous studies (Chapter 4). Enhancement of DNA repair with nicotinamide is 
likely to mediate its effect on AKs and NMSCs reduction observed in this study. 
Nicotinamide is also a known inhibitor of PARP, as previously shown in Chapter 3 
(Section 3.4). In mice, pharmacologic inhibition of PARP with 3,4-dihydro-5-[4-(1-
piperidinyl)butoxyl]-1(2H)-isoquinolinone (DPQ) protects against chemically  
induced skin carcinogenesis through modulation of the activity of transcription 
factors involved in tumour promotion (activator protein (AP)-1, hypoxia inducible 
factor (HIF)-1α) and inhibition of tumour promotion and inflammation genes 
(Martin-Oliva et al., 2006). Furthermore, PARP inhibition with nicotinamide was 
shown to inhibit nuclear factor-kappa beta (NF-κΒ) in vitro and suppress 
lipopolysaccharide-induced TNF-α production in mice (Pero et al., 1999). NF-κΒ 
inhibition prevents activation of its target genes, resulting in suppression of 
inflammation and expression of genes associated with tumour progression in skin 
carcinogenesis (Martin-Oliva et al., 2004). Nicotinamide is highly immune protective 
in humans (Damian et al., 2008). UV immunosuppression can occur even with 
extremely low, sub-erythemal doses of sunlight, as would be encountered during 
normal daily activities (Damian and Halliday, 2002). Immune suppression plays a 
key role in the malignant transformation of AKs (Frost and Green, 1994). 
Nicotinamide protection from photoimmunosuppression may therefore mediate the 
reduction in AKs and skin cancer incidence observed in this study.  
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In summary, administration of oral nicotinamide is effective in reducing AKs within 
a few months, and appears to substantially reduce new NMSCs.  Nicotinamide is 
extremely well-tolerated, even at high doses as used previously in trials for diabetes 
prevention (Visalli et al., 1999). Nicotinamide is already widely commercially 
available as 500mg tablets, and costs ~$US5 - $10 per month at the doses used here. 
The results of these trials suggest nicotinamide at the dosages used in these studies 
are safe with no severe adverse reactions reported, and significantly effective in 
reducing precancerous AKs lesions even in heavily sun-damaged individuals, 
suggesting its promise for skin cancer chemoprevention. A larger, longer trial is now 
indicated to more formally assess and confirm the effect of nicotinamide on skin 
cancers. 
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CHAPTER 6 DISCUSSION  
 
Excessive exposure to solar ultraviolet radiation (UVR) is a major etiologic factor in 
the development of non-melanoma skin cancers (NMSCs) (Armstrong and Kricker, 
2001). UVR is carcinogenic via its mutational and immunosuppressive effects on 
skin (Halliday, 2005). UVR damages DNA directly, resulting in formation of 
cyclobutane pyrimidine dimers (CPDs), and also indirectly by producing reactive 
oxygen species (ROS), which induce the oxidative photolesion 8-oxo-7,8-dihydro-
2’-deoxyguanine (8-oxodG) (Melnikova and Ananthaswamy, 2005). Considerable 
evidence suggests that CPDs are important photoproducts in the induction of UV-
immune suppression (Kripke et al., 1992, Kuchel et al., 2005). There is also strong 
evidence that ROS contribute to UV-immune suppression (Kuchel et al., 2003). 
 
Research by our group has identified nicotinamide, either topically or orally, to have 
a significant protective effect against UV-induced immune suppression in humans 
(Damian et al., 2008, Yiasemides et al., 2009, Sivapirabu et al., 2009). Nicotinamide, 
an amide form of vitamin B3 (niacin), is the major precursor for the synthesis of 
pyridine nucleotides, nicotinamide adenine dinucleotide (NAD) and its 
phosphorylated form, NADP (Magni et al., 2004, Bogan and Brenner, 2008). Besides 
its main function as coenzyme in energy metabolism, NAD also serves as a substrate 
for protein-translational modifications, such as mono- and poly(ADP-ribosyl)ation 
by mono(ADP-ribosyl)transferases (ARTs) and poly(ADP-ribosyl)polymerases 
(PARPs) and deacetylation by sirtuins, which all play regulatory roles in the 
maintenance of genomic stability (Kirkland, 2009b). Genotoxic and oxidative 
stresses, including those caused by exposure to UVR and alkylating agents, deplete 
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cellular NAD (Ying et al., 2005). Maintenance of NAD levels in skin cells positively 
correlates with cellular survival after UVR (Jacobson et al., 2001). In HaCaT 
keratinocytes, nicotinamide was shown to upregulate succinic dehydrogenase (SDH), 
a key enzyme in the Krebs cycle and mitochondrial electron transport chain 
(Sivapirabu et al., 2009), and to prevent UV-induced cellular energy loss and 
glycolytic blockade (Park et al., 2010). Repetitive UVA irradiations have been 
shown to induce mitochondrial DNA deletions (Berneburg et al., 1999, Koch et al., 
2001, Berneburg et al., 2004, Krishnan et al., 2004), which led to a decrease in 
mitochondrial function and energy production (Berneburg et al., 2005). 
Nicotinamide’s functions in cellular bioenergetics and in NAD-dependent regulatory 
pathways likely mediate its photoprotective effects. The aims of this project were to 
investigate regulation of UV-induced DNA damage by nicotinamide and to 
determine the effect of nicotinamide on precancerous skin lesions, actinic keratoses 
(AKs), in humans. The hypotheses proposed in this study are that nicotinamide 
supplementation normalizes cellular energy during UV irradiation and this positively 
regulates DNA repair, preventing formation of DNA mutations and UV-immune 
suppression, and hence inhibits skin carcinogenesis.  
 
Hypothesis 1 – nicotinamide prevents mitochondrial deletions 
To investigate the role of energy metabolism in mitochondrial DNA mutagenesis, the 
effect of nicotinamide was assessed on the UV-induced-4977 bp mitochondrial DNA 
common deletion (mtDNA-CD). mtDNA-CDs have been proposed to represent long-
term biomarkers for UV exposure in human skin, as their levels tend to increase in 
human skin chronically exposed to solar UVR (Birch-Machin and Swalwell, 2010). 
In order to induce mtDNA-CDs, HaCaT human keratinocytes and primary human 
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fibroblasts were repetitively irradiated with 8 J/cm2 UVA 3 times/day for 4 
consecutive days per week, for 1, 2, or 3 weeks, to give a total number of UVA 
irradiations of 12, 24, or 36 times respectively. Cell viability was maintained at more 
than 80% in all groups (‘No UV’, ‘NoUV + Nic’, ‘UV’, ‘UV + Nic’) after 12 and 24 
UVA irradiations. However, excessive cell death seen with 30 or more UVA 
irradiations prevented further processing of the cells for DNA extraction. mtDNA-
CD was measured quantitatively using real-time and nested PCR. Despite repetitive 
attempts, this study failed to detect mtDNA-CD following 12 and 24 UVA 
irradiations in all studied groups in both HaCaT and fibroblast cells using real-time 
and nested PCR.  Hence, the effect of nicotinamide on mtDNA-CD could not be 
examined.   
 
Three main reasons were proposed for the inability to detect mtDNA-CD in this 
study. Firstly, selective decrease in survival in cells harbouring higher number of 
mtDNA-CD may have prevented their detection. mtDNA-CD causes deletion of all 
or part of the genes encoding multiple subunits of electron transport chain proteins, 
which are essential for maintaining normal mitochondrial function (Peng et al., 
2006). Deficiency in oxidative phosphorylation results in selective growth 
disadvantage in cells containing high numbers of deleted mtDNA (Wallace, 1989). 
Interestingly, a meta-analysis of 38 studies found that mtDNA-CDs were 
significantly lower in tumour cells than in adjacent non-cancerous tissue among 
various types of cancer, including skin cancers (Nie et al., 2013). It was suggested 
that higher mtDNA-CD frequency occurs during the early stages of carcinogenesis. 
As the cancerous cells proliferate, mtDNA-CD is selected against, resulting in a 
higher frequency of mtDNA-CD in the adjacent tumour tissue compared to the 
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cancerous tissue (Nie et al., 2013). Secondly, given a known very low level of 
mtDNA-CD in high-turnover tissues and cultured cells, such as skin (Pogozelski et 
al., 2003), the detection system used in this study may not have been sufficiently 
sensitive. Despite successful amplification of a positive control derived from a 
commercial plasmid, multiple attempts using both RT- and nested-PCR primers on 
irradiated samples could not convincingly detect mtDNA-CD above the reliable 
threshold level. Lastly, 12 and 24 irradiations with 8 J/cm2 UVA in these studies may 
have been insufficient to cause enough mtDNA-CD for detection in cultured cells, 
while higher doses of UVA resulted in excessive cell death. Previous studies in 
normal human fibroblasts showed that 12 exposures to 8 J/cm2 UVA failed to cause 
detectable mtDNA-CD, whereas 24 and 36 irradiations with 8 J/cm2 UVA resulted in 
detectable and maximal induction of mtDNA-CD respectively (Berneburg et al., 
1999, Berneburg et al., 2005). These studies used a different irradiation source 
(UVASUN5000 Biomed irradiation device, filtered to consist of wavelengths greater 
than 340nm) from the one used in my study (1000 W xenon-arc Oriel solar 
simulator, filtered to consist of wavelengths between 320 and 400nm). The presence 
of UVA2 radiation (320 to 340nm) in my study may have caused more DNA 
photolesions that were lethal when the cells were irradiated 30 times or more with 8 
J/cm2 UVA.  
 
Hypothesis 2 – nicotinamide stimulates repair of UV-induced nuclear 
DNA damage 
The effect of nicotinamide on nuclear DNA repair was assessed using an 
unscheduled DNA synthesis (UDS) assay. This assay is based on the incorporation 
of the thymidine analogue bromodeoxyuridine (BrdU) into a stretch of DNA being 
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synthesized during excision repair of damaged DNA (Beisker and Hittelman, 1988). 
DNA repair synthesis following removal of damaged DNA occurs in discrete foci, 
which can be visualized in the UDS assay as punctate nuclei. This is in contrast to 
semi-conservative replication of DNA during S-phase of the cell cycle, which occurs 
diffusely throughout the nuclei, and hence can be detected as uniform staining of 
nuclei in the UDS assay (Nakagawa et al., 1998, Sreevidya et al., 2010).  
 
HaCaT keratinocytes were incubated in Dulbecco’s Modified Eagle’s (DMEM) 
medium, supplemented with 50µM nicotinamide for 24 hours before exposure to a 
single dose of 4 J/cm2 ssUV, consisting of 90.4% UVA and 9.6% UVB. DMEM 
medium contains 32.8µM nicotinamide. Hence, after 50µM nicotinamide 
supplementation, the total nicotinamide concentration in the media was 82.8µM with 
32.8µM in the control cultures. The ssUV dose used in this study is equivalent to 
approximately 15 minutes of noon spring sunlight in Sydney and was suberythemal 
in previous studies in humans, yet it causes almost 30% immune suppression on 
human skin in vivo after a single exposure (Sivapirabu et al., 2009). This ssUV dose 
did not cause excessive cell death and had no apparent effect on cell cycle arrest as 
viability exceeded 88% up to at least 2 hours after ssUV irradiation and similar 
numbers of cells (4%) were in S-phase in all treatment groups.  The dose of ssUV in 
this study however resulted in an almost threefold increase in the proportion of cells 
undergoing UDS within 45 minutes of irradiation, showing that it damaged DNA and 
initiated DNA repair. Nicotinamide treatment for 24 hours before irradiation and 
during the 45 minutes incubation time after irradiation caused a further significant 
23.3% relative increase in the number of cells undergoing UDS. Nicotinamide 
stimulated not only the proportion of cells undergoing repair of UV-induced DNA 
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damage, but also the repair rate in each cell. The number of grains within a cell 
reflects the amount of incorporated thymidine per cell during excision repair and this 
also increased with nicotinamide treatment, suggesting an increased rate of DNA 
repair synthesis in UV damaged cells.  
 
The mechanism involved in nicotinamide stimulation of UDS is not completely 
understood. Human cells predominantly utilise nicotinamide, rather than nicotinic 
acid as a main precursor for NAD biosynthesis (Magni et al., 2004). NAD is an 
essential coenzyme for ATP generation in glycolysis and oxidative phosphorylation 
(Benavente et al., 2009). Nicotinamide supplementation prevented ATP depletion 
and glycolytic blockade induced by ssUV irradiation or hydrogen peroxide (H2O2) in 
HaCaT cells (Park et al., 2010) and primary human fibroblasts (Rovito and Oblong, 
2013) respectively. DNA repair is an ATP-dependent process. Both DNA 
polymerases α and β are dependent on sufficient ATP to stimulate UDS in HeLa 
cells (Seki and Oda, 1986). DNA helicase, which participates in repair of DNA 
intrastrand crosslinks, is translocated on DNA in an ATP-dependent manner (Deans 
and West, 2011). ATP is also required during the excisional (Dresler and Lieberman, 
1983) and patch ligation (Seki et al., 1987) steps of DNA repair. Modification of 
chromatin structure, which plays a central role in the DNA damage response, is 
highly dependent on ATP. Chromatin structure determines access to DNA and often 
serves as a docking or signaling site for repair and signaling protein. A family of 
related ATP-dependent complexes, known as chromatin-remodelling enzymes, uses 
the free energy derived from ATP hydrolysis to modify chromatin in order to 
facilitate efficient DNA repair (Lans et al., 2012).  
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There is some evidence that increased UDS, following treatment of cells with DNA 
damaging agents, is tightly linked to activation of the NAD-dependent nuclear 
enzyme, PARP (Berger et al., 1979, Miwa et al., 1981, Sims et al., 1981, Jacobson et 
al., 1983). In human lymphocytes (Berger et al., 1979) and primary human 
fibroblasts (Jacobson et al., 1983), exposure to UVR resulted in rapid increases in 
poly(ADP-ribose) and depletion of its substrate, NAD. Nicotinamide, a known 
inhibitor of PARP, enhanced UDS and prevented NAD depletion caused by exposure 
to DNA damaging agents (Miwa et al., 1981, Sims et al., 1981). The inhibitory 
concentration of nicotinamide on PARP-1, which accounts for more than 90% of 
cellular poly(ADP-ribosylation) under genotoxic stress (Smith, 2001), was examined 
in my study. A 66% reduction in PARP-1 resting activity was shown with 50µM 
nicotinamide and more than 95% reduction in activity was shown with 500µM 
nicotinamide.  PARP is a nuclear protein, which binds tightly to DNA and requires 
DNA strand breaks for activation. PARP activation consumes NAD, forming long, 
branched poly(ADP-ribose) polymers, which attach to the PARP itself, resulting in a 
negatively-charged PARP, triggering its release from DNA and allowing access for 
DNA repair enzymes (Satoh and Lindahl, 1992). Poly(ADP-ribose) polymers are 
degraded in the nucleus by poly(ADP-ribose) glycohydrolase (PARG), releasing 
ADP-ribose monomers and nicotinamide. How does nicotinamide, which provides 
NAD for PARP activation, facilitating DNA repair, also endogenously inhibit 
PARP? Firstly, this paradox could be explained in part by subcellular 
compartmentalization of NAD pools and nicotinamide metabolism. There are three 
subcellular compartments of NAD: nuclear, cytosolic, and mitochondrial, and there 
are two enzymes involved in the biosynthesis of NAD from nicotinamide: 
nicotinamide phosphoribosyltransferase (NAMPT), which converts nicotinamide 
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into nicotinamide adenine mononucleotide (NMN), and nicotinamide 
mononucleotide adenynyltransferase (NMNAT), which catalyzes the formation of 
NAD from NMN and ATP (Sauve, 2008). Evidence suggests that the NAD content 
in each subcellular compartment is regulated by differential expression of distinct 
NAMPT and NMNAT enzymes in each subcellular compartment. NAMPT, which is 
present both extracellularly (eNAMPT) and intracellularly (iNAMPT; in cytosol and 
possibly also in nuclei), has been shown to be upregulated by cellular stress (Yang et 
al., 2007, Imai, 2009). The presence of three distinct compartment-specific isoforms 
of NMNAT, NMNAT 1-3, located in nucleus, Golgi complex, and mitochondria 
respectively, suggest differential regulation of the NAD pool in each compartment 
(Berger et al., 2005). Therefore, this regulation likely determines whether 
nicotinamide is utilized to replenish NAD or inhibit PARP during cellular stress. 
Secondly, excessive PARP activation is a major cause of cell death after genotoxic 
stress (Ying et al., 2005). Although initial PARP-1 activation is necessary to 
facilitate access of DNA repair proteins, sustained PARP-1 activity can lead to NAD 
depletion. Consumption of ATP for NAD synthesis or impairment of NAD-
dependent steps of glycolysis lead to energy failure and necrotic cell death (Ha and 
Snyder, 1999). Since nicotinamide also forms in the nucleus as a degradation product 
of poly(ADP-ribose) polymers, it possibly serves as a negative feedback regulator, 
preventing PARP overactivation. Moreover, high intracellular ATP level is also 
genome-protective. While apoptosis is necessary to prevent survival of cells with 
overwhelming DNA damage, it is a highly ATP-dependent process (Miyoshi et al., 
2006). Therefore, inhibition of excessive PARP-1 activity by nicotinamide is 
possibly a cellular protective mechanism, preventing energy failure and allowing 
cells to either repair the genome or undergo apoptosis.  
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Hypothesis 3 – nicotinamide enhances repair of UV-induced CPDs 
and 8-oxodG 
UDS assesses the re-synthesis step of DNA repair. It does not assess formation and 
excision repair of specific UV-induced DNA lesions, such as CPD and 8-oxodG. The 
comet assay is a sensitive and quantitative method for measuring DNA strand breaks 
at the single cell level (Singh et al., 1991). In this study, lesion-specific 
endonucleases, T4N5, which recognizes CPDs and abasic sites, and hOGG1, which 
cleaves 8-oxodG and DNA-containing formamidopyrimidine moieties, were utilized 
to increase the assay range of detection and sensitivity.  In parallel with the samples 
incubated with either T4N5 or hOGG1, control samples were incubated with a buffer 
alone. The score from these control samples was subtracted from the “+ T4N5 or + 
hOGG1” score to give “net T4N5- or hOGG1- sensitive sites”. As neither T4N5 nor 
hOGG1 has absolute specificity, immunostaining of whole human skin with specific 
anti-thymine dimer (Besaratinia et al., 2011) and anti-8-oxodG monoclonal 
antibodies (Soultanakis et al., 2000) was also performed in this study. The 
combination of the two detection techniques gives confidence in the final 
conclusions.  Immunostaining of whole human skin permits visualization of CPDs 
and 8-oxodG photolesions in the epidermis and avoids potential artefactual DNA 
damage induced during cell harvesting and lysis during extraction of DNA 
photolesions in the comet assay.  
 
For the comet assay study, HaCaT keratinocytes were incubated with 50µM 
nicotinamide in DMEM media for 24 hours before exposure to 4 J/cm2 ssUV. The 
medium contains 32.8µM nicotinamide, therefore the total nicotinamide 
concentration in the medium was 82.8µM. Following irradiation, the cells were 
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further incubated for 0, 30, 60, 90, and 120 minutes in the Petri dish to allow DNA 
repair, before detachment for comet assay. Due to the highly adherent nature of the 
HaCaT keratinocytes, particularly after UV exposure (Wischermann et al., 2007), the 
cells were incubated with 0.02% EDTA in PBS for 10 mins at 37°C. This reduced 
the duration of trypsinization to 5 minutes, hence minimizing background DNA 
damage (Hill and Hill, 1991). Due to the additional 15 minutes at 37°C taken to 
harvest the cells, which allows partial repair to occur, the final time course was 15, 
45, 75, 105, and 135 minutes post UV irradiation. For the immunostaining of human 
skin, whole human skin cut into 4×4 mm pieces was incubated with 50µM 
nicotinamide in RPMI 1640 media for 24 hours before exposure to 4 J/cm2 ssUV. 
The RPMI 1640 media contains 8.2µM nicotinamide, hence the total nicotinamide 
concentration in the media was 58.2µM.  Following exposure to the ssUV, the skin 
sections were further incubated for 15, 45, 75, 105, and 135 minutes, to allow DNA 
repair. The incubation times were selected to match the comet assay study, in order 
to enable comparison of repair of ssUV-induced CPDs and 8-oxodG between HaCaT 
keratinocytes and whole human skin.  
 
From the time course study, nicotinamide was shown to significantly enhance CPDs 
and 8-oxodG repair in both HaCaT keratinocytes and human epidermis. 
Nicotinamide had no effect on the formation of these photolesions as there was no 
reduction with nicotinamide in CPDs detected by either system or in 8-oxodG 
photolesions detected by the comet assay at the first timepoint after irradiation (15 
minutes).  It also suggests that nicotinamide does not have any UV filtering effect, 
consistent with previous studies in human volunteers which show the lack of 
nicotinamide effect on sunburn threshold (minimal erythema dose) (Damian et al., 
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2008, Yiasemides et al., 2009). Nicotinamide significantly enhanced repair of both 
ssUV-induced CPDs and 8-oxodG, although repair rates of both photolesions were 
slower in ex vivo skin than in in vitro keratinocytes. Similarly, Mouret et al, using an 
HPLC-mass spectrometry assay to study the formation and repair of UVB-induced 
CPDs, showed that repair of CPDs was slower in whole human skin than in primary 
cultured human keratinocytes and fibroblasts (Mouret et al., 2008). At 135 minutes 
after ssUV irradiation, approximately 80% of initial T4N5-sensitive sites in HaCaTs’ 
DNA and 60% of CPDs in human epidermis were repaired. The CPDs’ repair rate in 
this study likely corresponds to the first phase of biphasic repair as described in 
multiple other studies using varying methods of detection (Paterson et al., 1973, 
Ahmed and Setlow, 1977, D'Ambrosio et al., 1981, Reusch et al., 1988, McCarthy et 
al., 1997). There is great variability in the rates of CPD repair in both cultured cells 
and human epidermis reported in the literature. This may reflect varying cell types, 
culture conditions, measurement methods and donors’ age and skin phototypes from 
which the epidermis was derived. There is evidence that slower repair of CPDs is 
associated with increasing age (Bykov et al., 1999, Yamada et al., 2006) and with 
skin phototypes I and II (Young et al., 1996). This partly explains the increased 
frequency of skin cancers in older individuals (Diffey and Langtry, 2005) and those 
with lighter skin, eye, hair colour or an inability to tan (Neale et al., 2007). In this 
study, the ex vivo skin was obtained from 3 human female volunteers with ages 
ranging from 30 to 40 years and skin phototype III or IV. The small number of 
volunteers limits the ability to compare repair according to age, gender and skin 
phototype. Future studies on kinetics of DNA photolesions repair should include 
male and female volunteers with a wider range of ages and skin phototypes.  
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At 75 minutes after ssUV irradiation, approximately 80% of initial hOGG1-sensitive 
sites and 70% of 8-oxodG in human epidermis were repaired. The repair rate of 8-
oxodG was faster than CPDs in both in vitro and ex vivo studies, consistent with 
previous studies using similar UV doses and detection methods (Javeri et al., 2008, 
Frost et al., 2011). Differential analysis of 8-oxodG repair in upper and lower 
epidermis showed similar enhancement of repair with nicotinamide. This is 
particularly important as unrepaired DNA photolesions in the lower part of 
epidermis, which contains highly proliferating basal cells, are more likely to give rise 
to mutations and skin cancers.  
 
The combination of the in vitro and ex vivo systems used in these studies provides 
evidence that nicotinamide enhances repair of different UV-induced photolesions 
and therefore acts on a number of pathways. As the proposed mechanism of 
nicotinamide in DNA repair involves provision of ATP and NAD, it is likely that 
nicotinamide’s effect on DNA repair extends beyond CPDs and 8-oxodG. ATP-
dependent chromatin-remodelling complexes have been shown to be involved in 
various DNA repair pathways including NER, BER, HR, and NHEJ (Menoni et al., 
2007, Lans et al., 2012, Lai et al., 2013). CSB protein, which is required in TCR-
NER to displace RNA polymerase in order to enable access to damaged DNA for 
repair, exhibits DNA-stimulated ATPase activity (Selby and Sancar, 1997). XPB and 
XPD helicases of the multi-subunit transcription factor-IIH (TFIIH), which are 
responsible for opening of DNA double helix around the DNA damage during both 
TC-NER and GG-NER, function in an ATP-dependent manner (Evans et al., 1997). 
ATP is also required for the activity of DNA ligases I and III (Martin and MacNeill, 
2002), both of which are involved in NER and BER. PARP, which consumes NAD 
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and releases nicotinamide to form poly(ADP-ribose) polymers, is essential in the 
recruitment of key proteins in BER, XRCC1 and DNA Polymerase-β (De Murcia et 
al., 1994, Dantzer et al., 1999). Interestingly, poly(ADP-ribose) polymers generated 
from PARP activity, have been shown to generate ATP used for the DNA ligation 
step in BER (Oei and Ziegler, 2000, Maruta et al., 2007).  
 
Nicotinamide enhancement of DNA photolesion repair may be a key mechanism of 
nicotinamide’s immune protective effect from UVR in humans, highlighting DNA 
damage as an important biological damage response that leads to UV-induced 
immune suppression. DNA repair is the main mechanism of DNA damage removal 
to prevent mutations from occurring. Slower repair of CPDs was associated with 
mutational hotspots on the p53 gene (Tornaletti and Pfeifer, 1994) and higher risk of 
developing BCCs  (Alcalay et al., 1990, Xu et al., 2000, Segerback et al., 2008, 
Mabruk et al., 2009). Similarly, a decreased rate of 8-oxodG removal in Ogg1 
knockout mice predisposes them to skin cancers (Kunisada et al., 2005) and is 
possibly associated with higher risk of BCCs in humans (Huang et al., 2012). 
Therefore, efficient removal of CPDs and 8-oxodG plays a key role in preventing 
skin carcinogenesis. Nicotinamide enhancement of CPDs and 8-oxodG repair 
therefore makes nicotinamide a promising agent for skin cancer chemoprevention in 
humans. The next study therefore investigated the effect of nicotinamide on 
precancerous skin lesions, actinic keratoses (AKs).  
 
Hypothesis 4 – nicotinamide reduces actinic keratoses 
 
This study aimed to determine whether oral nicotinamide reduced AKs in high-risk 
patients with sun-damaged skin and multiple AKs. Two randomized, double-blinded, 
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placebo-controlled clinical trials were designed to assess the effect of two different 
doses of oral nicotinamide (500mg twice daily or 500mg once daily) on AKs. To be 
eligible for the study, participants needed to be older than 18 years, have at least 4 
AKs symmetrically distributed over face or scalp and/or upper limbs, and have not 
received other treatment for AKs within the last one month prior to the study 
commencement. Participants who were pregnant, lactating, immunosuppressed, 
concurrently taking other nicotinamide supplements and/or photosensitizing agents 
and/or carbamazepine, had active dermatitis and/ or liver disease, were excluded 
from the trials. Carbamazepine has been reported to interact with nicotinamide 
(Bourgeois et al., 1982) and high dose nicotinamide (3 gram daily or more) 
potentially caused exacerbation of pre-existing liver disease (Winter and Boyer, 
1973, Haslam et al., 1984). Although there is no report of nicotinamide interaction 
with oral contraceptives, women of childbearing potential who were taking the oral 
contraceptive pill were advised to use additional, barrier contraception during these 
studies. All participants were advised to apply sunscreen with sun protection factor 
(SPF) 30+ daily during the study as well as to follow general sun protective 
measures. Before commencement in the trials, each participant underwent a complete 
skin examination by a dermatologist or a dermatology registrar (trainee) to confirm 
eligibility in the study and to treat pre-existing skin cancers. At commencement of 
the trials, patients were randomly assigned to receive either placebo or nicotinamide. 
Remaining tablets at the conclusion of trials were counted to assess compliance. In 
both trials, only palpable AKs (grade II and III AKs) were counted. Visible AKs 
were not included in the studies due to low sensitivity in detection and high inter- 
and intra-observer variation observed in a previous human trial on 1% nicotinamide 
lotion (Moloney et al., 2010). AKs were counted (blinded to allocation) at baseline, 
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2-month and 4-month assessments. Location of each AK was documented on a body 
grid chart, which includes scalp, face, and upper limbs. Representative AKs were 
also photographed in each patient. Each follow-up visit included assessment for any 
side effects and any skin cancers that developed during the study. Suspicious lesions 
were biopsied and referred for standard treatment. All skin cancers diagnosed during 
the study were confirmed histologically by pathologists blinded to allocation. Whole 
blood was also taken from each participant at baseline and 2-month visits for full 
blood count (FBC), electrolyte urea creatinine (EUC), liver function tests (LFT), and 
total NAD(H) and NADP(H) analyses.  
 
35 volunteers were recruited in a 500mg daily nicotinamide study (study 1) between 
June and October 2009. 1 patient from the nicotinamide group withdrew from the 
study at 2 months due to the development of invasive SCC.  41 volunteers were 
enrolled in a 500mg once daily nicotinamide study (study 2) between August and 
November 2010. 2 patients from the placebo group withdrew from the study soon 
after baseline assessment due to nursing-home placement and frailty. 2 patients from 
the nicotinamide group withdrew from follow-up due to personal reasons soon after 
baseline assessment. All these patients had their baseline AK count carried forward 
and were included in the primary analysis. Nicotinamide 500mg twice daily 
significantly reduced AKs by 35% relative to placebo within 2 months. The 
reduction was maintainted at 4 months. Nicotinamide 500mg once daily significantly 
reduced AKs by 29% relative to placebo within 4 months. The reduction was smaller 
but still significant at 15% at 2 months. In both studies, nicotinamide was equally 
effective in individuals with higher and lower baseline AK counts and reduced AKs 
across all sites observed (face, scalp, upper limbs). Both trials did not intend to 
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investigate nicotinamide’s effect on non-melanoma skin cancer (NMSC) incidence 
as a primary end point. This is because of the short duration of the trials and the low 
numbers of NMSCs expected to develop in 4 months. However, combined NMSC 
analysis for the two trials showed a significant reduction in skin cancers in the 
nicotinamide group [2 patients developed 4 skin cancers (2 BCCs, 2 SCCs)], 
compared to the placebo group [11 patients developed 20 new skin cancers (12 
BCCs, 8 SCCs)]. Compliance, as measured by counting the tablets returned at the 
end of the trials, was excellent (>94% dispensed tablets were taken) in all 
participants involved in both trials. In study 1 (nicotinamide 500mg twice daily), no 
side effects were reported during the study, whilst in study 2 (nicotinamide 500mg 
once daily), one patient in the nicotinamide group, who also took multiple other 
medications concurrently, described nausea following nicotinamide intake and 
withdrew from the study. No other potential side effects related to oral nicotinamide 
intake were reported, and no clinically significant changes in FBC, EUC, and LFT 
analyses were observed at 2-month follow-up. Erythrocyte NAD(H) and NADP(H) 
were quantified at baseline and 2-months. Niacin number, which reflects long-term 
storage of intracellular NAD, was calculated as (erythrocyte NAD(H)/NADP(H) × 
100) (Jacobson et al., 1999). There was no significant difference in baseline niacin 
number between placebo and nicotinamide groups. Nicotinamide 500mg twice daily 
or once daily supplementation for 2 months did not significantly increase niacin 
number compared to baseline and compared to placebo group. Large inter-individual 
variations in NAD(H) levels were observed at baseline (placebo NAD(H) range: 
2.73-10.06; nicotinamide NAD(H) range: 2.47-11.34) and at 2 months (placebo 
NAD(H) range: 3.45-8.68; nicotinamide NAD(H) range: 3.38-20.93) without 
(placebo) or with nicotinamide supplementation.  
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This is the first human study on the effect of oral nicotinamide on AKs. Moloney et 
al investigated the effect of topical nicotinamide on AKs. In this RCT involving 26 
patients, topical 1% nicotinamide applied twice daily for 3 months significantly 
reduced AKs by 22%. However, the difference in AK reduction between 
nicotinamide and placebo groups was not sustained after 6 months of application 
(Moloney et al., 2010). This study is also the first that demonstrated the efficacy of 
nicotinamide on NMSCs in humans. In BALB/cAnNTacfBR mice, topical 2.5% 
nicotinamide prevented UVB-induced immunosuppression and skin tumour 
(predominantly SCC) formation in the mice (Gensler, 1997). Similarly, oral niacin 
(0.5% and 1% in the diet) significantly prevented UVB-induced immunosuppression 
and markedly reduced skin SCC incidence and multiplicity in these mice (Gensler et 
al., 1999).  
 
My study could not detect a significant increase in niacin status with nicotinamide 
intake. However the wide range of NAD(H) observed in this study (baseline 
NAD(H) variabilities were 3.7-fold and 4.5-fold for placebo and nicotinamide groups 
respectively; 2-month NAD(H) variabilities were 2.5-fold and 6.1-fold for placebo 
and nicotinamide groups respectively) limits the interpretation of data. A previous 
large study involving 1300 subjects in Western countries also found up to 3-fold 
variability in baseline whole blood NAD(H) (Jacobson, 1993). In metabolic ward 
study (subjects were given controlled amount of niacin or niacin equivalent), niacin 
depletion and repletion were shown to decrease and increase erythrocyte NAD(H) 
respectively (Fu et al., 1989). However, in a study involving subjects with clinical 
pellagra, erythrocyte NAD(H) or NAD(H) and NADP(H) ratio, were not 
significantly decreased compared to control subjects (healthy volunteers consuming 
  
 216
a western-style diet) (Creeke et al., 2007). In the later study, spot urine 
concentrations of niacin (also nicotinamide) metabolites N1-methylnicotinamide 
(NMN) and N1-methyl-2-pyridone-5-carboxamide (2-pyr) as measured by high 
performance liquid chromatography (HPLC), were shown to be significantly lower 
in pellagrins and markedly higher following treatment with nicotinamide and food 
supplementation (Creeke et al., 2007). 24 hour-urine measurement of nicotinamide 
and/or niacin metabolites 2-pyr and NMN by HPLC is available in the clinical 
laboratory at the Biochemistry department, Royal Prince Alfred Hospital, Sydney. A 
ratio of 2-pyr to NMN has been considered as a marker of niacin status with normal 
ratio defined as between 1 to 4, and niacin (and nicotinamide) deficiency as less than 
0.5 (Sauberlich, 1999).  However, 24-urine measurement is impractical in a clinical 
trial setting involving large number of subjects. Epidermal NAD content is possibly a 
better indicator of photoprotective effects with nicotinamide and/or niacin 
supplementation. A previous study in mice showed an increase in epidermal NAD 
content after 3 weeks of dietary supplementation with niacin (Gensler et al., 1999), 
which like nicotinamide is also a precursor for NAD and NADP. Jacobson et al 
investigated the association between skin NAD content and the incidence of AKs and 
SCC in humans and found an inverse correlation between skin NAD content and 
malignant phenotype (i.e. higher skin NAD was associated with less malignant 
lesions/AKs) (Jacobson et al., 1999). Recently, two-photon tomography, a novel 
non-invasive three-dimensional optical imaging technique, was shown to enable 
quantification and visualization of cellular NAD(P)H in human facial skin. 
Interestingly in this study, it was shown that NAD(P)H levels in the facial skin were 
significantly lower in the older subjects compared to those in younger subjects. In 
was hypothesized that chronological ageing and photodamage contribute toward 
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lower levels of the nucleotides in older individuals (Miyamoto and Kudoh, 2013). 
Future studies should include quantification of skin NAD(P)H with nicotinamide 
supplementation utilizing this technology. If nicotinamide supplementation is 
associated with an increase in NAD levels in human skin, it will be interesting to see 
whether nicotinamide prevents NAD decline with in vivo UV-irradiation of the skin.  
 
Nicotinamide’s enhancement of DNA photolesions repair and protection from UV-
immune suppression are likely involved in reduction in AKs and NMSCs observed in 
this study. Inflammation in AKs is a marker of malignant transformation (Berhane et 
al., 2002, Quaedvlieg et al., 2006). Nicotinamide’s anti-inflammatory effect may 
play a role in preventing malignant transformation of AKs and reducing NMSCs in 
this study. Anti-inflammatory effects of nicotinamide have been proposed to be 
mediated through inhibition of NF-κB gene transcription, which leads to decreased 
production of TNF-α and other inflammatory mediators such as IL-1β, IL-6, and IL-
8  (Fukuzawa et al., 1997, Pero et al., 1999, Ungerstedt et al., 2003). PARP inhibition 
by nicotinamide has been shown to be involved in suppression of NF-κB gene 
transcription (Pero et al., 1999).  
 
Conclusions 
Nicotinamide offers a safe, effective, and convenient option for prevention of AKs. 
Current approaches to the treatment of AKs including surgical methods (cryotherapy, 
shave, curettage and electrodessication), medical therapies (5-fluorouracil (5-FU), 
imiquimod, ingenol mebutate) and physical therapies (photodynamic therapy, laser 
resurfacing) are variably effective. However, they can be associated with significant 
local skin reactions such as pain, erythema, oedema, erosions, hypo- or hyper- 
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pigmentation and scarring (Berman and Amini, 2012) as well as substantial cost. 
Prevention is better than the requirement for therapy and advances in prevention 
would be very advantageous for skin cancer in this country. There are many 
chemopreventive agents that have been trialed in humans for efficacy against AKs or 
skin cancers. Topical DL-α-tocopherol (vitamin E) (Foote et al., 2009), oral 
betacarotene (Greenberg et al., 1990, Green et al., 1999, Frieling et al., 2000, 
Darlington et al., 2003), and oral selenium (Clark et al., 1996) were not effective at 
reducing either AKs or skin cancers. Both oral and topical retinoids have been shown 
to significantly reduce AKs and/ or skin cancer in most human studies (Kraemer et 
al., 1988, Alirezai et al., 1994, Bavinck et al., 1995, Moon et al., 1997, Gibson et al., 
1998, McKenna and Murphy, 1999).  However, retinoids are known for multiple 
toxicities including dry skin and mucous membranes, photosensitivity, 
hyperlipidaemia, and elevation in liver enzymes. They are also highly teratogenic, 
precluding their use in pregnancy and in women of child-bearing potential (Wright et 
al., 2006). The DNA repair enzyme T4N5 in liposomes has been shown to 
significantly reduce AKs and BCCs in patients with xeroderma pigmentosum 
(Yarosh et al., 2001) and to markedly decrease AK counts from baseline in 17 
healthy human volunteers with multiple AKs (DeBoyes et al., 2010). Currently the 
liposomes are limited by availability and high cost. The nonsteroidal anti-
inflammatory drug (NSAID) celecoxib has been shown to reduce NMSCs (Elmets et 
al., 2010). However, it is associated with several side effects such as gastritis, renal 
impairment, and hypertension, which can be a serious issue in elderly patients 
(Barkin et al., 2010). Sunscreen has been shown to reduce the incidence of AKs and 
SCCs by almost 40% (Thompson et al., 1993, van der Pols et al., 2006). However, 
sunscreen effectiveness is limited by poor compliance, even in individuals at greatest 
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skin cancer risk (Neale et al., 2002). Less than half of the participants in these trials 
regularly used sunscreen, despite having previous multiple skin cancers. 
Nicotinamide can be added topically in sunscreen or moisturizer (as is now the case 
with a number of commercially available products) and/ or fortified into staple foods 
such as bread, cereals, tea, and milk products.  
 
In summary, nicotinamide is a safe and effective oral chemopreventive agent for 
AKs. In the two clinical trials, nicotinamide either 500mg once daily or twice daily 
for 4 months was well-tolerated in most patients. Compared to recommended daily 
intake (RDI) (14-16mg/day), the doses used in this study are 30-70 times higher. 
However, the doses used are approaching pharmacologic doses used in various 
inflammatory skin dermatoses (1000 to 3000 mg/day) (Niren, 2006). No significant 
adverse effects were reported in the trials. No change in basic blood profile including 
full blood count, renal and liver function tests, was found with the two nicotinamide 
doses over the four months period. Unlike niacin, nicotinamide rarely causes 
flushing (Ranchoff and Tomecki, 1986), and does not influence blood pressure, heart 
rate or body temperature (Stratford et al., 1992). Although nicotinamide crosses the 
placental barrier, there is no reported teratogenecity data on nicotinamide in humans 
(Knip et al., 2000). The trials showed reduction in NMSCs with oral nicotinamide. 
Due to the short duration of trials and the relatively small numbers of NMSCs 
developed in these periods, the effect of oral nicotinamide on NMSC reduction needs 
to be validated in a larger trial over a longer period of time, with numbers of new 
NMSCs as the defined primary endpoint.  
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APPENDIX 1 – QUESTIONNAIRE FOR EX VIVO SKIN 
VOLUNTEERS 
 
Patient Name:        DOB:   
Contact Details Address: 
   Phone: 
   Mobile: 
   Email: 
Past Medical History  Medications   Allergies 
 
        Smoker/Non Smoker 
 
Are you pregnant or breastfeeding?     Y N 
Do you have a past history of melanoma or skin cancers?  Y N 
  If yes what type? 
Have you had sun exposure in the past 4 weeks?   Y N 
Do you feel that you scar easily?     Y N 
Do you suffer from dermatitis or psoriasis?    Y N 
Do you have current or past internal cancer?    Y N 
Do you take any immunosuppressive medications?   Y N 
Are you taking a vitamin (what type)?    Y N  
    
 
Fitzpatrick Skin Phototyping 
Which best describes your skin: 
I Always burns easily, never tans 
II Burns very easily, minimally tans 
III Burns moderately, tans slowly 
IV Burns minimally, tans well 
V Rarely burns, tans very easily 
VI Black skin, never burns, becomes darker after sun exposure 
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APPENDIX 2 – INFORMATION FOR TRIAL PARTICIPANTS 
 
Efficacy of oral nicotinamide in the treatment and prevention  
of actinic keratoses 
Introduction 
You are invited to take part in a research study into whether nicotinamide 
(vitamin B3) tablets reduce the number of new and existing actinic keratosis (also 
known as sun spots) on sun-damaged skin. Between 40-60% of Australian adults will 
develop actinic keratoses of which approximately 8% can progress to form a skin 
cancer. The development of actinic keratoses is directly related to exposure to 
ultraviolet (UV) rays in sunlight, which causes a temporary decrease in the activity 
of immune cells in the skin (“immunosuppression”). Since the immune system is one 
of the first lines of defence against tumours, there is concern that UV-induced 
immunosuppression, if it occurs frequently over a long period of time, may cause an 
increased risk of skin cancers. 
Nicotinamide is available as an over-the-counter vitamin supplement. 
Nicotinamide has been shown to have immune-protective and cancer-preventive 
effects in mice, and also in humans. Our preliminary studies in human volunteers 
have shown nicotinamide lotion and tablets to be safe and effective in reducing UV 
immunosuppression. It may be thus useful for helping to reduce numbers of sunspots 
and skin cancers, and may help reduce other effects of UV immunosuppression. We 
predict that taking nicotinamide tablets over a six month period will result in a 20-
50% reduction in actinic keratoses. 
This study is being conducted by Associate Professors Diona Damian and 
Fergal Moloney, both consultant dermatologists in the Department of Dermatology 
at the Royal Prince Alfred Hospital, and Dr Devita Surjana, Honorary Research 
Fellow in the Department of Dermatology at Royal Prince Alfred Hospital. 
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Study Procedures 
If you agree to participate in this study, you will be asked to sign the 
Participant Consent Form.  You will then be asked about conditions that might 
exclude you from the study. These include: 
-if you have had any treatment for sun spots in the past month 
-if you are pregnant or breastfeeding 
-if you are currently using immunosuppressive or photosensitising medications. 
-if you are unable to attend for follow up at two or four months 
-if you have active dermatitis on your skin 
-if you have liver disease 
-if you are taking certain epilepsy medications such as carbamazepine (which could 
interact with nicotinamide) 
 Should you agree to participate, we will take a baseline blood sample (~ 
20mL). One further blood test (~20mL) will be required 2 months later. One half of 
the participants will be randomly allocated (like the toss of a coin) to take a tablet 
containing 500 mg of nicotinamide (TWICE daily – TRIAL 1; ONCE daily – TRIAL 
2) for four months. The remaining participants will be randomly allocated to take a 
placebo tablet (i.e. containing only lactose but no active ingredients) each day for 
four months. The placebo tablet will be indistinguishable from the nicotinamide 
tablets and both you and your doctor will be unaware of which treatment you are 
receiving until the end of the study. Your total number of actinic keratoses will be 
counted and photographed at the baseline visit, again at two months and for the final 
visit at four months. 
We recommend that you continue with standard prevention measures for people with 
actinic keratoses such as sun avoidance and the daily application of a factor 30+ 
sunscreen. 
 
Risks 
We do not anticipate any adverse effects from the nicotinamide tablets. Although 
nicotinamide is not reported to have significant interactions with commonly used 
medications, its effects on blood levels of the contraceptive pill are unknown. 
Women of childbearing potential who are taking the oral contraceptive pill will be 
advised to use additional (barrier) contraception during the course of the study. There 
may be risks associated with this study that are presently unknown and 
  
 223
unforeseeable. If you have any symptoms or concerns you should discuss these with 
us as soon as possible. 
 
Benefits 
The potential direct benefit lies in the potential for nicotinamide to treat your actinic 
keratosis in a safe and effective manner. It may also serve to prevent the 
development of new actinic keratoses in sun-damaged areas. If effective, this will in 
turn potentially serve to decrease your risk of certain types of skin cancer. An 
indirect benefit will be in the contribution this research makes to furthering medical 
knowledge towards the future prevention of skin cancer. 
 
Compensation for injuries or complications 
If you suffer any injuries or complications as a result of this study, you should 
contact the study doctor as soon as possible, who will assist you in arranging 
appropriate medical treatment. If you are eligible for Medicare, you can receive any 
medical treatment required to treat the injury or complication, free of charge, as a 
public patient in any Australian public hospital. 
 
In addition, you may have a right to legal action to obtain compensation for any 
injuries or complications resulting from the study. Compensation may be available if 
your injury or complication is sufficiently serious and is caused by unsafe drugs or 
equipment, or by the negligence of one of the parties involved in the study (for 
example, the researcher, the hospital, or the treating doctor). You do not give up any 
legal rights to compensation by participating in this study. 
 
Costs 
Participation in this study will not cost you anything nor will you be reimbursed for 
your time. 
 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  
You can withdraw at any time without having to give a reason.  Whatever your 
decision, please be assured that it will not affect any medical treatement you may be 
having at the RPAH or your relationship with the investigators. 
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Confidentiality 
All the information collected from you for the study will be treated confidentially, 
and only the researchers named above will have access to it.  The study results may 
be presented at a conference or in a scientific publication, but individual participants 
will not be identifiable in such a presentation. 
 
Further Information 
When you have read this information, Dr Surjana will discuss it with you further and 
answer any questions you may have.  If you would like to know more at any stage, 
please feel free to contact her on 9515 6788. This information sheet is for you to 
keep. 
 
Ethics Approval 
This study has been submitted for approval to the Ethics Review Committee (RPAH 
Zone) of the Sydney South West Area Health Service.  Any person with concerns or 
complaints about the conduct of this study should contact the Secretary on 02 9515 
6766 and quote protocol number X09-0004. 
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APPENDIX 3 – PARTICIPANT CONSENT FORM 
 
 
RESEARCH STUDY INTO THE EFFICACY OF ORAL 
NICOTINAMIDE IN THE TREATMENT AND PREVENTION OF 
ACTINIC KERATOSIS 
 
I, 
…………………………………………………………………………………..…… 
[name] 
 
of 
…………………………………………...……………………………………..…… 
[address] 
 
have read and understood the Information for Participants on the above named 
research study and have discussed the study with 
 
…………………….…………………………………………………………… 
 
I have been made aware of the procedures involved in the study, including any 
known or expected inconvenience, risk, discomfort or potential side effect and of 
their implications as far as they are currently known by the researchers. 
 
I freely choose to participate in this study and understand that I can withdraw at any 
time. 
 
I also understand that the research study is strictly confidential. 
 
I hereby agree to participate in this research study. 
 
 
NAME:    
 ............................................................................................. 
 
SIGNATURE:   
 ............................................................................................. 
 
DATE:    
 ............................................................................................. 
 
 
NAME OF WITNESS:  
 ............................................................................................. 
 
SIGNATURE OF WITNESS:
 ............................................................................................. 
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APPENDIX 4 – QUESTIONNAIRE FOR TRIAL PARTICIPANTS 
 
EFFICACY OF ORAL NICOTINAMIDE IN THE TREATMENT 
AND PREVENTION OF ACTINIC KERATOSES 
 
Subject Details        Date: 
Name: DOB:                                   Age: 
Phone: Occupation:           Indoors            Outdoors 
Email: Smoking hx:   Yes        No 
  
Skin Type 
Eye colour Sunscreen use: Always      Sometimes      Never 
Hair colour in teens Fitzpatrick skin type:  
 
Medical History 
Relevant allergies 
 
Relevant medical problems 
 
Relevant medications 
 
Vitamin supplements 
 
Pregnant/ Breastfeeding 
 
Immunosuppression 
 
Photosensitivity 
 
Steroid use (oral, inhaled, top) 
 
NSAID use 
 
Alcohol intake (weekly units) 
 
 
Skin Cancer History 
Previous NMSC, number/type 
 
Previous melanoma, number/type 
 
Prior AK treatment Cryotherapy               Yes               No 
 
Topical 5-FU             Yes               No 
 
5% Imiquimod           Yes               No 
 
PDT                            Yes              No 
 
Diclofenac Sodium     Yes              No 
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APPENDIX 5 – ACTINIC KERATOSES COUNTING FORM 
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